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Summary 
 
The two B-cell non-Hodgkin lymphoma entities chronic lymphocytic leukemia (CLL) and 
mantle cell lymphoma (MCL) are lymphoproliferative neoplasms characterized by 
different aggressive clinical courses. However, they show striking geneotypic similarities 
like recurrent chromosomal gains of 3q25-q29, 12q13-q14 and 18q21-q22. The genetic 
pathomechanisms affected by these aberrations are mainly not understood. Several 
studies reported the high resolution detection of chromosomal imbalances in MCL and 
CLL using array CGH, accurately defining the gained regions. These imbalances, however, 
still contain too many genes in order to enable a reasonable selection of candidates. The 
aim of the present study was to identify genes with oncogenic potential in recurrently 
gained chromosomal regions of MCL and CLL using high resolution expression arrays, 
followed by studying the effect of gene silencing on cell proliferation. First, the 
expression of 24 primary CLL and 6 primary MCL patients, as well as 6 cell lines was 
profiled, and the identified genes in the three gained regions (3q, 12q, and 18q) were 
compared to published data. Second, the 72 candidate genes derived from this analysis 
were functionaly investigated by the use of an RNA interference screen in a multiwell 
format. Third, the changes in cell viability were validated in primary CLL cells and 
downstream effects of the identified candidate genes were analyzed. The three genes 
CCDC50, SERPINI2 and SMARCC2 emerged as candidates mediating a reduction in cell 
viability in cell lines and in primary CLL cells. CCDC50 was identified as a candidate gene 
with a 3.5-fold mean overexpression in primary cells of MCL and CLL patients. Gene 
knockdown and reporter gene assays revealed a role of CCDC50 in promoting cell 
survival. MCL and CLL cell lines with stable CCDC50 knockdown revealed 75% less 
proliferation than the parental cells. Interestingly, and in contrast to results shown in 
Hela cells, the data of this study gave rise to a survival stimulating effect of CCDC50. 
TNFα induced NFκB activation revealed a direct correlation of inducibility and CCDC50 
expression. Genome wide expression profiling studies identified several target genes of 
p53 signaling pathways as upregulated in accordance with low CCDC50 transcript levels. 
Overexpression of pro-apoptotic genes like TP53I3 and BAX and downregulation of 
apoptosis-protecting genes like BNIP3L and GADD45A were a plausible cause for the 
reduction in cell viability in primary CLL cells and cell lines after CCDC50 silencing. In 
conclusion, CCDC50 was identified as activated candidate gene in MCL and CLL that is 
responsible for cell survival and plays a role in NFκB and p53 signaling pathways. 
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Zusammenfassung 
 
Die beiden B-Zell Non-Hodgkin Lymphome, chronisch lymphatische Leukämie (CLL) und 
Mantelzell-Lymphom (MCL), sind als lymphoproliferative Neoplasien durch unter-
schiedlich aggressive Krankheitsverläufe charakterisiert. Dennoch zeigen sie ausgeprägte 
Gemeinsamkeiten genetischer Natur. Häufig auftretende Veränderungen sind zum 
Beispiel genetische Zugewinne auf den Chromosomen 3q25-q29, 12q13-q14 und 18q21-
q22. Die Pathomechanismen, die durch diese Aberrationen ausgelöst werden, sind 
größtenteils noch nicht aufgeklärt. Die Methode „array CGH“ (vergleichende genomische 
Hybridisierung auf Biochips) ermöglicht es, genomweite Veränderungen der DNA-
Kopienzahl, die durch den Zugewinn oder den Verlust bestimmter Chromosomen-
regionen entstanden sind, sehr sensitiv zu erkennen. Amplifizierte Regionen in MCL und 
CLL enthalten oftmals Onkogene, die bei der Tumorentstehung und -entwicklung eine 
entscheidende Rolle spielen. Viele Publikationen, in denen die array CGH Methode 
benutzt wurde, konnten die veränderten Chromosomenregionen in MCL und CLL auf so 
genannte “minimal veränderte Regionen“ eingrenzen. Trotzdem enthalten diese noch zu 
viele Gene, um eine geeignete Auswahl an Kandidaten für weitere funktionelle Studien 
treffen zu können. Das Ziel dieser Studie war es, Kandidatengene mit onkogenem 
Potential zu identifizieren, die in häufig amplifizierten chromosomalen Regionen von 
MCL und CLL liegen. Dazu wurden umfassende Expressionsprofile von primären Zellen 
aus 24 CLL und 6 MCL Patienten sowie von 6 Zelllinien beider Entitäten erstellt. Die 72 
identifizierten und überexprimierten Kandidatengene, die in den häufigen 
Zugewinnregionen 3q25-q29, 12q13-q14 und 18q21-q22 lokalisiert sind, wurden mittels 
der RNA Interferenz-Methode antagonisiert. Abschließend wurden die beobachteten 
Verluste in der Zellviabilität in Zelllinien und in primären CLL-Zellen durch den Einsatz 
von vier einzelnen siRNA-Sequenzen pro Gen validiert. Die Gene CCDC50, SERPINI2 und 
SMARCC2 wurden dabei als Kandidatengene bestätigt, deren mRNA Knock-down sowohl 
den Verlust der Zellviabilität in primären Zellen als auch in Zelllinien induzierte. CCDC50 
konnte schon in früheren Studien als überexperimiertes Gen in MCL im Vergleich zu 
anderen Leukämien und zu gutartigen Lymphknotengeweben identifiziert werden. In 
dieser Arbeit zeigten quantitative PCR Messungen eine mittlere 3.5-fache 
Überexpression in primären Zellen der Lymphome MCL und CLL. Reportergenanalysen 
belegten darüber hinaus, dass CCDC50 im NFκB-Signalweg beteiligt ist, der u.a. die  
Viabilität von MCL- und CLL- Zellen reguliert. Weiterhin wurden Zelllinien mit stabilem 
CCDC50 Knock-down generiert. Diese zeigten eine bis zu 75% verminderte 
Zellproliferation im Vergleich zu parentalen Zellen mit unveränderter CCDC50- 
Expression. Im Gegensatz zu Experimenten, die in früheren Studien in Hela-Zellen 
durchgeführt wurden, belegten die Ergebnisse in diesen Untersuchungen einen 
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stimulierenden Effekt von CCDC50 auf das Überleben und die Proliferation von MCL und 
CLL Zellen. Die TNFα-induzierte NFκB-Aktivität konnte in HEK-293T-Zellen direkt mit dem 
CCDC50-Expressionslevel korreliert werden. Durch genomweite Expressionsstudien, die 
nach der Modifikation der CCDC50-Expression durchgeführt wurden, konnte eine 
Mehrzahl von Genen aus dem p53-Signalweg als dereguliert identifiziert werden. Die 
Überexpression der Apoptose-induzierenden Gene TP53I3 und BAX, sowie eine 
Herunterregulierung von Genen, die vor Apoptoseinduktion schützen (z.B. BNIP3L und 
GADD45A), sind eine plausible Erklärung für die Reduktion der Zellviabilität nach CCDC50 
Knock-down in primären CLL-Zellen sowie in Zelllinien. Zusammenfassend konnte in 
dieser Arbeit CCDC50 als hochreguliertes Gen identifiziert werden, das in MCL und CLL 
die Zellproliferation fördert und an den NFκB- und p53-Signalwegen maßgeblich beteiligt 
ist. 
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1 Introduction 
1.1 Cancer 
Cancer is the second most common cause of death in Germany and the Western world 
after cardio-vascular diseases. According to estimations by the World Health 
Organization (WHO), cancer causes around 25% of all deaths worldwide. The 
development of cancer is the result of microevolution of an initial cell clone towards 
malignancy. Such aberrant development is suppressed in healthy organisms by multiple 
defense systems (Klein et al., 2007). 
1.1.1 The hallmarks of cancer 
Hanahan and Weinberg reviewed in 2000 six crucial steps in the transformation process 
of a normal to a malignant cell (Hanahan and Weinberg, 2000). The ‘hallmarks of cancer’ 
are alterations in cell physiology that constitutively influence malignant cell growth 
(Figure 1). All of these physiological changes are novel capabilities acquired during tumor 
development. They represent the successful suppression of an anticancer defense 
mechanism tightly connected to cells and tissues. The mechanistic pathways vary from 
cell to cell and not all six hallmarks have to be fulfilled in each malignant cellular 
transformation. 
 
 
 
 
Figure 1: Acquired capabilities of cancer (Hanahan and Weinberg, 2000). 
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Tumor cells generate many of their own growth signals, thereby reducing their 
dependence on stimulation from their normal tissue microenvironment. This liberation 
from dependency on exogenously derived signals disrupts a critically important 
homeostatic mechanism that normally ensures a proper behavior of the various cell 
types within tissues (Hanahan et al., 2000). Aquired growth signal autonomy is achieved 
through alteration of extracellular growth signals, influence on transcellular transducers 
of growth signals and their impact on intracellular circuits that translate those signals 
into action. While most soluble mitogenic growth factors are made by one cell type in 
order to stimulate proliferation of another, many cancer cells acquire the ability to 
synthesize growth factors to which they are responsive, creating a positive feedback 
signaling loop often termed autocrine stimulation (Hanahan et al., 2000). 
Cancer is a disorder that can be characterized by uncontrolled cell division or the cellular 
resistance to apoptosis. This is a physiological process that occurs in all tissues and under 
a variety of circumstances. The balance between normal cell division, differentiation and 
programmed cell death (apoptosis) is tightly regulated to ensure the integrity of organs 
and tissues. Non-malignant cells are programmed to maintain the function of the tissues 
of which they are a part. Development of cancer is a consequence of changes in somatic 
cells, which enable uncontrolled cell division or resistance to apoptosis. The DNA 
sequence itself is either affected (genetic origin) or changes in DNA methylation and 
demethylation (epigenetic origin) can cause uncontrolled cell division in cancer. 
Alterations of the genetic information in malignant cells can be single point mutations, 
deletions (a mutation in which a part of a chromosome or a sequence of DNA is missing), 
gains of genomic material (a mutation in which a part of a chromosome or a sequence of 
DNA is additional), chromosomal rearrangements, including translocations and 
epimutations (a change in heritable chromatin marks, such as an increase or decrease in 
the density of DNA methylation). According to current models, cells with genomic 
alterations that best promote growth and enhance cell survival are selected to multiply. 
Malignant cells with less efficient mutations may therefore be lost by competition within 
the tumor. This process is called ‘clonal evolution’ (Nowell et al., 1976; Gao et al., 2007). 
Only a few of these changes result in carcinogenesis and aberrations in a limited number 
of genes are sufficient for tumor formation. Proteins encoded by affected genes are 
generally involved in cellular maintenance, DNA repair machinery or regulatory 
mechanisms that control cell growth, proliferation and apoptosis.  
1.1.2 Oncogenes 
Genes are potential oncogenes, when their activation leads to enhanced cell growth, 
loss of differentiation and the resistance to undergo apoptosis. A proto-oncogene is a 
normal gene that can transform into an oncogene due to mutations or increased 
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expression, i.e. activation. Proteins encoded by proto-oncogenes participate in various 
ways to receive and process growth-stimulatory signals that originate from the 
extracellular environment. When these genes suffer mutation, the flow of growth-
promoting signals released by these proteins becomes deregulated. According to the 
theory of Weinberg, the oncoproteins release a steady stream of growth stimulating 
signals resulting in a constant proliferation associated with cancer cells (Weinberg, 
2007). 
The activation of a proto-oncogene can be caused by one of the following events: (1) 
Gene duplication is a chromosome abnormality that may result in an increased amount 
of protein level. Amplifications of chromosomal bands coding for proto-oncogenes can 
result in the overexpression of the corresponding protein that causes increased 
proliferation or the resistance to apoptosis. MYC genes are one example for proto-
oncogenes, activated in the described manner (Weiss et al., 1982). They encode 
transcription factors, which drive cell proliferation and regulate cell growth, 
differentiation, apoptosis and stem cell renewal when activated by cellular signals. (2) 
Point mutations within proto-oncogenes can generate constitutively active proteins or 
cause an increase in protein or enzyme activity. Alternatively, point mutations can lead 
to a loss of normal cell proliferation, i.e. the RAS oncogene. RAS proteins are GTPases 
and transfer signals from G-protein coupled receptors, following metabolism, into its 
inactive form GDP-RAS. Point mutations in RAS lead to amino-acid changes that can 
cause a reduction of GTPase activity. Consequently, GTP-RAS is inactivated, cannot 
perform its original function and leads to inadequate cellular signaling responses. (3) A 
chromosomal translocation can lead to increased gene expression by putting the proto-
oncogene under the control of a strong promoter or enhancer leading to high gene 
expression levels, and it can lead to the formation of a constitutively active fusion 
protein. One example is the overexpression of cyclin D1 in mantle cell lymphoma. MCL is 
characterized by a t(11;14)(q13;q32) translocation (Espinet et al.,1999; Stamatopoulos 
et al., 1999) and an overexpression of CCND1 promotes cell cycle progression. A gain-of-
function mutation is always dominant on the cellular level. A single mutation in a gene is 
sufficient to promote carcinogenesis. 
1.1.3 Tumor suppressor genes 
Tumor suppressor genes (TSGs) are often involved in the regulation of the cell cycle, 
induction of apoptosis and decrease in cellular adhesion. TSGs are growth controlling 
genes that operate to constrain or suppress cell proliferation. When these genes are 
inactivated or lost, tumor formation progresses. To promote tumor formation, both 
alleles of a gene have to be inactivated by (a) mutation, (b) deletion or (c) silencing i.e. 
due to methylation of promoter-associated CpG islands or due to histone modifications. 
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The principle that both gene copies have to be lost was originally formulated by Alfred 
Knudson´s ‘two-hit’ hypothesis (Knudson et al., 1971). When a TSG is inactivated, it 
looses its growth-suppressing effects on the cell. A prominent example of a TSG is TP53.  
Loss or mutation of TP53 is probably the most common aberration in human cancer. The 
wild type allele of TP53 suppresses cell proliferation, and p53 only acquires growth-
promoting effects, when it sustains a point mutation in its reading frame. Because of this 
discovery, the p53 gene was categorized as a tumor suppressor gene, which was finally 
confirmed (Vogelstein et al., 2000; Weinberg, 2007). TP53 maps to chromosome 17p13 
that is consistently deleted in CLL (Döhner et al., 1999; Döhner et al., 2000), and other 
cancers like colorectal carcinomas (Baker et al., 1990). Unlike oncogenes, an intact single 
copy of a tumor suppressor gene is usually sufficient to maintain its proper function. 
1.2 Leukemia 
Leukemia is a malignant cancer of the bone marrow and blood characterized by the 
uncontrolled proliferation of blood cells, usually white blood cells (leucocytes). Leukemia 
is clinically and pathologically subdivided into the following categories: myeloid or 
lymphocytic, each of which can be acute or chronic: Acute Myeloid Leukemia (AML), 
Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Chronic 
Lymphocytic Leukemia (CLL). In lymphocytic leukemias, the cancerous change takes 
place in a type of marrow cell that normally forms lymphocytes like T-cells, B-cells, and 
natural killer cells. In myeloid leukemias, the cancerous change takes place in a type of 
marrow cell that forms granulocytes, erythrocytes, monocytes, and megakaryocytes. 
1.2.1 Acute Leukemia 
Acute leukemia is characterized by the rapid increase of immature blood cells. This 
process makes the bone marrow unable to produce healthy blood cells. Immediate 
treatment is required in acute leukemia due to the rapid progression and accumulation 
of malignant cells. Acute forms of leukemia are the most common forms of leukemia in 
children (Jemal et al., 2005). 
1.2.2 Chronic Leukemia 
Chronic leukemias have few or no blastoid cells. Compared to acute leukemias, chronic 
lymphocytic leukemia and chronic myelogenous leukemia usually progress more slowly. 
Chronic leukemias occur mostly, but not exclusively in older people and are often 
diagnosed in a routine blood test, as no symptoms manifest until the disease reaches an 
advanced stage. Aberrant cells are excessively accumulating, but it can take months or 
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even years for the disease progression. Treatment can frequently be postponed until the 
disease reaches a more malignant subform. 
1.3 B-cell neoplasms 
The World health organization classification of hematological malignancies categorizes 
neoplasms primarily to their cell lineage: myeloid, lymphoid, dendritic cells and mast 
cells. Within each category, distinct diseases are defined according to a combination of 
cell morphology, immunophenotype, genetic features and clinical syndromes (Martin-
Subero et al., 2003). A so called ‘cell of origin’ is assigned for each neoplasm, which 
represents the stage of differentiation of the tumor. Two major categories of lymphoid 
neoplasms are described by the WHO classification: (1) Hodgkin lymphomas (HL), 
characterized by the growth of Reed-Sternberg cells and (2) non-Hodgkin lymphomas 
(NHL). The latter include B-cell neoplasms, T-cell neoplasms and NK (neutral killer cell) 
neoplasms. Lymphomas and lymphocytic leukemias are included in the category of 
lymphoid neoplasms. B-cell chronic lymphocytic leukemia and small B-cell lymphocytic 
leukemia are classified as different manifestations of the same neoplasm. B-cell 
lymphocytic leukemias comprise among others: small B-cell chronic lymphocytic 
leukemia (CLL) and mantle cell lymphoma (MCL).  
B-cell lymphoma outcomes are extremely variable in the clinic. Some patients die within 
four weeks after diagnosis while others are cured or at least achieve 10-year survival 
without clinical symptoms. Interestingly, all of these tumors show similar phenotypes, 
but can be distinguished by their specific gene expression patterns (Küppers et al., 
2005). About 95% of all lymphomas are of B-cell origin, the remaining are T-cell 
malignancies. This might be surprising, given similar frequency of B- and T-cells in the 
human body. This fact can be explained by the specific factors that influence the 
pathogenesis of B-cell lymphomas (Küppers et al., 2005). About 15 types of B-cell 
lymphomas are distinguished in the WHO lymphoma classification (Table 1). This is not 
only relevant in terms of lymphoma pathogenesis but also for the treatment of the 
patients. However, B-cell tumors are not as autonomous as previously thought. Key 
factors that are crucial for normal B-cell differentiation and survival are also required for 
the malignant growth of most B-cells lymphomas (Küppers et al., 2005).  
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Table 1: Human mature B-cell lymphomas (Küppers et al., 2005) 
 
Lymphoma/Leukemia Cellular origin of B-cell Frequency * 
Diffuse large B-cell lymphoma GC or post-GC B-cell 30-40% 
Follicular lymphoma GC B-cell 20% 
Multiple myeloma Plasma cell 10% 
Classical Hodgkin´s lymphoma Defective GC B-cell 10% 
B-cell chronic lymphocytic leukemia  Memory / naïve / marginal zone  
CD5
+ 
 B-cell 
7% 
MALT lymphoma Marginal zone  7% 
Mantle cell lymphoma  Mantle zone, CD5
+ 
 B-cell 5% 
Burkitt´s lymphoma GC 2% 
Nodal marginal zone lymphoma Marginal zone 2% 
Splenic marginal-zone lymphoma Subset of naïve B-cells that have 
partially differentiated into marginal 
zone B-cells 
1% 
Primary mediastinal B-cell lymphoma Thymic B-cell 2% 
Post transplant lymphoma GC B-cell >1% 
Lymphoplasmatic lymphoma (Post) GC B-cell 1% 
Hairy cell leukemia Memory B-cell <1% 
B-cell prolymphocytic leukemia Memory B-cell <1% 
Primary effusion B lymphoma (Post) GC B-cell 0.5% 
Lymphocyte-predominant Hodgkin´s 
lymphoma 
GC B-cell 0.5% 
 
*Frequency=Frequency among lymphomas. Numbers refer to frequencies in Europe and North America. 
GC=Germinal Center. Lymphomas investigated in this thesis work are highlighted in red. 
 
1.3.1 B-cell development 
B-cells are lymphocytes that play a key role in the immune response. The early 
development of B-cells takes place in differentiation steps, resulting in variable and 
specific structures of the B-cell receptor (BCR). Early B-cell development occurs in the 
bone marrow. The BCR is composed of two heavy chain and two light chain 
immunoglobulin (Ig) polypeptides which are covalently linked by bisulfite bridges. The 
intracellular signaling components activated by BCR crosslinking include activation of 
multiple tyrosine kinases. Signaling is depending on (1) the differentiation stage of the B-
cell that recognizes the antigen and (2) the activation of other B-cell surface receptors 
that modulate BCR signaling. The activated B-cell might be stimulated to proliferate or to 
undergo further differentiation steps (Rajewsky et al., 1996). The BCR consists of 
variable (V) regions that bind the antigenes, and constant (C) regions that mediate the 
effector function of immunogobulins (Figure 2a). B-cells differentiate into mature naïve 
B-cells and leave the bone marrow. It was shown that B-cell precursors undergo 
apoptosis, if they fail to express a BCR or an autoreactive BCR (Rajewski et al., 1996). 
Mature naïve B-cells can be activated by antigen binding to the BCR and participate in 
immune responses. The activation of B-cells often depends on antigen-presenting T-cells 
and takes place in the germinal centers of lymph nodes, where the Ig genes are modified 
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by somatic hypermutation and class-switch recombinations upon activation (Figure 2b, 
c).  
 
 
Figure 2: Molecular processes that remodel immunoglobulin genes (Küppers et al., 2005). 
 
 
In T-cell dependent immune responses, antigen-activated B-cells undergo clonal 
expansion (Figure 3). Activated B-cells migrate into B-cell follicles, start to proliferate and 
differentiate into centroblasts thereby establishing germinal centers. The proliferating 
centroblasts activate the process of somatic hypermutation, generating mutations at a 
high rate in the V region genes and thereby leading to the formation of antibody 
variants. Centroblasts then differentiate into resting centrocytes, which are selected for 
high affinity of their BCR to the cognate antigen. Germinal-center B-cells with acquired 
affinity-increasing mutations will be able to interact with germinal-center T-cells and 
follicular dendritic cells (FDC) thus receiving survival signals and thereby escape the 
default apoptosis pathway of germinal-center B-cells. Finally, selected germinal-center 
B-cells differentiate into memory B-cells or plasma cells and leave the germinal center 
(Küppers et al., 2003; Küppers et al., 2005). However, the process can also proceed 
without T-cells in marginal zones, which occur all around the lymphoid foillicle (Chiorazzi 
et al., 2005). 
 
 
 
Figure 3: B-cell differentiation in a germinal center (Küppers et al., 2005). 
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1.3.2 The cellular origin of human B-cell lymphomas 
Distinct stages of B-cell development and differentiation are characterized by the 
particular structure of the BCR and expression patterns of differentiation markers. These 
processes take place in specific histological structures and the analysis of these features 
is used to determine the origin of the various human B-cell lymphomas (Table 1). 
Classification of B-cell lymphomas is based on the observation that malignant B-cells 
seem to be arrested at a particular differentiation stage (Figure 4), which reflects their 
origin (Greaves et al., 1986; Küppers et al., 1999; Shaffer et al., 2002). The cellular origin 
of B-cell lymphomas was analyzed by gene expression profiling. These studies identified 
a germinal center B-cell gene expression profiling signature that is associated with 
follicular lymphoma (Alizadeh et al., 2000, Rosenwald et al., 2001, Rosenwald et al., 
2003). Mantle cell lymphoma cells populate in the mantle zone of the follicles and 
constantly express CD5. Whereas most mantle cell lymphomas are believed to be 
derived from CD5+ (naïve) B-cells of the mantle zone, about 20–30% of cases carry 
mutated V-region genes, indicating that they have passed through the germinal center. 
The marginal zone is located around the mantle zone and consists of post-germinal 
center memory B-cells and naïve B-cells that are involved in T-cell independent immune 
responses. The origin of B-cell chronic lymphocytic leukemia (B-CLL) cells still remains 
unclear but has been discussed to derive from CD5+ B-cells, memory B-cells or naïve B-
cells (Chiorazzi et al., 2003; Küppers et al., 2005).  
 
 
 
Figure 4: Cellular origin of B-cell lymphomas (Küppers et al., 2005). 
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1.4 Mantle cell lymphoma 
Mantle cell lymphoma (MCL) is a lymphoid neoplasm characterized by abnormal 
proliferation of mature B-lymphocytes. It was discussed earlier that MCL cells probably 
derive from naïve B-cells residing in the primary follicles or in the mantle zones of 
secondary follicles (Weisenburger et al., 1996) and are expressing CD5. MCL represents 
5–10% of all NHL and occurs more frequently in males (male:female ratio is 2.7:1) with 
advanced age (median age 60 years, range 29-85). This tumor is considered one of the 
aggressive clinical lymphoid neoplasms with poor responses to conventional 
chemotherapy and relatively short survival. The clinical evolution is usually very 
aggressive with frequent relapses. Only few patients are cured by current therapies. 
1.4.1 Oncogenic mechanisms in MCL 
The genetic and molecular mechanisms involved in the pathogenesis of MCL combine 
the dysregulation of cell proliferation and survival pathways with a high level of 
chromosome instability based on the disruption of DNA damage response pathways. 
MCL is also characterized by the proliferation of mature B-lymphocytes that have a 
striking tendency to disseminate throughout the body, infiltrate lymphoid tissues, bone 
marrow, peripheral blood and extranodal sites. They also enter territories that normally 
do not contain lymphoid cells.  Concordant with its origin from pre-germinal center cells, 
MCL has been considered to carry no or very few somatic mutations in V-gene 
sequences of Ig (VH) genes. However, 15–40% of MCLs may carry somatic 
hypermutations indicating that some tumors originate from cells that have undergone 
the influence of mutations of the follicular germinal center (Welzel et al., 2001; Camacho 
et al., 2003; Kienle et al., 2003; Orchard et al., 2003). The load of mutations in MCL is 
lower than in other lymphoid neoplasms such as chronic lymphocytic leukemia or 
follicular lymphoma (Hamblin et al., 1999; Crespo et al., 2003) suggesting a smaller 
influence of the germinal center microenvironment. Contrary to chronc lymphocytic 
leukemia, the Ig mutational status in MCL is not associated with the prognosis of the 
patients (Orchard et al., 2003; Welzel et al., 2001; Camacho et al., 2003; Kienle et al., 
2003, Carreras et al., 2005). The genetic hallmark of MCL is the t(11;14)(q13;q32) 
translocation that juxtaposes the proto-oncogene CCND1, which encodes cyclin D1 at 
chromosome 11q13, to the Ig heavy chain gene at chromosome 14q32 including 
regulatory sequences. This event leads to the overexpression of cyclin D1, which has an 
important pathogenetic role: deregulating cell cycle control by overcoming the 
suppressor effect of retinoblastoma 1 (RB1) and the cell cycle inhibitor p27. As a 
consequence of this translocation CCND1, which is not expressed in normal 
B-lymphocytes, becomes constitutively overexpressed. This genetic alteration is thought 
to be the primary event in the pathogenesis of the tumor, facilitating the deregulation of 
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the cell cycle at the G1–S phase transition (Campo et al., 1999; Jaffe et al., 2001). 
Breakpoint region analysis of the two chromosomes has suggested that the 
t(11;14)(q13;q32) translocation occurs in the bone marrow in an early B-cell at the pre-B 
stage of differentiation, when the cell is initiating the Ig gene rearrangement by the 
recombination of the V(D)J segments. In addition to this translocation, MCL tumor cells 
carry a high number of secondary chromosomal and molecular alterations targeting 
proteins that regulate cell cycle and senescence (BMI1, INK4a, ARF, CDK4 and RB1) or 
interfere with the cellular response to DNA damage (ATM, CHK2 and p53). 
1.4.2 Secondary genetic alterations 
Despite the important role of the t(11;14) translocation and cyclin D1 overexpression in 
the development of MCL, several observations suggest that these mechanisms may not 
be sufficient for the complete transformation and the aggressive behavior of the tumor. 
Transgenic mouse models show that the overexpression of cyclinD1 is not sufficient to 
induce malignant transformation of the cells. Moreover, cooperations with other 
oncogenes like C-MYC are neccessarry (Lovec et al., 1994). Cytogenetic studies identified 
secondary genetic alterations that may be involved in the progression of MCL (Bea et al., 
1999; Bentz et al., 2000; Allen et al., 2002; Kohlhammer et al., 2004; Rubio-Moscardo et 
al., 2005; Tagawa et al., 2005; Rinaldi et al., 2006; Sander et al., 2008). MCL is a 
malignant lymphoid neoplasm with the highest level of genomic instability (Salaverria et 
al., 2007). Further studies suggest that genes involved in cell death may also be targeted 
by oncogenic events, and they may influence the tumor response to new therapeutic 
agents (Damle et al., 2002; Tobin et al., 2003). Previous investigation on genomic 
aberrations detected by fluorescence in situ hybridization (FISH) revealed the most 
common genomic changes in 103 MCL patients, all containing the translocation 
t(11;14)(q13;q32) (Table 2,  Sander et al., 2008). Alterations of the 8q24 locus, including 
the t(8;14)(q24;q32) translocation that activates MYC, are uncommon, but have been 
identified in MCL with a very rapid clinical course. Crucial target genes such as p16 INK4a 
on chromosome 9p21, BMI-1 on 10p12, ATM on 11q22.3, CDK4 on 12q14, and p53 on 
17p13 have been confirmed. Losses of 11q and 13q occur at similar frequencies in all 
histological variants of MCL, whereas the highly proliferative and clinically aggressive 
variants have more complex karyotypes with frequent losses of 9p, 9q and 17p and gains 
of 3q and 12q (Salaverria et al., 2007, Rubio-Moscardo et al., 2005). Copy number gains 
of 3q have been identified as prognostic markers of patients with low proliferation 
(Salaverria et al., 2007).  
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Table 2: Genomic changes in t(11;14)(q13;q32) positive MCL, (Sander et al., 2008). 
 
Aberration Chromosome Occurrence (%) 
Gain 3q26 45 
 8q24 19 
 15q23 18 
 12q12 17 
 7p15 15 
 18q21 14 
Deletion 13q14 43 
 11q22 41 
 9p21 35 
 13qter 33 
 1p22 32 
 17p13 26 
 6q27 22 
 8p22 21 
 6q21 16 
 10p15 13 
1.5 B-cell chronic lymphocytic leukemia 
B-cell chronic lymphocytic leukemia (B-CLL) is the most common leukemia of adults in 
the Western world (Rozman et al., 1995). It is characterized by a highly heterogenous 
clinical outcome, while some patients are dying within months, others have a normal 
lifespan.  
1.5.1 Oncogenic mechanisms in CLL  
Unlike other leukemias, there is only a small proportion of proliferating neoplastic cells, 
which are localized in the so-called ‘pseudofollicles’ in the lymph nodes and are 
scattered in the bone marrow of the patients (Granziero et al., 2001). Due to a selective 
survival advantage, the majority of leukemic cells in B-CLL are non-proliferating cells 
arrested in the G0/G1 phase, which accumulate gradually in lymphoid organs, bone 
marrow, and peripheral blood. This indicates that expansion of the tumor might take 
place in other tissues affected by the lymphoma. Indeed, proliferation of B-CLL is largely 
restricted to proliferation centers in lymph nodes and bone marrow, where the cells are 
in intimate contact with CD4+ T-cells and dendritic cells. The in vitro survival of B-cells 
can be significantly extended in co-culture with stromal cells, and B-CLL proliferation can 
be induced by triggering the CD40 receptor. As the ligand CD40L is expressed by a 
fraction of T-cells in the proliferation centers, it is intriguing to speculate that the T-
cell/B-CLL cell interaction in CD40 activated microenvironment provides important 
survival and proliferating signals for the malignant clone. Intrinsic defects, resistance to 
programmed cell death, and an altered, survival-stimulating microenvironment are 
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discussed as major pathogenic factors for B-CLL (Dighiero et al., 1991; Meinhardt et al., 
1999; Caligaris-Cappio et al., 2003; Ghia et al., 2005). 
1.5.2 Secondary genetic alterations 
In contrast to many other types of B-cell lymphomas, which carry characteristic 
chromosomal translocations involving one of the Ig loci and a proto-oncogene (Willis 
and Dyer, 2000), translocations are very rare in B-CLL. However, genomic aberrations are 
very common and the clinical heterogeneity has been shown to correlate with the 
pattern of genetic changes. A comprehensive FISH analysis revealed the most common 
genomic changes in a set of 325 B-CLL patients (Table 3) (Döhner et al., 2000). Further 
FISH analyses on 506 CLL patients have been conducted recently (Haferlach et al., 2007).  
 
 
Table 3: Incidence of chromosomal abnormalities in 325 B-CLL patients (Döhner et al., 2000). 
 
Aberration Chromosome Occurrence [%] 
Deletion  13q 55 
 11q 18 
 17p 7 
 6q 6 
Gain 12q 16 
 8q 5 
 3q 3 
Translocation t(14q32) 4 
Normal karyotype  18 
 
The most frequent abnormalities are losses of genomic material. These deletions effect 
chromosome bands 13q14, 11q22-q23, 17p13 and 6q21. 17p and 11q deletions are 
associated with rapid progression of the disease and short survival times of the patients, 
whereas deletion of 13q14 as a single abnormality predicts longer survival times. The 
tumor suppressor gene p53 is affected by 17p deletion; ATM (ataxia teleangiectasia 
mutated) is altered in a proportion of cases with 11q deletion (Schaffner et al., 1999; 
Schaffner et al., 2000). The most common gains of genomic material affect 12q13, 8q24 
and 3q26 (Monni et al., 1998; Bea et al., 1999; Bentz et al., 2000; Döhner et al., 2000). 
1.6 Recurrent genomic patterns in MCL and CLL  
MCL and CLL are characterized by recurrent chromosomal aberrations. Although MCL is 
associated with t(11;14)(q13;q32) and a higher karyotype complexity, there are striking 
similarities between their genetic aberrations. The two common deletions 11q and 13q 
are much more frequent in MCL and CLL when compared to other types of B-cell 
lymphomas. In addition, both malignancies share the frequently occurring chromosomal 
Introduction 
 
 
13 
 
gains in regions on 3q25-q29, 8q24, and 12q12-q14. For some chromosomal loci, the 
affected genes were recently identified such as MYC on chromosome 8q24, TP53 on 
chromosome 17p13 and ATM on chromosome 11q23, whereas CDK4 is predicted as 
candidate gene on chromosome 12q13. Among predicted candidate genes on 
chromosome 3q25-q29 were BCL6, SERPINI2 and ECT2 (Hernandez et al., 1996; el Rouby 
et al., 1993; Schaffner et al., 1999, Bentz et al., 1999; Schaffner et al., 2000; Tagawa et 
al., 2005; Rubio-Moscardo et al., 2005; Jares et al., 2008; Sander et al., 2008). 
1.6.1 Chromosomal gain of region 3q25-q29 
Pathological relevant genes are located in gained genomic region 3q26-q29 (Bentz et al., 
2000). One of the predicted candidate genes was the proto-oncogne BCL6 which could 
not be confirmed in most of the investigated MCL cases (Bentz et al., 2000). Analysis of 
global gene expression profiling in MCL cells identified a proliferation signature based on 
the expression of 20 genes that enable to discriminate patients with different median 
survival, confirming increased proliferation as the best predictor for poor survival. Some 
genetic alterations, particularly the gains on chromosome 3q and losses on 9p, 9q and 
17p have prognostic significance associated with a shorter survival (Bea et al., 1999; 
Allen et al., 2002; Rubio-Moscardo et al., 2005; Thelander et al., 2005). Most interesting, 
the impact of 3q gains and 9q losses on survival is independent of the proliferation 
activity of the tumor. Robust molecular and genetic prognostic predictors on 3q may 
therefore become an essential tool in clinical practice to define the best therapy for each 
patient. 
1.6.2 Chromosomal gain of region 12q13-q14 
Among their genomic aberrations, MCL and CLL show trisomy 12 as the most frequent 
ones (CLL 16%, MCL 17%) (Döhner et al., 1999; Döhner et al., 2000; Sander et al., 2008).  
The segment that was duplicated in all cases included 12q13-q21.2, indicating that this 
region contains the relevant genes, involved in the pathomechanism of B-CLL tumors. 
Trisomy 12 was shown to result from one homolog, rather than from loss of one 
homolog and triplication of the remaining one (Döhner et al., 1999). In recent B-CLL 
studies the presence of trisomy 12 in combination with 11q deletions, was discussed to 
be associated with a bad clinical prognosis (Athanasiadou et al., 2006; Mittal et al., 
2007). Nevertheless, the pathogenic role of trisomy 12 in MCL and CLL remains 
unresolved, but upregulated RNA expression levels have been observed for chromosome 
12 candidate genes (Winkler et al., 2005). So far, CDK4 is one of the most frequently 
discussed candidate gene on chromosome 12q13.  
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1.6.3 Chromosomal gain of region 18q21-q22 
Gain of chromosome 18q and translocation t(14;18) are frequently found in B-cell non-
Hodgkin lymphomas (B-NHL) (Galteland et al., 2005). Recent FISH analysis in primary 
MCL cases revealed a gain of chromosome 18q21 in 14% (Sander et al., 2008) leading to 
increased BCL2 transcription levels. The anti-apoptotic role of BCL2 in correlation to MCL 
and CLL disease pathways was described in recent publications. Therefore, BCL2 is the 
most frequent discussed candidate gene on chromosome 18q21. 
1.7 Recombinase Mediated Cassette Exchange  
A molecular tool for the functional antagonization of inactivated tumor suppressor 
genes or activated oncogenes in MCL and CLL was recently established in our group 
(Pscherer et al., 2006). This system is based on the targeted integration of transgenes 
into a disease background, i.e. the parental tumor cell line, via recombinase mediated 
cassette exchange (RMCE). Genomic deletions can be compensated via integration of 
respective genomic DNA, whereas overexpression of genes can be antagonized by 
integrating short hairpin RNA (shRNA) coding plasmids (Figure 5). Notably, this site-
specific shRNA-strategy circumvents the interferon response, often induced when 
applying transient RNAi knockdown (Pscherer et al., 2006). The production of stable cell 
lines is a multistep system based on site directed recombination events. In this work, 
overexpressed candidate genes were silenced via integration of shRNA coding plasmids 
into the genome (Figure 5). The RMCE system allows the antagonization of single 
overexpressed or downregulated genes without inducing further changes to the cell. The 
resulting functional changes identified upon supplementation of the gene/shRNA, show 
the biological relevance of the single genetic defects in CLL and MCL. 
 
1. Genomic Complementation 
genes with decreased copy numbers
pBACe3.6
Genomic  Insert
loxP pSUPERdL
shRNA  Insert
loxP511 loxP+CRE Recombinase
pGK  HSV-TK  Neo
loxP511 loxP
selection 
cassette
2. Gene specific silencing via RNAi              
genes with DNA copy number gains
Genomic InsertZeo
loxP511 loxP loxP511 loxP
shRNA InsertZeo
loxP511
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Figure 5: Schematic overview of recombinase mediated cassette exchange (RMCE). The selection cassette, 
carrying a Herpes Simplex Virus (HSV) Thymidin Kinase (TK) and a neomycine resistance gene (Neo) is 
flanked by two lox sites (loxP and loxP511). The cassette is randomly integrated into the genome of a cell 
line. (1) For genomic complementation, a BAC clone, inserted in the pBACe3.6 vector, can replace the 
selection cassette via homologous recombination (left side, yellow). (2) Gene specific silencing via RNAi is 
performed with a pSUPERdL (suppression of endogenous RNA) vector, carrying the shRNA for the gene of 
interest. Homologous recombination allows replacement of the neomycine selection cassette via the 
shRNA coding construct and the zeocin (Zeo) resistance cassette (right side, blue).  
1.8 Cellular model systems 
Along with other improvements, the advent of continuous human leukemia/lymphoma 
cell lines as a resource of abundant, accessible and manipulable living cells has 
contributed significantly to a better understanding of the pathophysiology of 
hematopoietic tumors (Drexler et al., 2006). The major advantages of continuous cell 
lines are the unlimited supply and worldwide availablility of identical cell material, and 
the infinite viable storability in liquid nitrogen. Leukemia/lymphoma cell lines are 
characterized generally by monoclonal origin and differentiation arrest, sustained 
proliferation in vitro under preservation of most cellular features, and specific genetic 
alterations. The most practical classification of leukemia/lymphoma cell lines assigns 
them to one of the physiologically occurring cell lineages, based on their 
immunophenotype, genotype and functional features (Drexler et al., 2006). MCL and CLL 
cell lines have been well characterized by matrix comparative genomic hybridization 
(mCGH), used to modulate specific gene activities and functionally analyze candidate 
genes within their genetic disease background (Korz et al., 2002; Pscherer et al., 2006). 
The MCL cell line JVM-2 shows gains on chromosomes 3q25-q29 and 12q13-q14 and the 
MCL cell line Granta-519 shows a typical gain on chromosome 18q21-q22 (Figure 6). 
Based on these results the two MCL cell lines were used in this study for gene 
modulation experiments.  
  
 
 
Figure 6: Array CGH in MCL cell lines JVM-2 and Granta-519. Recurrent chromosomal gains in the MCL cell 
line JVM-2 (3q25-q29 and 12q13-q14) and in the MCL cell line Granta-519 (18q21-q22) are highlighted in a 
red circle (modified according to Pscherer et al., 2006).  
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1.9 RNA interference  
In 1998 RNA interference (RNAi) was discovered as a mechanism that can be exploited 
as an experimental tool by Andrew Fire and Craig Mello, a finding that was awarded with 
the Nobel Prize for Medicine in 2006 (Fire et al., 1998). Fire and co-workers discovered 
the presence of double stranded RNA (dsRNA) formed by the annealing of sense and 
antisense RNA. Although the biology of RNAi is not fully understood, it has become a 
powerful experimental tool and is currently being developed for human gene therapy. 
Silencing of candidate genes, thought to play a specific role in tumorigenesis and poor 
prognosis, is used as a technique to validate the predicted gene functions. RNAi can be 
directed against cancer through various pathways leading to suppression of tumor 
growth, metastasis and increased apoptosis.  
1.9.1 Mechanisms of RNAi  
RNAi is guided by small RNAs that include small interfering RNA (siRNA) and microRNAs 
(miRNAs). The process of RNAi begins with the cleavage of 21-23 bp long dsRNA by the 
Dicer enzyme complex into siRNAs. These siRNAs are incorporated into Argonaute 2 
(AGO2) and the RNAi-induced silencing complex (RISC). In case the RNA duplex loaded 
onto RISC has perfect sequence complementarity, AGO2 cleaves the passenger (sense) 
strand so that active RISC containing the guide (antisense) strand is produced. The siRNA 
guide strand recognizes target sites to direct mRNA cleavage, carried out by the catalytic 
domain of AGO2 (Figure 7).  
The processing of miRNAs begins with endogenously encoded primary miRNA transcripts 
(pri-miRNAs) that are transcribed by RNA polymerase II (Pol II) and are processed by the 
Drosha enzyme complex to yield precursor miRNAs (pre-miRNAs). These precursors are 
then exported to the cytoplasm by exportin 5 and subsequently bind to the Dicer 
enzyme complex, which processes the pre-miRNA for loading onto the AGO2–RISC 
complex. When the RNA duplex loaded onto RISC has imperfect sequence 
complementarity, the passenger (sense) strand is unwound leaving a mature miRNA 
bound to active RISC. The mature miRNA recognizes target sites (typically in the 3′-UTR) 
in the mRNA, leading to direct translational inhibition. Binding of miRNA to target mRNA 
may also lead to mRNA target degradation in processing (P)-bodies (de Fougerolles et 
al., 2007). 
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Figure 7: Mechanism of RNA interference in mammalian cells (de Fougerolles et al., 2007). 
1.9.2 Loss-of-function screen 
The most obvious application of RNAi screening, direct loss-of-function (LOF) screening, 
involves identifying and functionally characterizing genes of interest on the basis of their 
LOF phenotypes. Such studies offer the broadest discovery potential as they simply 
analyze single-gene LOF phenotypes in otherwise unmodified cells. This approach has 
proved effective for many types of genes, including those that encode structural 
components, cell-surface receptors, transcription factors and enzymes. The high activity, 
long protein half-life and high endogenous expression of some genes might make it 
difficult to generate detectable LOF phenotypes, especially in the case of certain 
enzymes, as residual activity might be sufficient to fulfill their cellular roles (Boutros et 
al., 2008). Importantly, using multiple siRNAs for the same target gene theoretically 
increases silencing from 70% to 95%. Although the concept of using such a pool of 
siRNAs (Figure 8c-d) is attractive for achieving a higher probability of strong silencing in 
fewer experimental samples, it assumes that the silencing performance of the pool is at 
least as good as the individual siRNAs (Figure 8a). In fact, when carefully optimized, such 
‘low-complexity siRNA pools’ (3-6 siRNA molecules per pool) generally perform better 
than the worst of their constituent siRNAs but not quite as well as the best, because 
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poorly performing siRNAs have been found to compete with better ones. For validation 
of hits, shRNA coding inserts cloned in expression vectors (Figure 8e) can be used to 
establish stable cell lines (Echeverri et al., 2006). Various read out options are available 
to investigate the phenotype of a cell after functional gene knockdown. Until recently, 
assays that are based on the use of plate readers like those using luminescent reporters 
were the most favored ones for cell-based screening due to their simplicity of workflow, 
their strong robustness, and generally high reproducibility (Echeverri et al., 2006; 
Boutros et al., 2008). In the case of selection-based RNAi screens using pooled libraries, 
fluorescent reporter-based assays enable fluorescence activated cell sorting FACS of 
treated cells, offering powerful read-outs. 
 
 
 
Figure 8: Silencing reagents for siRNA screens in mammalian cells (Echeverri et al., 2006). (a) siRNAs 
consist of a 19-bp duplex with 2-base overhangs at the 3´. (b) Synthetic siRNAs with non-canonical siRNA 
structures and/or a modified RNA backbone. (c) Low-complexity pools of <10 molecules that target the 
same transcript. (d) High-complexity pools of siRNA-like molecules can be synthesized by in vitro digestion 
of long dsRNAs and reveal endoribonuclase cleaved siRNAs (esiRNAs). (e) Vector-based library reagents, 
expressing short hairpin RNA (shRNA) constructs, are delivered virally. (f) A new vector design offers an 
RNase II- or RNase III-driven shRNA insert within a backbone from a known miRNA, producing ‘shRNAmiRs’ 
that enter the RNAi pathway as pri-miRNAs (primary miRNA), upstream from conventional shRNAs. 
Esi=endonuclease cleaved siRNA; CDS=coding sequence. 
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1.10 Aim of the work 
The aim of the present work was to identify and functionally characterize genes with 
oncogenic potential in recurrently gained chromosomal regions of MCL and CLL (3q25-
q29, 12q13-q14 and 18q21-q22). Profiling of MCL and CLL genomes and transcriptomes 
on array CGH and expression array platforms are methods of choice to reveal a focused 
set of overexpressed candidate genes located in the respective chromosomal regions. 
Antagonization of upregulated genes can be successfully achieved in a loss-of-function 
assay. A transient RNAi screen and subsequent functional analyses proving changes in 
cell viability are versataile approaches to uncover those genes with survival stimulating 
effects on MCL or CLL. Moreover, tumor model cell lines with stable gene knockdown, 
achieved for example by RMCE, can give even stronger evidence of the candidate gene´s 
role in the pathogenesis of MCL and CLL. Reporter-gene assays and genome wide 
expression profiling studies following overexpression and silencing of a candidate gene, 
can give detailled insights into its involvement in cell survival and cell proliferation 
pathways. Since genes identified through this approach promote tumor cell 
proliferation, the respective candiates are possible targets for diagnosis and anti-cancer 
therapies. 
 
  
20 
 
 
Material 
 
21 
 
2 Material and Methods 
2.1 Material 
2.1.1 Chemicals and biochemicals 
Chemicals Supplier 
2-mercaptoethanol (thioethylene glycol) Sigma-Aldrich, Munich, Germany 
2-Propanol (Isopropanol)  Merck, Darmstadt, Germany 
α-Thioglycerol Sigma-Aldrich, Munich, Germany 
Acrylamide / Bis-Acrylamide (30% w/v) Merck, Darmstadt, Germany 
Acetic acid  Roth, Karlsruhe, Germany 
Agarose Sigma-Aldrich, Munich, Germany 
Ammonium Persulphate (APS) Sigma-Aldrich, Munich, Germany 
Ammonium acetate solution 7.5 M Sigma-Aldrich, Munich, Germany 
Ampicillin Roche Diagnostics, Mannheim, Germany 
Bacto Agar Difco Laboratories Inc, Detroit, USA  
Bacto Tryptone Difco Laboratories Inc, Detroit, USA 
Bacto Yeast Extract Difco Laboratories Inc, Detroit, USA 
Bathocuproinedisulfonic acid disodium salt (BCS) Sigma-Aldrich, Munich, Germany 
Bicinchoninic acid (BCA)  Sigma-Aldrich, Munich, Germany 
Bromphenoleblue AppliChem GmbH, Darmstadt, Germany 
Bovine serum albumine (BSA) Sigma-Aldrich, Munich, Germany 
Complete EDTA-free protease inhibitor cocktail  Roche Diagnostics, Mannheim, Germany 
Copper-(III)-sulfate  Sigma-Aldrich, Munich, Germany 
Chloroform  Merck, Darmstadt, Germany 
DEPC treated water Ambion, Austin, USA 
Dithriotheital (DTT) Sigma-Aldrich, Munich, Germany 
Ethylenediaminetetraacetic acid (EDTA)  Merck, Darmstadt, Germany 
Dimethylsulfoxid (DMSO) Sigma-Aldrich, Munich, Germany 
Ethanol  Merck, Darmstadt, Germany 
Ethidium bromide Sigma-Aldrich, Munich, Germany 
Ficoll 400  Biochrom AG, Berlin, Germany 
Formamide   Merck, Darmstadt, Germany 
Glycerine  Roth, Karlsruhe, Germany 
Glycine  Roth, Karlsruhe, Germany 
Hepes  Sigma-Aldrich, Munich, Germany 
Hydrochloride acid (HCl) Merck, Darmstadt, Germany 
Isoamylalcohol  Merck, Darmstadt, Germany 
Maleic acid Sigma-Aldrich, Munich, Germany 
Magnesium chloride Merck, Darmstadt, Germany 
Methanol Merck, Darmstadt, Germany 
Milk powder  Sigma-Aldrich, Munich, Germany 
N-Lauroylsarcosine sodium salt Sigma-Aldrich, Munich, Germany 
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Chemicals Supplier 
Nuclease free water Ambion, Austin, USA 
Paraformaldehyde  Sigma-Aldrich, Munich, Germany 
Pepsin  Sigma-Aldrich, Munich, Germany 
Phenol  Roth, Karlsruhe, Germany 
Potassium chloride (KCl) Sigma-Aldrich, Munich, Germany 
Potassium dihydrogen phosphate (KH2PO4)  Carl Roth, Karlsruhe, Germany 
Sephadex-G50 Sigma-Aldrich, Munich, Germany 
SOC medium Invitrogen, Karlsruhe, Germany 
Sodium acetate (NaAc)  Merck, Darmstadt, Germany 
Sodium chloride (NaCl)  Merck, Darmstadt, Germany 
Sodium citrate  Merck, Darmstadt, Germany 
Sodium dodecyl sulfate (SDS) Carl Roth, Karlsruhe, Germany 
Sodium hydrogen phosphate (Na2HPO4)  Sigma-Aldrich, Munich, Germany 
Sodium hydroxide (NaOH)  Merck, Darmstadt, Germany 
Sodium pyruvate Gibco BRL, Invitrogen, Karlsruhe, Germany 
TEMED  Bio-Rad Laboratories, Munich, Germany 
Tricine  Carl Roth, Karlsruhe, Germany 
Tris-Base  Sigma-Aldrich, Munich, Germany 
Triton X-100 Sigma-Aldrich, Munich, Germany 
Trizol reagent Invitrogen, Karlsruhe, Germany 
Tween-20  Sigma-Aldrich, Munich, Germany 
Xylencyanol Sigma-Aldrich, Munich, Germany 
2.1.2 Enzymes 
Restriction Enzymes Supplier 
BamHI (50 U/µl) New England Biolabs, Frankfurt aM,  Germany 
BglII (50 U/µl) New England Biolabs, Frankfurt aM,  Germany 
EcoRI (50 U/µl) New England Biolabs, Frankfurt aM,  Germany 
HindIII (50 U/µl) New England Biolabs, Frankfurt aM,  Germany 
NcoI (50 U/µl) New England Biolabs, Frankfurt aM,  Germany 
NotI (50 U/µl) New England Biolabs, Frankfurt aM,  Germany 
ScaI (50 U/µl) New England Biolabs, Frankfurt aM,  Germany 
 
 
Enzymes Supplier 
Bca DNA Polymerase (2 U/μL) Takara Bio Europe, Madion, USA 
DNAseI (10 U/µl) Roche Diagnostics, Mannheim, Germany 
EuroTaq (5 U/µl) EuroClone, Siziano, Italy 
SuperScript II reverse transcriptase (200 U/µl) Invitrogen, Karlsruhe, Germany 
T4 DNA Ligase (200 U/µl) New England Biolabs, Frankfurt aM,  Germany 
T4 Polynucleotide Kinase (1 U/µl) New England Biolabs, Frankfurt aM,  Germany 
T4 DNA Polymerase (3 U/µl) New England Biolabs, Frankfurt aM,  Germany 
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2.1.3 Kits 
Kit Supplier 
All Prep RNA Protein Kit Qiagen, Hilden, Germany 
ABsolute™ QPCR SYBR® Green ROX mix ABgene, Epsome, UK 
B-cell Isolation Kit II, untouched isolation Miltenyi Biotech, Berglisch Gladbach, Germany 
Big Dye Terminator Sequencing Kit Applied Biosystems, Forster City, USA 
CellTiter-Glo® Luminescent Cell Viability Assay Promega, Karlsruhe, Germany 
Caspase-Glo® 3/7 Assay Systems Promega, Karlsruhe, Germany 
Dual-Glo-Luciferase Assay System Promega, Karlsruhe, Germany 
ECL Western Blot Detection Kit GE Healthcare Europe GmbH, Freiburg, Germany 
ECL + Western Blot Detection Kit GE Healthcare Europe GmbH, Freiburg, Germany 
EndoFree Plasmid Maxi Kit  Qiagen, Hilden, Germany 
MicroRNeasy Kit Qiagen, Hilden, Germany 
Qiagen DNA Gel Extraction Kit Qiagen, Hilden, Germany 
Qiagen DNA Purification Kit Qiagen, Hilden, Germany 
Qiagen Plasmid Purification Kit Qiagen, Hilden, Germany 
RNeasy Mini Kit Qiagen, Hilden, Germany 
2.1.4 Other materials 
Name Supplier 
3MM Paper Whatman, Dassel, Germany 
ABI PRISM™ optical adhesive covers Applied Biosystems, Forster City, USA 
Adenosine 5´Triphosphate (ATP) New England Biolabs, Frankfurt aM,  Germany 
Anti-Digoxigenin-AP, Fab fragments Roche Diagnostics Mannheim, Germany 
Blocking reagent Roche Diagnostics Mannheim, Germany 
CotI human DNA Roche Diagnostics Mannheim, Germany 
CDP Star Roche Diagnostics Mannheim, Germany 
Deoxynucleotide (dNTP) set  Amersham Bioscience, Freiburg, Germany 
DNA mass standard (1 kB DNA ladder) Invitrogen, Karlsruhe, Germany 
DNA mass standard (smart ladder) Eurogentec, Seraing, Belgium 
DIG High Prime Roche Diagnostics Mannheim, Germany 
Hering sperm DNA solution Invitrogen, Karlsruhe, Germany 
FalconTM 50 ml conical tubes BD Biosciences, San Jose, USA 
FalconTM 15 ml conical tubes BD Biosciences, San Jose, USA 
Human genomic DNA (standard) Roche Diagnostics Mannheim, Germany 
Hyperfilm ECL GE Healthcare Europe GmbH, Freiburg, Germany 
Hybond N+ nylon membrane GE Healthcare Europe GmbH, Freiburg, Germany 
ImmobilinTM -P- PVDF membrane Millipore, Schwalbach, Germany 
Intensification screen Dr.Goos-Suprema, Heidelberg, Germany 
Lumi film chemiluminescent Roche Diagnostics Mannheim, Germany 
MACS® cell separation columns Milentyi Biotech, Bergisch Gladbach, Germany 
Midi MACS
TM
 separator Milentyi Biotech, Bergisch Gladbach, Germany 
Microcentrifuge tubes, PCR, clean, 0.5 ml Eppendorf, Hamburg, Germany 
Microcentrifuge tubes, PCR, clean, 1.5 ml Eppendorf, Hamburg, Germany 
Microcentrifuge tubes, PCR, clean, 2.0 ml Eppendorf, Hamburg, Germany 
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Name Supplier 
Microcon YM-100 centrifugal filter devices Millipore, Schwalbach, Germany 
Microcon YM-30 centrifugal filter devices Millipore, Schwalbach, Germany 
MicroAmp plates, optical 384-well reaction plate PE Applied Biosystems, Weiterstadt, Germany 
Millex-LCR filter, 0.45 µm, 25 mm, non-sterile Millipore, Schwalbach, Germany 
PCR tubes, 0.2 ml Molecular Bioproducts, Dan Diego, USA 
Propidium iodide BD Bioscience, Heidelberg, Germany 
Random hexamer primers  Invitrogen, Karlsruhe, Germany 
Rnase Out Invitrogen, Karlsruhe, Germany 
RNAse ZAP Ambion, Austin, USA 
Salmon sperm DNA Invitrogen, Karlsruhe, Germany 
Second strand buffer for SSII cDNA synhesis Invitrogen, Karlsruhe, Germany 
T4 gene 32 protein Roche Diagnostics Mannheim, Germany 
TNFα Calbiochem, Darmstadt, Germany 
Universal human reference RNA Stratagene, La Jolla, CA 
VECTASHIELD with DAPI Linaris, Wertheim-Bettingen, Germany 
X-ray cassette Dr. Goos-Suprema, Heidelberg, Germany 
 
Bacteria Supplier 
OneShot
R
 Top10 Electrocomp
TM
 E.coli Invitrogen, Karlsruhe, Germany 
 
2.1.5 Solutions 
2.1.5.1 Standard Solutions 
Standard Solutions Composition 
20x SSC 3M NaCl 
0.3 M Sodium citrate 
pH=7.0 
10x PBS 137 mM NaCl 
27 mM KCl 
100 mM NaH2PO4 
17 mM KH2PO4 
dissolve in ddH2O 
1x TBS-T 20 mM Tris-Base 
137 mM NaCl 
3.8 ml 1M HCl 
0.1% (v/v) Tween 20 
dissolve in 1l ddH20 
5x Loading buffer 100 mM EDTA 
30% (v/v) Glycerine 
0.25% (w/v) Bromophenolblue 
dissolve in ddH2O 
5x TBE 0.445M Tris-Borat , pH=8.0 
10mM EDTA, pH=8.0 
20% SDS 20% SDS (w/v) 
dissolve in ddH20 
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2.1.5.2 Medium and antibiotics 
Medium and antibiotics Composition 
LB medium 1% (w/v) Bacto-Trypton 
0.5% (w/v) Bacto-Yeast-Extract 
1% (w/v) NaCl 
in H2O  
adjust to pH=7.5 
S.O.C. Medium  2% Trypton 
0.5% Yeast Extract 
10 mM NaCl 
2.5 mM KCL 
10 mM MgCL2 
10 mM MgSO4 
20 mM Glucose 
Ampicillin Stock solution: 100 mg/ml  
in H2O 
sterile filtered and aliquoted, stored at -20°C 
working concentration: 100 µg/ml 
Chloramphenicol Stock solution: 34 mg/ ml  
in ethanol 
sterile filtered and aliquoted, stored at -20°C 
working concentration: 100 µg/ml 
Kanamycin Stock solution: 100 mg/ml  
in ethanol 
sterile filtered and aliquoted, stored at -20°C 
working concentration: 100 µg/ml 
2.1.5.3 Southern blot solutions 
Southern blot solutions Composition 
Denaturation Solution 0.5M NaOH 
1.5M NaCl 
Neutralization Solution 0.5 M TrisHCl 
1.5M NaCl 
Hybridisation buffer 5xSSC 
0.1% N-lauroylsarcosine 
0.02% SDS 
1% Blocking Solution 
Blocking Solution 10x 10 g Blocking Reagent 
100 ml ddH20 
Low Stingency Buffer 2x SSC 
0.1% SDS 
High Stingency Buffer 0.5x SSC 
0.1% SDS 
DIG I 0.1 M Maleic acid 
0.15M NaCl pH=7.5 
adjust to pH=7.5 using 5M NaOH  
DIG WASH DIG I  
0.3% Tween 20 
DIG II 10 ml 10x Blocking  
100 ml DIGI 
DIG III 0.1 M NaCl 
0.05M MgCl2 
adjust to pH 9.5 using 1M Tris-HCl pH=9.5  
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Southern blot solutions Composition 
Antibody Solution DIG-AB-FAB-Fragments (1:10.000) in DIG II 
CDP-Star solution CDP-Star 1:100 in DIG III 
2.1.5.4 Western blot solutions 
Western blot solutions Composition 
2x Laemmli buffer 50 mM Tris/HCl pH=8.0 
2.4% w/v SDS 
8% Glycerin 
0.2% w/v Bromphenol blue 
2.5% v/v β-Mercaptoethanol 
5x SDS-PAGE running buffer 25 mM Tris-Base 
200 mM Glycine 
10% (w/v) SDS 
ddH2O 
10x Western blot buffer 25 mM Tris-Base 
192 mM Glycin 
20% v/v Methanol (added when preparing 1x buffer) 
BSA- blocking buffer 3% BSA in PBS 
Milk-blocking buffer 10% Milk powder in TPBS-Tween (0.1%) 
APS 10% APS w/v in ddH20 
Stripping buffer 100 nM β-Mercaptoethanol 
2% SDS 
62.5 nM Tris-HCl, pH=6.7 
2.1.5.5 FISH solutions 
FISH solutions Composition 
Hypotonic buffer 3g KCL 
0.2 g EGTA 
4.8 g HEPES 
dilute in 1l H20 
adjust with KOH to pH=7.4 
Denaturation solution 49 ml Formamide  
7 ml 20x SSC  
14 ml ddH2O  
adjust to  pH=7.0 
Wash A 50% (v/v) Formamide pH=7.0 
30 ml 20x SSC 
120 ml ddH2O 
Wash B 0.5x SSC 
Wash C 0.1% (v/v) Tween 20 
4x SSC 
Blocking  3% (w/v) BSA 
4x SSC 
Detection 1% (w/v) BSA 
4x SSC 
DAPI 60 ml 2x SSC, pH 7.0 
45 μl DAPI 
Column buffer 
for Sephadex columns 
10 mM Tris-HCl pH 8.0 
1 mM EDTA pH 8.0 
0.1% (w/v) SDS 
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2.1.6 siRNA sequences  
siRNA Sense Sequence (5´ 3´) Supplier ID 
CCDC50#1 GCUGGCUAUUGAGGCAGAGtt Ambion 199977 
CCDC50#2 GGAUGAGGACAUAGCUCGCtt Ambion 129978 
CCDC50#3 CCUCUAUGCUGCAUAUACUtt Ambion 129979 
siCONTROL Non-
Targeting siRNA 
Pool #2 
siRNA#1: AUGAACGUGAAUUGCUCAA 
siRNA#2: UAAGGCUAUGAAGAGAUAC 
siRNA#3: AUGUAUUGGCCUGUAUUAG 
siRNA#4: UAGCGACUAAACACAUCAA 
Dharmacon D-001206-14-05 
ON-TARGET plus  
siCONTROL Non-
targeting Pool 
siRNA#1: UGGUUUACAUGUCGACUAA 
siRNA#2: UGGUUUACAUGUUGUGUG 
siRNA#3: UGGUUUACAUGUUUUCUGA 
siRNA#4: UGGUUUACAUGUUUUCCUA 
Dharmacon D-001810-10-05 
Silencer Firefly  
Luc GL2/3 
n/a Ambion AM4629 
Silencer 
Negative  
Control #1 
n/a Ambion AM4611 
PLK1 Pool Pool PLK1_6: CCGGATCAAGAAGAATGAATA 
PLK1_7: CGCGGGCAAGATTGTGCCTTAA 
PLK1_11: AACGAGCTGCTTAATGACGAG 
PLK1_2: CAACGGCAGCGTGCAGATCAA 
Qiagen SI 02223837 
SI 02223844 
SI 04376365 
SI 00071624 
DUSP5 Pool DUSP5_14: CAAGTGAGCGTTCCTCGCCAA 
DUSP5_9: CGCGACCCACCTACACTACAA 
DUSP5_10: ATGAGTGTTGAGTGGATGTAA 
DUSP5_13: CTGCATGGCTTACCTTATGAA 
Qiagen SI 04345124 
SI 03194282 
SI 03206903 
SI 04228700 
KIF11 Pool KIF11_7: GAAGATAAGATAGAAGATCAA 
KIF11_8: CTCGGAAGCTGGAAATATAA 
KIF11_6: ACGGAGGAGATAGTTCGTTTA 
KIF11_12: CAGGAATTGATTAATGTACTC 
Qiagen SI 02653770 
SI 03019793 
SI 02653693 
SI 04376358 
BCL2 Pool BCL2_12: AACCGGGAGATGGTGATGAAG 
BCL2_9: TCCATTATAAGCTGTCGCAGA 
BCL2_10: AAGTTCGGTGGGTCATGTGT 
BCL2_11: AACTGGGGGAGGATTGTGGCC 
Qiagen SI 00299418 
SI 00299397 
SI00299404 
SI 00299411 
CCND1 Pool CCND1_5: AACACCAGCTCCTGTGCTGCG 
CCND1_6: GCCCTCGGTGTCCTACTTCAA 
CCND1_1: AAGGCCAGTATGATTTATAAA 
CCND1_2: ATGCATGTAGTCACTTTATAA 
Qiagen SI 02654540 
SI 02654547 
SI 00147812 
SI 00147819 
All Stars 
Negative Control 
n/a Qiagen 1027280 
All Stars Cell 
Death Control 
n/a Qiagen 1027298 
ARHGAP9 CGGUUAGAUUUGGACAGUATT Ambion S34646 
Ctrl_control_1 AATTCTCCGAACGTGTCACGT Qiagen SI 03650325 
Ctrl_AllStars_1 n/a Qiagen SI 03650318 
siGLO Risc Free n/a Dharmacon D-001600-01-20 
n/a=no sequence available 
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2.1.7 Vectors 
Vector Supplier 
pSUPER R. Agami, The Netherlands Cancer Institute, Amsterdam, NL 
pSUPERdL Pscherer et al., 2006 
pCMV6-XL4-CCDC50 OriGene Technologies Inc, Rockville, USA 
pCMX_h-Cre E. Greiner (DKFZ Heidelberg) with approval of F. Stewart (Desden) 
pTER H. Clevers, Netherlands Institure for Developmental Biology, NL 
pGKneo E.Greiner (DKFZ Heidelberg) with approval of F. Stewart (Desden) 
pGKP511TkneoP Pscherer et al., 2006 
pCMV-Renilla Luciferase Dr. Mathas, Prof. Doerken, Max-Delbrueck Center in Berlin 
p-6xNFKB-Firefly-luciferase Dr. Mathas, Prof. Doerken, Max-Delbrueck Center in Berlin 
2.1.8 Primers 
2.1.8.1 Primer for PCR, sequencing, and cloning 
Primer Sequence (5´  3´) 
castestLPr CGCCAAGCTGGCGCGGGATAACT 
castestf GTGCCACCTGACGTCTAAGAAAC 
pSUPER-intern_fw TGCGCCCTGGCAGGAAGAT 
pSUPER-intern_rev AGCGAGTCAGTGAGCGAGGAA 
pSUPER-up CCATTCAGGCTGCGCAACTGTT 
petra3_rev CGAAGAACTCCAGCATGAGATCCC 
pGKSacRf  GCT GGAGTTCTTCGCCGTTTC 
P511OKrev2 TTCCATTGCTCAGAGGTGCTGT 
sh_CCDC50_fw GATCCCCCCTCTATGCTGCATATACTTTCAAGAGAAGTATATGCAGCATAGA
GGTTTTTGGAAA 
sh_CCDC50_rev AGCTTTTCCAAAAACCTCTATGCTGCATATACTTCTCTTGAAAGTATATGCAG
CATAGAGGGGG 
sh_Luciferase_for GATCCCCCTTACGCTGAGTACTTCGATTCAAGAGATCGAAGTACTCAGCGTA
AGTTTTTGGAAA 
sh_Luciferase_rev AGCTTTTCCAAAAACTTACGCTGAGTACTTCGATCTCTTGAAGTATATGCAGC
ATAGAGGGGG 
TKneo-BglII_fw CGTTCTCGCGGCCATAGCAA 
TKneo-NcoI_rev AACACGGCGGCATCAGAGCA 
NotI_pTER_fw CGATTGCGGCCGCTGATTTAAC 
BamHI_pTER_rev CGGAGGATCCAAGCTCTAGCTA 
T7_fw TAATACGACTCACTATAGGG 
M13_rev TTTCACACAGGAAACAGCTATGAC 
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2.1.8.2 Primer for quantitative real-time PCR 
qRT-PCR Primer 
Forward Sequence 
(5´ 3´) 
Reverse Sequence 
(5´ 3´) 
ACTL6A TCTGTCAGTTTCTCTCTCTTTGCTC AGAAGTGGTTGCAGTGCTGA 
APOD GGAAGTGCCCCAATCCTC TTCGTACCATCTTCCGAGATACT 
ARHGAP9 CCAACCATGACACTCTACGG TGCGATTCTTATCTGAGTGTGC 
DCTN2 ACTAGCGACCTACCTGAGGA TCATAGGCAGCATTAGGATTGAC 
DDIT3 CAGAGCTGGAACCTGAGGAG CTGCAGTTGGATCAGTCTGG 
CCDC50 TGACCGGGAAGCCCGCGTTAAAGG TTCCTGCAGGCTGTGAGCCAGGGT 
ECT2 CTCTAGGTGAGCACCCCTGT TGTGCCGTTTTCTTGCTATCT 
IL8 AGACAGCAGAGCACACAAGC ATGGTTCCTTCCGGTGGT 
ITGB7 CAGTTGGGGAGCTGAGTGAG CACGGTGGAAGACAGGCTAT 
YEATS2 ACGGAGTGTGTCGTTCAGC AAATGCATGTCAAATCAGAAGC 
LaminB1 CTGGAAATGTTTGCATCGAAGA GCCTCCCATTGGTTGATCC 
MALT1 TTGAATTCAGCCAGTGGTCA GAGACGCCATCAACACTTCTC 
PAK2 AAGGGGTTCAGCCAAAGAAT TCCATGACCACAAACAATTCA 
PFN2 AGGTGGGGAGCCAACATAC CACCTTCCTTTCCCATGACTA 
RHEBL1 TCTCTGAGCCCGCAGTTC CACAAATTGATGTGCCAAAGA 
RKHD2 TTGGGAGTGATCCTTCTGGT AGGAGACAGACGAGGAGTAGATG 
TIMELESS AATTCGCCAGAAGGTTTCCT AATTCGCCAGAAGGTTTCCT 
TNFAIP3 TGCACACTGTGTTTCATCGAG ACGCTGTGGGACTGACTTTC 
2.1.9 Antibodies 
2.1.9.1 Southern blot antibodies 
Name Blocking Solution Dilution Supplier 
DIG-AB-FAB-Fragments In DIG II 1:10000 Roche, Mannheim, Germany 
2.1.9.2 Western blot antibodies 
AB Name 
Produced 
in 
Blocking 
Solution Dilution Supplier 
1° Anti-CCDC50-
Antibody 
rabbit 3% BSA-PBS 1:800 Sigma-Aldrich, Munich, 
Germany 
1° Anti-GAPDH- 
Antibody 
mouse 5% Milk-TBST 1:5000 Calbiochem, Darmstadt, 
Germany 
2° Anti-mouse IgG, 
HRP-linked 
Antibody 
 5% Milk-TBST 1:5000 Cell Signaling Inc., Danvers, 
USA  
2° Anti-rabbit IgG, 
HRP-linked 
Antibody 
 5% Milk-TBST 1:2000 Cell Signaling Inc., Danvers, 
USA 
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2.1.9.3 FACS antibodies 
Name Supplier 
CD19-PE antibody, clone LT19 Miltenyi Biotech, Bergisch Gladbach, Germany 
CD20-PE antibody, clone LT20 Miltenyi Biotech, Bergisch Gladbach, Germany 
Mouse IgG1 antibody Miltenyi Biotech, Bergisch Gladbach, Germany 
2.1.10 Cell culture 
2.1.10.1 Cell lines 
Cell line No Supplier 
CA-46 ACC 73 DSMZ, Braunschweig, Germany 
DG-75 ACC 83 DSMZ, Braunschweig, Germany 
EHEB ACC 67 DSMZ, Braunschweig, Germany 
GRANTA-519 ACC 342 DSMZ, Braunschweig, Germany 
HEK-293T CRL-1573 ATCC, Manassas, VA, USA 
HS5 CRL11882 ATCC, Manassas, VA, USA 
HT ACC 567 DSMZ, Braunschweig, Germany 
JEKO-1 ACC 553 DSMZ, Braunschweig, Germany 
JVM-2 ACC 12 DSMZ, Braunschweig, Germany 
L428 ACC 197 DSMZ, Braunschweig, Germany 
L540 ACC 72 DSMZ, Braunschweig, Germany 
LCL-WEI ACC 218 DSMZ, Braunschweig, Germany 
MEC-1 ACC 497 DSMZ, Braunschweig, Germany 
MEC-2 ACC 500 DSMZ, Braunschweig, Germany 
MC-116 AC 82 DSMZ, Braunschweig, Germany 
RAJI ACC 319 DSMZ, Braunschweig, Germany 
RAMOS ACC 603 DSMZ, Braunschweig, Germany 
SUDHL-5 ACC 571 DSMZ, Braunschweig, Germany 
SUDHL-6 ACC 572 DSMZ, Braunschweig, Germany 
2.1.10.2 Transfection reagents 
  
Transfection Reagents Supplier 
Cell Line Nucleofector Kit V Lonza, Cologne, Germany 
Cell Line Nucleofector Kit T Lonza, Cologne, Germany 
Cell Line Optimization 96-well Nucleofector Kit Lonza, Cologne, Germany 
Cell Line 96-well Nucleofector Kit SF Lonza, Cologne, Germany 
DarmaFECT
TM
 1 siRNA transfection reagent Dharmacon, Chicago, USA 
Geneporter Genlantis, San Diego, USA 
HiPerfect Qiagen, Hilden, Germany 
Oligofectamine
TM
 Invitrogen, Karlsruhe, Germany 
Primary B-cell Nucleofector Kit Lonza, Cologne, Germany 
RNAiFECT Qiagen, Hilden, Germany 
TransIT Mirus Bio LLC, Madison, USA 
X-tremeGENE Roche Diagnostics, Mannheim, Germany 
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2.1.10.3 Cell culture solutions 
2.1.11 Tumor samples  
2.1.11.1 MCL samples used for expression profiling 
MCL Patient Sex 
Age 
at Dx 
Follow-up 
(months) State  Therapy 
FISH on 
3q27 Leukemic MP 
W-7466/02 M 39 22.9 0 CHOP n.a. ? C 
W-16866/98 M 70 81.1 0 CHOP-like Gain No C 
W-19656/01 M 52 39.3 0 Unknown Gain ? C 
W-2039/99 M 78 36.6 1 Unknown Gain ? C 
W-28663/01 M 55 15.3 1 CHOP-like Normal ? C 
W-H2568/97 M 56 94.2 0 intensified normal No C 
MCL patient: W=derived from A. Rosenwald, Würzburg; Dx=age at diagnosis; sex: M= Male; state: 0=alive, 
1=dead; therapy: CHOP=Cyclophosphamid, Hydroxydaunorubicin (Doxorubicin), Vincristin (Oncovin), 
Predniso(lo)n); leukemic: No=not leukemic, ?=not investigated; MP=Morphology: C=Classical. All primary 
samples were derived from lymph nodes.  
 
2.1.11.2 MCL samples used for qRT-PCR experiments 
MCL Patient Sex 
Age at 
Dx 
Follow-up 
(months) State  Therapy 
Derived 
from 
FISH on 
3q27 MP 
W-15586/99 M 61 12.9 1 CHOP LN Normal C 
W-C2039/99 M 78 36.6 1 n.a. LN  n.a. C 
W-28663/01 M 55 15.3 1 CHOP LN Normal C 
W-7466/02 M 39 22.9 0 CHOP LN n.a. C 
W-16866/98 M 78 81.1 0 CHOP LN gain C 
W-19656/01 M 52 39.3 0 n.a. LN gain C 
K-1363/04 M 75 n.a. n.a. n.a. LN n.a. n.a. 
K-184/92 M 75 n.a. n.a. n.a. LN n.a. n.a. 
K-1646/05   F 46 n.a. n.a. n.a. BM n.a. n.a. 
MCL patient: W=derived from A. Rosenwald, Würzburg, K=derived from R. Siebert, Kiel;  Dx=age at 
diagnosis; sex: M=Male, F=Female; state: 0=alive, 1=dead; therapy: CHOP=Cyclophosphamid, 
Hydroxydaunorubicin (Doxorubicin), Vincristin (Oncovin), Predniso(lo)n); Derived from: LN=lymph node, 
BM=bone marrow; MP=Morphology: C=Classical.  
  
Product Supplier 
Dulbecco´s Modified Eagle Medium Gibco BRL, Invitrogen, Karlsruhe, Germany 
FCS (fetal cow serum) Biochrom, Berlin, Germany 
Ganciclovir Sigma-Aldrich, Munich, Germany 
L-Glutamin Gibco BRL, Invitrogen, Karlsruhe, Germany 
Penicillin-Steptomycin (1000 U/ml) Gibco BRL, Invitrogen, Karlsruhe, Germany 
RPMI 1640 Gibco BRL, Invitrogen, Karlsruhe, Germany 
Geneticin (G418) Invitrogen, Karlsruhe, Germany 
Zeocin Invitrogen, Karlsruhe, Germany 
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2.1.11.3 CLL samples used for expression profiling 
CLL  Sex CD19+ FISH VH status VH-Gen gl 
17-1 M  n.a.  17p- n.a.  n.a.  
17-2 M  n.a. 17p- n.a. n.a. 
17-11 F   n.a. 17p-  n.a.  n.a. 
17-15 F  n.a.  17p- n.a.  n.a.  
13-1 I M  n.a. 13q- n.a. n.a. 
13-1, II M   n.a. 13q-  n.a.  n.a. 
13-2 F   n.a. 13q-  n.a.  n.a. 
12 M 96% 13q- mutated/Ther V3-72  
14 F  n.a. Normal unmutated V1-02 
16 F 77% 13q- unmutated V1-69 
34 M  66% 12q+ unmutated/C V4-39 
25 M   n.a. 13q unmutated/C/Ther V4-b 
36 M   n.a. 13q- mutated V1-69 
40 M  87.50% 13q- mutated V3-07 
17-8 M  n.a.  17p- (94%) n.a.   V7-4.1 
17-10 F n.a. 17p- (83%), 13q- (30%) n.a. V3-53 
17-12 M   n.a. 17p- (78%), 6q- (71%)  n.a.  V1-03 
17-14 F n.a. 17p- (95%), 13q- (95%) n.a. V1-69 
12-1 F n.a. 12q (84%) n.a. V3-33 
12-2 F n.a.  12q (82%) n.a.  V4-39 
12-3 M  n.a.  12q (80%), 13q- (87%) n.a.  V5-51 
12-8 M  n.a. 12q (81%) n.a.  V3-30/3-30.5 
Sex: F=Female, M=Male, n.a.=no additional information / value not determined, source: H. Döhner and S. 
Stilgenbauer, University hospital, Ulm, Number of tumors is anonymous and assigned by M. Seiffert, DKFZ 
Heidelberg and H. Döhner and S. Stilgenbauer, University hospital, Ulm. 
 
2.1.11.4 CLL samples used for qRT-PCR experiments 
CLL  Sex CD19+ FISH VH status VH-Gen gl 
5 M 84%  normal unmuated 100% V3-11 
6 M 80%  13q- mutated 92% V3-43 (of+stop) 
7 M 80% Normal mutated 94,06% V4-34 
9 F 70% 13q- mutated 91,78% V3-72 
11 M n.a. 13q- unmutated 99,21% V2-70 
12 M 96% 13q- mutated 96,1% V3-72 
14 F n.a. Normal unmutated 98,3% V1-02 
15 M n.a. 13q- mutated 90,99% V3-23 
16 F 77% 13q- unmutated 100% V1-69 
18 M 89% 13q- mutated V4-39 
19 M 78% 13q- mutated V5-51 
21 M 61% n.a unmutated V1-02 
22 F 91% 11q- unmutated/C/Ther V1-02 
25 M n.a. 13q- unmutated V4-b 
26 M 92% 13q- unmutated V3-30 
28 F 93% 13q- mutated V4-34 
29 M 89% 13q- mutated V1-69 
30 F 71% n.a. n.a. n.a. 
32 M 90% n.a. mutated V4-39 
34 M 66% 12q+ unmutated V4-39 
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CLL  Sex CD19+ FISH VH status VH-Gen gl 
37 M 78% 13q- mutated/A V5-51 
39 M 98% 13q- unmutated V4-b 
40 M 87.5% 13q- mutated V3-07 
41 M n.a. 13q- mutated/Ther V3-72 
48 F n.a. n.a. mutated/A/Ther V1-18 
50 M n.a. 13q- n.a. n.a. 
51 M n.a. 13q- mutated/Ther V3-72 
63 M n.a. 13q- mutated n.a 
Sex: F=Female, M=Male, n.a.=no additional information / value not determined, source: H. Döhner and S. 
Stilgenbauer, Ulm, Number of tumors is anonymous and assigned by M. Seiffert, DKFZ Heidelberg and H. 
Döhner and S. Stilgenbauer, University hospital, Ulm. 
2.1.12 Instruments 
Instrument Supplier 
7900 HT Fast Real Time PCR Systems Applied Biosystems, Forster City, USA 
ABI PRISM 3100 Genetic Analyzer, 16 Capillary 
DNA Sequencer 
Applied Biosystems, Forster City, USA 
ABI PRISM 7900 Sequence Detection System Applied Biosystems, Forster City, USA 
Agilent DNA microarray scanner Agilent Technologies, Palo Alto, USA 
Automatic developing machine Amersham, Freiburg, Germany 
Axioplan microscope Carl Zeiss, Jena, Garmany 
Balance BL 610 und BL150S Sartorius AG, Goettingen, Germany 
BD FACSArray™ Bioanalyzer System BD Biosciences, San Jose, USA 
BD FACSCanto II workstation BD Biosciences, San Jose, USA 
BD FACSCalibur workstation BD Biosciences, San Jose, USA 
Biofuge fresco refrigerated tabletop cantrifuge Heraeus / Kendro, Hanau, Germany 
Centrifuge 5810 R Eppendorf, Hamburg, Germany 
EAS gel documentation system Herolab, Wiesloch, Germany 
GS 6, GS 6KR, Centrifuge Beckmann, Wiesloch, Germany 
GSA- and SS34-Rotor DuPont, Boston, USA 
Gel electrophoresis power supply E-C Apparatus Corporation, USA 
Heating block QBT2 Grant Instruments/CLF, Emersacker 
HMT 702 C Microwave oven Robert Bosch GmbH, Stuttgart, Germany 
Hybridization incubator Bachofer GmbH, Reutlingen, Germany 
LB-940 Mithras Multilabel Reader Berthold Technologies, Bad Wildbach, Germany 
Mastercycler PCR-Maschine Eppendorf, Cologne, Germany 
Micro-centrifuge NeoLab Laborbedarf, Heidelberg 
Mini-Protean 3 gel and electrophoresis system  Bio-Rad Laboratories, Munich, Germany 
Multifuge 3 SR Heraeus / Kendro, Hanau, Germany 
NanoDrop ND-1000 Spectrophotometer  NanoDrop Technologies, San Diego, USA 
Nucleofactor device Lonza, Cologne, Germany 
96-well-Shuttle Nucleofection System Lonza, Cologne, Germany 
SDS-PAGE gel apparatus Biorad Laboratories, Munich, Germany 
Speedvac concentrator apparatus Eppendorf, Cologne, Germany 
Thermomixer compact Eppendorf, Cologne, Germany 
Unimax 1010 Shaker Heidolph Instruments, Schwabach, Germany 
UV-Stratalinker 1800 Stratagene,  La Jolla, CA 
Varifuge 3.0/3.0R Labor centrifuge Heraeus / Kendro, Hanau, Germany 
Waterbath SW22 Julabo Labortechnik, Seelbach, Germany 
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2.1.13  Software 
 
 
Software Supplier 
BD FACS Diva BD Biosciences, San Jose, USA 
CellQuest Pro
TM
 BD Biosciences, San Jose, USA 
Excel 2007 Microsoft, Redmond, USA 
Fast PCR 5.4 Professional Institute of Biotechnology, Helsinki, FL 
Multiple Experiment Viewer TM4, Boston, USA   
SDS 2.0 Applied Biosystems, Forster City, USA 
MikroWin 2000  Berthold Technologies, Bad Wildbach, Germany 
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2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Cultivation of cell lines 
Cells were obtained from the DSMZ (Braunschweig, Germany). GRANTA-519 (ACC 342), 
MEC-1 (ACC 497) and MEC-2 (ACC 500) cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM, Invitrogen, Karlsruhe, Germany). CA-46 (ACC 73), DG-75 (ACC 
83), EHEB (ACC 67), HT (ACC 567), JEKO-1 (ACC 553), JVM-2 (ACC 12), L428 (ACC 197), 
L540 (ACC 72), LCL-WEI (ACC 218), MC-116 (AC 82), RAJI (ACC 319), RAMOS (ACC 603), 
SUDHL-5 (ACC 571) and SUDHL-6 (ACC 572) cells were cultured in RPMI 1640 medium 
(Invitrogen) supplemented with 2 mM L-glutamine (Invitrogen, Carlsbad, CA). Both 
media were supplemented with 10%-20% fetal calf serum (according to the instructions 
of the DSMZ) and 100 mg/ml penicillin/streptomycin. Cells were cultured at 37°C in a 5% 
CO2 humidified incubator. The human bone marrow stroma cell line HS-5 was purchased 
from the American Type Culture Collection (Manassas, VA, USA). HS-5 cells were 
maintained in DMEM supplemented with 10% FCS, 4mM L-glutamine, 4.5 g/l glucose, 
100 U/ml penicillin and 100 mg/ml streptomycin. Cells were cultured at 37°C in a 10% 
CO2 humidified incubator. 
2.2.1.2 Isolation of lymphocytes from whole blood 
Human lymphocytes were isolated from peripheral blood by density centrifugation using 
a step gradient consisting of a mixture of the carbohydrate polymer Ficoll and the 
density iodine-containing compound metrizamide. This yields a population of 
mononuclear cells (lymphocytes) at the interface that has been depleted of red blood 
cells and most polymorophonuclear leukocytes and monocytes. Lymphocytes were 
isolated from whole blood using the Leucosep columns according to the manufacturer´s 
protocol (Greiner Bio-One, Frickenhausen, Germany).  
2.2.1.3 Cultivation of primary B-CLL cells 
Peripheral blood mononuclear cells were isolated by Ficoll density gradient from B-CLL 
patients. Thereafter, B-CLL preparations consisted of >80% CD19 positive cells as 
measured by fluorescent activated cell sorting and were used without further 
enrichment. Fractions of B-CLL cells were cryopreserved in cell culture medium 
containing 10% fetal calf serum and 10% dimethylsulfoxide. After thawing, B-CLL cells 
were cultured for 1 day with HS-5 stroma cell conditioned medium before experiments 
were performed. CD19 positive cells from healthy donors were enriched by magnetic 
bead-activated cell sorting using CD19-MicroBeads according to the manufacturer’s 
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instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). The purity of the CD19+ cell 
preparations was >95% as measured by flow cytometry. All cells were maintained in 
Dulbecco’s modified Eagle’s medium supplemented with 10% FCS, 4mM L-glutamine, 4.5 
g/l glucose, 100 U/ml penicillin, 100 mg/ml streptomycin, and were cultured at 37°C in a 
10% CO2 humidified incubator. For experiments with conditioned medium from HS-5 
cultures, the medium was removed from more than 70% confluent stromal cell layers, 
freed from cells by centrifugation for 10 minutes at 1000 g, sterile filtered through a 
Millipore 0.45 µM filter and added immediately to B-CLL cells in culture. For survival 
studies, lasting for several days, the conditioned medium was replaced daily. Primary 
cell samples were obtained from B-CLL and MCL patients and healthy donors after 
informed consent (University of Ulm, University of Kiel, and University of Würzburg). All 
MCL and B-CLL cases matched the standard diagnostic criteria according to the World 
Health Organization.  
2.2.2 Transfection methods 
2.2.2.1 Chemical transfection of cell lines 
Chemical transfections using TransIT, DarmaFECTTM1 siRNA transfection reagent 
(Dharmacon, Chicago, USA), OligofectamineTM (Invitrogen, Karlsruhe, Germany), 
RNAiFECT (Qiagen, Hilden, Germany), X-tremeGENE (Roche Diagnostics, Mannheim, 
Germany), HiPerfect (Qiagen, Hilden, Germany) and Geneporter (Genlantis, San Diego, 
USA) were performed according to the manufacturer´s instructions.  
2.2.2.2 Nucleofection of cell lines and primary CLL cells 
Transient transfections of cell lines were performed using the Nucleofector device 
(Lonza, Cologne, Germany) according to the manufacturer´s instructions with 2x106 cells 
and 2 µg plasmid DNA or 500nM siRNA (in 100 µl volume) and applying the following 
parameters: solution T, program O-017 (GRANTA-519, JVM-2 and JEKO-1) and solution 
V, program X-001 (EHEB, JVM-2, MEC-1, MEC-2). Cells were harvested at 24h, 48h and 
72h post transfection (p.t.) for isolation of RNA, protein or for functional assays. For 
transient transfections of primary CLL cells, a total of 5x106 primary B-cells were 
electroporated using program U-015 and the primary B-cell solution with 500nM siRNA 
(in 100 µl volume). After nucleofection, primary cells were added to sterile filtered HS-5 
conditioned media. Every 24h fresh HS-5 conditioned medium was added to the cells.  
Using the 96-well shuttle nucleofection, a total of 4x105 cells of the cell lines JVM-2 or 
GRANTA-519 and of primary CLL cells were transfected with 500nM siRNA (in 100 µl 
volume), solution SF with program 96-DN-100.  
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2.2.2.3 Stable transfection and Antioxidants  
Many cell lines are sensitive to growth at low cell density and undergo apoptosis 
induced by oxidative stress, if the cell density is decreased below a critical threshold 
(Brielmeier et al., 1998). In stable transfection experiments this cell density-dependent 
growth may be the limiting factor, since during drug selection the cell density drops 
below the critical threshold, precluding outgrowth of transfected clones. Therefore, 
0.1% -thioglycerol, 0.02 mM BCS and 1% sodium pyruvate were added to stable 
transfected cells. 2x106 JVM-2 cells were transfected with different concentrations of the 
vector pSUPERdL-Zeo_sh_CCDC50 (100ng, 200ng, 500ng, 1ug, 2ug and 5µg) using Lonza 
Solution T and program O-017. Cells were cultivated in medium containing antioxidants 
and zeocin (50 ng/ml). After four weeks of selection, stable cell clones grew out, while 
mock transfected cells died under the selection pressure.   
2.2.3 Molecular biological standard methods 
2.2.3.1 DNA isolation  
2x107 cells were harvested by centrifugation (1000 rpm, 10 min, RT) and DNA was 
isolated using the Blood & Cell Culture DNA Midi Kit (Qiagen, Hilden, Germany) 
according to the manufacturer´s protocol. Quantification of DNA samples was carried 
out on the Nanodrop device (Nanodrop Technologies, Wilmington, DE) set for DNA 
measurement (A260 / A280 ratio). 
2.2.3.2 Plasmid DNA isolation 
E.coli colonies containing the plasmid of interest were picked from LB-agar plates and 
grown for mini preps in 5 ml LB medium and for maxi-preps in 300 ml LB-medium 
containing the respective antibiotic over night at 37°C in a shaking incubator (200 rpm). 
Isolation of plasmid DNA was performed using the Plasmid Mini or Maxi Kit according to 
the manufacturer´s protocol (Qiagen, Hilden, Germany). 
2.2.3.3 RNA Isolation  
Total RNA was extracted using 2x106 cells. The cells were centrifuged for 10 minutes at 
1000 rpm at RT. The cell pellet was resuspended in 1 ml TRIZOL reagent (Invitrogen), 
incubated for 5 minutes at RT, then 300 µl chloroform was added. Cells were mixed 
thoroughly and incubated for another 5 minutes at RT. Cells were centrifuged for 15 
minutes in a pre-cooled centrifuge at 4°C at 13000 rpm. The aqueous phase was placed 
into fresh tubes and mixed with an equal volume of 70% ethanol. The RNA solution was 
applied to miniRNeasy columns (Qiagen) and further isolation of RNA was performed 
according to the manufacturer´s protocol. RNA samples were finally dissolved in 20 µl 
RNAse free water and heated to 37°C for 30 min.  
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An alternative protocol was used to isolate both, RNA and protein. 2x106 cells were 
harvested by centrifugation (800 rpm, 10 min, RT), cell pellets were lysed and column 
purified using the All Prep RNA / Protein Kit according to the manufacturer´s protocol 
(Qiagen, Hilden, Germany). Quantification of RNA samples were carried out on the 
Nanodrop device (Nanodrop Technologies, Wilmington, DE) set for RNA measurement 
(A260 / A280 ratio).  
2.2.3.4 Protein isolation  
A total of 2x106 cells (primary CLL cells or cell lines) were harvested by centrifugation 
(800 rpm, 10 min, RT). Cell pellets were lysed and column purified using the All Prep 
RNA/Protein Kit according to the manufacturer´s protocol (Qiagen, Hilden, Germany). 
2.2.3.5 Quantificatinon by spectrophotometry 
The absorption maximum of proteins is at 280 nm due to the absorbance of aromatic 
amino acids. In addition, some contaminants (notably phenol) can significantly 
contribute to an error in concentration estimation as they also absorb strongly at 
260nm. The ratio OD260/OD280 can therefore be used as an indication for the purity of 
nucleic acid solutions. Pure DNA solutions have a ratio of > 1.8, whereas contaminations 
by phenol or proteins cause a decrease of this value. DNA solutions with a ratio smaller 
than 1.5 were considered inappropriate for further analysis.  
2.2.3.6 Cloning 
To obtain the vectors pSUPERdl_Zeo-sh_CCDC50 and pSUPERdl_Zeo-sh_luciferase, the 
short hairpin RNA coding oligonucleotides sh_CCDC50 and sh_Luciferase (chapter 
2.1.8.1) were cloned into the expression vector pSUPERdL_Zeo. pSUPERdL_ZEO was 
obtained by cloning the zeocin expression unit SV40 promoter + Zeocin resistance gene 
+ SV40 polyA out from the pTER plasmid (van de Wetering et al., 2003) into the Not I and 
BamH I sites of pSUPERdL (Pscherer et al., 2006) using te primers: NotI_pTER_fw and 
BamHI_pTER_rev (chapter 2.1.8.1). The sequence for the short hairpin RNA coding insert 
was designed according to siRNA sequence from CCDC50 (Ambion, 129979).  
2.2.3.7 Vector restriction enzyme digests 
Digests were carried out in 20 μl volume with a DNA content of 1 μg for 1 h with 10 U of 
each enzyme. For digestions over night, a minimum volume of at least 50 μl is 
recommended. For cloning of the short hairpin RNA coding insert sh_CCDC50 into the 
vector pSUPER_Zeo, 1µg vector was digested for 1h at 37°C using each 10 U each of the 
restriction endonucleases Hind III and Bgl II. 
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2.2.3.8 Annealing of oligos 
To obtain DNA oligonucleotides for hairpin RNA expression, sense and antisense oligos 
were annealed. The oligonucleotides were dissolved in nuclease free water to a 
concentration of 3 mg/ml. For the annealing of the oligonucleotides, 1 μl of each 
100pmol primer (sh_CCDC50_fw and sh_CCDC50_rev) were added to 48 μl annealing 
buffer (100nM potassium acetate, 30mM HEPES-KOH (pH=7.4), 2mM Mg-acetate), 
incubated 4 minutes at 95°C, then incubated 10 minutes at 70°C and subsequently 
slowly cooled down to 4°C. 
2.2.3.9 Phosphorylation of oligos 
Next the annealed oligos were phosphorylated by adding 2 µl of the annealed oligos to 
1 µl PNK (polynucleotide kinase) buffer, 1 µl 10 mM ATP, 1 µl T4 PNK and 5 µl H20. This 
mix was incubated 30 minutes at 37°C. To heat inactivate the PNK enzyme, the complete 
mix was incubated finally for 10 minutes at 70°C. 
2.2.3.10 Ligation 
For the ligation of the digested vector pSUPERdL_Zeo with the annealed and 
phosphorylated oligonucleotides, 2 µl of the latter were added to 1 µl T4 ligase buffer, 
50 ng restriction enzyme digested pSUPERdL_Zeo, 5 µl H20 and 1 µl T4 ligase (200 U). 
This ligation was incubated for 1 h at RT.  
2.2.3.11 Transformation in competent bacteria 
One Shot® TOP10 chemically competent E.coli (Invitrogen, Karlsruhe, Germany) was 
used to amplify plasmid DNA. The transfer of plasmids into bacteria requires that the cell 
membrane is permeable for the plasmids, which is achieved by a short time heat 
incubation at 42°C. 50 μl of electro-competent E.coli were thawed on ice, mixed with the 
complete ligation reaction and incubated on ice for 30 minutes. For the plasmid uptake, 
the bacteria were shifted to 42°C for 60 s and briefly equilibrated on ice. 250-300 μl of 
SOC medium (chapter 2.1.5.2) was added and cells were incubated for 1 h at 37°C while 
shaking (800 rpm). The suspension was plated onto LB-agar plates containing the 
respective antibiotic. LB plates were incubated over night at 37°C. 
2.2.3.12 Primer design 
Genomic DNA PCR primers were designed with the software tool “Fast PCR, 5.4 
Professional” (Institute of Biotechnology, Helsinki, FL). To avoid conformation of primer 
dimers, it was insured that the 3’ end of the forward primer and the 3’ end of the 
reverse primer were not able to hybridize by homologous base pairing. The 5 first and 5 
last residues of each primer should contain 2-3 G- or C-residues; if possible the last 
residue at the 3’ end should also be G or C to ensure a stable start position for the 
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enzyme. To avoid false primer annealing, stretches of more than 4 residues of the same 
nucleotides were excluded. 
2.2.3.13 PCR reaction 
Cyclic reaction series of denaturation, reannealing of forward and reverse primer and 
polymerization with a thermostable DNA polymerase allow the in vitro amplification of 
DNA (Saiki et al., 1988). A PCR reaction contained: 150 ng DNA template, 5 µl of 1 
pmol/µl forward primer, 5 µl of 1 pmol/µl reverse primer, 2 μl dNTP-mix (2.5 mM each), 
2.5 μl 10xRB buffer (160mM (NH4)2SO4; 670mM Tris-HCl (pH 8.8); 0.1% Tween-20), 2 µl 
of 1 pM  DMSO, 1 μl (5Units) EuroTaq DNA polymerase (EuroClone, Siziano, Italy). The 
mixture was filled up with ddH20 to a volume of 25 μl. Cycling reactions were 94°C for 5 
minutes; 35 cycles of 94°C for 45s, 55°C for 45s, 72°C, for 45 s, 72° for 7 minutes, hold at 
4°C. A minimum of 5 µl of the PCR reaction was analyzed on an agarose gel.  
2.2.3.14 PCR purification and gel extraction  
PCR product purification was performed using the QIAquick PCR Purification Kit 
according to the manufacturer´s protocol (Qiagen, Hilden, Germany). In cloning 
approaches, the restriction digested vector was separated in a 1% agarose gel and 
stained in with ethidium bromid for 5 minutes at RT. Under 254 UV nm light, vector and 
insert bands were carefully cutted out and extracted from the agarose gel using the 
QIAquick Gel Extraction Kit according to the manufacturer´s protocol (Qiagen, Hilden, 
Germany). 
2.2.3.15 Sequencing 
Sequencing of DNA was performed according to the Dideoxy-Sequencing method shown 
by Sanger (Sanger et al., 1977). The reaction mix contained fluorescent labled dideoxy-
derivates for all of the four nucleotides (Rosenblum et al., 1997). Due to initial 
denaturation steps during the reaction, sequencing of dsDNA is possible. The sequencing 
reaction was done according to the manufacturer´s protocol using the PRISM Big 
DyeDeoxy Terminator Cycle Sequencing Kit. The reaction contained an initial 
denaturation step for 2 minutes at 96°C and 25 cycles of 5 s at 96°C, 10 s at 55°C, and 4 
minutes at 60°C. After this reaction the samples were precipitated at RT with 2.5 Vol 
100% ethanol and 1/10 Vol 3M NaAc, washed with 70% ethanol, dried and resuspended 
in 10 µl formamide. Fragment separation and detection via laser induced excitation of 
the fluorescently labeled dideoxynucleotides was performed using an ABI3100 capillary 
DNA sequencing apparatus (Applied Biosystems, Forster City, USA) 
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2.2.3.16 qRT-PCR Primer design 
PCR primer for quantitative real-time PCR experiments were designed with the Primer 
design tool from Roche Applied Science: ‘universal probe library’ (https://www.roche-
applied-science.com/sis/rtpcr /upl/index.jsp?id=UP030000). Primer pairs were chosen to 
include at least one intron sequence in order to avoid product amplification resulting 
from DNA contamination of the RNA template.  
2.2.3.17 Synthesis of cDNA 
Reverse transcription is the transcription of RNA into single strand complementary DNA 
(cDNA). For a final volume of 20 µl cDNA solution, 1 µg of total RNA (in 8µl) was used 
together with 2 µl of 5x 1st strand buffer (250 mM Tris-HCl, pH 8.3, 375 mM KCl, 15 mM 
MgCl2) and 1 µl (10 units) DNAseI and incubated for 20 minutes at RT to allow genomic 
DNA digestion. 3 µl of a Master Mix1, which contained equal parts of 25mM EDTA, dNTP 
mix (10mM dNTP´s each), and 300 ng/µl random hexamer primer, were added to the 
mix and incubated in a thermo cycler for 10 minutes at 65°C and for 10 minutes at 25°C. 
This step removed secondary structures and allowed the annealing of primer to the 
RNA. After adding of 5 µl of a master mix 2 containing 5x 1st strand buffer, 0.1 M DTT 
and nuclease free water at a ratio of 2:2:1, the temperature was shifted to 42°C for 2 
minutes before adding 1µl of reverse transcriptase and 0.2 µl of T4 gene P32 protein. 
After the reverse transcription reaction for 50 minutes at 42°C, the enzyme was 
inactivated for 10 minutes at 95°C.  
2.2.3.18 Real-Time PCR analysis 
The PCR reaction mixtures consisted of 6 μl SYBR Green mixture, 100nM forward and 
reverse primer, respectively, and 2 μl cDNA template in a reaction volume of 12 μl (Korz 
et al., 2002). A standard curve consisting of a dilution series of the ‘Stratagene qPCR 
human reference’ cDNA (1:1, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128), was used to 
determine the efficiency of the PCR reaction. To quantify cDNA templates obtained from 
RNA samples real-time PCR was performed in a 7900 HT Fast Real-Time PCR System 
(Applied Biosystems, Forster City, USA) with the following settings: 30 minutes at 37°C,  
95°C for 15 minutes, then 40 cycles of 15 seconds at 95°C, 10 seconds at 60°C, 60 
seconds at 72°C. Final steps comprized 15 seconds at 95°C, 15 seconds of 60°C, and 15 
seconds at 95°C. The heating ramp between the last two steps was increased to 20 
minutes to obtain a melting curve of the final RQ-PCR products. This is necesarry 
because SYBR Green fluorescence products may also be derived from side products such 
as pimer dimers. Calculation of efficiency and relative quantification was performed in 
correlation to the housekeeping genes (PGK, DCTN2). Individual samples were always 
measured in triplicates to ensure reliability. 
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2.2.4 Expression arrays 
2.2.4.1 Probe Labeling and Illumina Sentrix BeadChip array Hybridization 
Biotin-labeled cRNA samples for hybridization on Illumina Human Sentrix-6 BeadChip 
arrays (Illumina Inc., San Diego, USA) were prepared according to a modified protocol of 
Illumina's recommended sample labeling procedure. Briefly, 250 ng total RNA was used 
for complementary DNA (cDNA) synthesis, followed by an amplification/ labeling step (in 
vitro transcription) to synthesize biotin-labeled cRNA according to the MessageAmp II 
aRNA Amplification kit (Ambion Inc., Austin, TX). Biotin-16-UTP was purchased from 
Roche Applied Science (Penzberg, Germany). The cRNA was column purified according to 
TotalPrep RNA Amplification Kit (Ambion, Austin, USA) and eluted in 60 µl of water. The 
quality of cRNA was controlled using the RNA Nano Chip Assay on an Agilent 2100 
Bioanalyzer and spectrophotometrically quantified by the NanoDrop device (NanoDrop, 
NanoDrop Technologies, San Diego, USA). Hybridization was performed at 58°C, in GEX-
HCB buffer (Illumina Inc., San Diego, USA) at a concentration of 50 ng cRNA/µl, unsealed 
in a wet chamber for 20h. Spike-in controls for low, medium and highly abundant RNAs 
were added, as well as mismatch control and biotinylation control oligonucleotides. 
Microarrays were washed twice in E1BC buffer (Ambion Inc., Austin, TX) at room 
temperature for 5 minutes. After blocking for 5 minutes in 4 ml of 1% (w/v) Blocker 
Casein in phosphate buffered saline Hammarsten grade (Pierce Biotechnology Inc., 
Rockford, IL), array signals are developed by a 10-minutes incubation in 2 ml of 1 µg/ml 
Cy3-streptavidin (Amersham Biosciences, Buckinghamshire, UK) solution and 1% 
blocking solution. After a final wash in E1BC buffer (Ambion Inc., Austin, TX), the arrays 
were dried and scanned. 
2.2.4.2 Scanning and data analysis 
Microarray scanning was done using a Beadstation array scanner, setting adjusted to a 
scaling factor of 1 and PMT settings at 430. Raw data extraction was done using the 
beadarray R package (svn release 1.7.0) from bioconductor.org. Next, outliers were 
removed when their expression value dropped below a threshold: the median + *MAD 
(median absolute deviation) expression of all negative control beads. Individual bead 
types were also flagged as filtered when their bead replicate count dropped below 17. 
All data was then used for the mean expression value calculations within beadarray. 
Finally, we discarded a bead type when the bead type’s filter flag was set across all 
samples. Data analysis was done by variance stabilizing and robust spline normalization 
of the remaining signals using the algorithms from lumi R package (release 1.1.0 from 
bioconductor.org). Subsequently, values of different time points were subtracted from 
values of the time point zero and related negative controls. The thresholds for individual 
samples were determined by calculating the median value of all values within one 
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sample and subtracting or adding the 1.5-fold standard deviation from each median 
value. Differentially regulated genes were defined by values higher (upregulated) or 
lower (downregulated) than each threshold. 
2.2.5 Southern blot analysis 
2.2.5.1 Digestion of genomic DNA with restriction enzymes and gel electrophoresis 
For Southern blot analysis, 2x107 cells were centrifuged (1000 rpm, 10 min, RT) and 
genomic DNA was isolated using the Blood & Cell Culture DNA Midi Kit (Qiagen) 
according to the manufacturer´s protocol. DNA quality was tested on a 1% TBE agaraose 
gel and the concentration measured by the NanoDrop device (NanoDrop Technologies, 
San Diego, USA) was compared to human genomic DNA standard on an agarose gel 
(Roche, Mannheim, Germany). 10 µg DNA was digested over night with 100 U of 
appropriate restriction endonucleases. Enzymes were finally heat inactivated at 65°C for 
20 minutes. Digested genomic DNA and a molecular weight marker were separated on a 
0.8% TBE agarose gel (15x17 cm) at 85V for 5 hours or 40V over night. Afterwards, the 
DNA was stained by soaking the gel for 5 minutes in 1 µg/ml ethidium bromide solution 
at RT. Images were taken with the digital camera device of the Gel Documentation 
System. 
2.2.5.2 Southern blot procedure 
To depurinate the DNA prior to transfer, the gel was soaked for 10 minutes at room 
temperature in 250 mM HCl. To denature the DNA in the gel, it was submerged in 
denaturation solution (0.5M NaOH, 1.5M NaCl) for 2 x 15 minutes at RT with gentle 
shaking, then rinsed with sterile, double distilled water and finally submerged in 
neutralization solution (0.5 M TrisHCl, 1.5M NaCl) for 2 x 15 minutes at RT. Before 
blotting, the gel was equilibrated for at least 10 minutes in 20x SSC. The transfer was 
performed over night. The wet membrane was finally exposed to UV-light using the UV-
Stratlinker (Stratagene, La Jolla, CA), which cross-linked the DNA to the membrane.   
 
2.2.5.3 Generation of a DIG-labeled probe   
The DIG-labeling method is based on a steroid isolated from digitalis plants (Digitalis 
purpurea and Digitalis lanata). Hybridized DIG-labeled probes may be detected with high 
affinity anti-digoxigenin (anti-DIG) antibodies that are conjugated to alkaline 
phosphatase. The Southern blot probe was generated by restriction digestion of the 
pGK511TKneoP vector with the restriction endonucleases BglII and NcoI, generating a 
1.7 kb insert and a 3.6 kb vector backbone. The digestion was analyzed on a 1% TBE 
agarose gel and the 1.7 kB insert was cut out of the gel and purified using the Qiaquick 
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Gel Extraction Kit (Qiagen, Hilden, Germany). In the random primed labeling reaction 
(DIG high prime, Roche, Mannheim, Germany), a Klenow enzyme copies the 1.7 kB 
TKneo template in the presence of hexameric primers and alkali-labile DIG-11-dUTP. On 
average, the enzyme inserts one DIG moiety in every stretch of 20-25 nucleotides. The 
resulting labeled product is a homogeneously labeled, sensitive hybridization probe (can 
detect as little as 0.10 – 0.03 pg target DNA). 
2.2.5.4 Radioactive labelling 
The 1.7 kb TKneo DNA probe was diluted to a concentration of 50ng in 6μl nuclease-free 
water and denaturated by heating at 90°C for 5 minutes. Then the probe was directly 
chilled on ice, and 3 µl dNTP (0.2 mM each), 2.5 µl 10x Bca buffer (Ladderman Labeling 
Kit, Takara Bio Europe) and 6 µl H20 were added. Immediately before adding 
radioactivity, 1 µl (2 Units) of the Bca-polymerase was added following addition of 2.5 µl 
α32P dATP and 30mM EDTA. The whole mixture was incubated 1h at 50°C. In order to 
clean the probe, 80 µl TE was added and loaded on a pre-equilibrated spin column 
(Pharmacia, MicroSpin column S-200HR). Centrifugation was performed for 2 minutes at 
3000 rpm. The eluate was recovered. The incorporation of the radioactivity was checked 
by counting the labeled probe using a Scintillation Counter versus the probe with non-
incorporated nucleotides. After denaturation of the labeled probe by heating at 95°C for 
10 minutes, the probe was placed directly on ice, centrifuged and used for hybridization 
of the Southern blot membrane.  
2.2.5.5 Probe hybridization and blot development 
For pre-hybridization the membrane was placed in a glass tube containing 10 ml pre 
warmed (62°C) hybridization buffer (5xSSC, 0.1% N-lauroylsarcosine, 0.02% SDS, 1% 
Blocking Solution) and incubated by rotating for 2h at 62°C in a hybridization oven. The 
labeled probe was heated for 10 minutes at 95°C and directly added to 10 ml of fresh 
pre-warmed hybridization buffer. The pre-hybridization buffer was replaced quickly by 
the probe-containing hybridization buffer in order to avoid drying of the membrane. The 
latter was incubated by rotation over night at 62°C. The membrane was subsequently 
washed with low strigency buffer (2x SSC, 0.1% SDS) for 2x5 minutes, incubated by 
rotating for 2x15 minutes with pre-warmed (62°C) high-stringency buffer (0.5x SSC, 0.1% 
SDS), washed for 2 minutes with DIG-Wash (DIG I , 0.3% Tween 20) and blocked 
afterwards for 30 minutes in DIG II buffer (10 ml 10x Blocking , 100 ml DIGI). The DIG-
antibody (Roche, Mannheim, Germany) was used for detection of DNA fragments, which 
the digoxigenin-labeled probe bound specifically. The antibody was diluted 1:10000 in 
blocking solution and incubated by shaking for 30 minutes at RT. The membrane was 
finally washed 3x5 minutes with DIG III buffer (0.1 M NaCl, 0.05M MgCl2, adjust to pH 
9.5 using 1M Tris-HCl pH=9.5). Immediately after substrate addition, CDP-Star generates 
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a luminescent signal. The membrane was placed in a plastic foil to prevent drying and 
then placed in a dark developing cassette and exposed to an X-ray film. Using DIG-
labeled probes, the film exposure time was between 1-15 minutes. When applying 
radioactively labeled probes, the film exposure time was one week.  
2.2.6 Western blot analysis 
2.2.6.1 Protein quantification 
For quantification of protein concentrations the enzymatic Biruet reaction was used, 
where proteins reduce Cu2+ ions to monovalent Cu+ ions in alkaline medium. Biuret 
reaction was performed with copper-(III)-sulfate and bicinchoninic acid (1:50 copper-
(III)-sulfate : bicinchoninic acid). 10 μl of protein solution was added to 200 μl of reaction 
mixture, incubated at 37°C for 30 minutes and then determined using the NanoDrop 
reader at 550 nm wavelengths. Standard curves were performed by measuring BSA 
standard amounts ranging from 10 ng/µl to 2 µg/µL. 
2.2.6.2 Western blot procedure 
For SDS-PAGE, gel solutions with 10% acrylamide in the resovling part and 5% in the 
stacking part were prepared. 30% Ammonium Persulphate (APS) and 0.001% N,N,N´,N´-
tetramethylethylendiamine (TEMED) were added to the gel solution to induce 
polymerization. Transfected B-CLL cells and cell lines were harvested by centrifugation 
(800 rpm, 10 min, RT). Cell pellets were lysed and column purified to isolate both RNA 
and protein from the same sample applying the All Prep RNA / Protein Kit (Qiagen). 
Protein samples were boiled in Laemmli buffer for 5 minutes and subsequently loaded 
into the slots of the gel. In addition a protein size maker (Spectra multicolor broad range 
protein ladder, Fermentas, St. Leon Rot, Germany) with 1x laemmli buffer was loaded 
into a slot of the gel. Electrophoresis was applied for 45 minutes at 160V and 70mA. The 
electrophoretic transfer of polypeptides from polyacrylamide (PAA) gel to a 
polyvinylidene floride (PVDF) membrane was performed by using a wet gel transfer 
apparatus. The PVDF membrane was briefly activated in 100% methanole and soaked for 
5 minutes in Western blot buffer (25 mM Tris-Base, 192 mM Glycin, 20% v/v Methanol) 
for 10 minutes. The PAA gels were carefully removed from the electrophoresis chamber, 
the stacking gel was cut and the gel was soaked 3 minutes in Western blot buffer. The 
Western blot ‘sandwich’ was assembled and the transfer was carried out for 2h at 100V 
and 250mA in ice-cold buffer. For protein detection with antibodies, the membrane 
containing the separated polypeptides were placed in a tank and washed with washing 
buffer (15 minutes) following soaking in blocking buffer (1h) at RT. After blocking, the 
membrane was again washed (3x15 minutes) and the diluted primary antibody was 
added over night at 4°C. After washing (3x15 minutes) the membrane was incubated 
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with the secondary antibody conjugated with horse radish peroxidase for 1h at RT. 
While washing (3x15 minutes) the membrane, the ECL chemilumescent substrate was 
prepared (ECL Western Blot Detection Kit). Following incubation of the membrane with 
the ECL solution for 1 minute in the dark at RT, the solution was drained off. The 
membrane was placed in a plastic foil to prevent drying and then placed in a dark 
developing cassette and exposed to an ECL film. The exposure time of the film was 
between 10 seconds and 10 minutes. 
2.2.7 Fluorescence in situ hybridization  
Fluorescent in situ hybridization (FISH) is a cytogenetic technique that is used to detect 
and localize the presence or absence of specific DNA sequences on chromosomes. For 
preparation of probes, nick translation and PCR with labeled nucleotides was used. 
Metaphase chromosomes were firmly attached to glass slides, where repetitive DNA 
sequences were blocked by addition of CotI DNA to the sample. Finally the nick 
translated DNA probe was applied to the chromosomal DNA on the slide and binds to 
those parts of the chromosome to which they show a high degree of sequence similarity. 
Afterwards, fluorescence microscopy is used for the detection of the probe that is 
hybridized to a specific chromosome (Lichter and Ried, 1994). 
2.2.7.1 Generation of FISH probes  
Nick-translation is a conventional method for the generation of labeled DNA probes. 
DNA is incubated with a limited amount of DNaseI which introduces on the one hand 
single strand breaks (i.e. “nicks”) into the DNA, on the other results in limited double 
strand breaks in order to generate short DNA fragments. The enzyme DNaseI generates 
free 3’- and 5’-ends of DNA, which are necessary for DNA polymerase action. The latter 
enzyme is also included in a nick translation reaction, because it mediates the 
incorporation of labeled nucleotides into the DNA sequence. In nick translations, 
template DNA sequences are used to generate short labeled DNA probes for FISH, 
carried out by the combined action of DNaseI and DNA polymerase. DNaseI, DNA 
polymerase digestion and labeling of template DNA was allowed for at least 1 h at 15°C 
in a 100 μl reaction volume including 10 μl NEB2 buffer (New England Biolabs), 10 μl of 
the fluorophores, 10 μl of 0.1x β-mercaptoethanol, 4 μl of DNA-polymerase (1 U/μl) and 
4 μl of 1:10.000 diluted DNAseI (10 U/μl). To control digestion efficiency, the DNA was 
denatured for 2 minutes at 100°C and analyzed by agarose gel electrophoresis. The DNA-
fragments can be further used as probes if they are digested to a size of around 
300-600 bp. DNAseI was inactivated by addition of 2 μl 0.5 M EDTA and 1 μl 10% SDS 
and incubation at 68°C for 10 minutes. Finally, the remaining enzymes and buffers were 
removed and DNA probes were isolated by custom prepared sephadex-columns. These 
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columns were filled with glass wool soaked with sephadex buffer, which is prepared by 
30 g sephadex-G50 in 500 ml 1x column buffer. The probes were applied to the prepared 
sephadex-columns and centrifuged for 5 minutes at 2300 rpm. Sephadex columns allow 
rapid and convenient separation of nick-translated DNA from unlabeled nucleotides and 
similar separations by the process of gel filtration. Molecules larger than the largest 
pores in the matrix are excluded from the matrix and elute first. Intermediate size 
molecules penetrate the matrix to varying extents, depending on their size. After 
eluation the FISH-probes were transferred to fresh tubes and stored at -20°C until 
further use.  
2.2.7.2 Generation of metaphase chromosomes  
Colcemid is a derivative of colchicine and is commonly used to arrest mitosis, causing 
the dividing cells to accumulate in metaphase. In order to prepare metaphase 
chromosomes, cultured cell lines were arrested in their cell cycle by addition of 0.6% 
(v/v) colcemid and incubation for 70 minutes at 37°C and 5% CO2. Colcemid was 
removed by centrifugation at 1000 rpm and subsequent removal of the supernatant. Cell 
pellets were carefully resupended in 12 ml pre-warmed 1x hypotonic buffer to swell the 
mitotic cells and incubated at 37°C for 30 min. The hypotonic buffer was removed by 
gentle centrifugation at 860 rpm at RT for 10 min. The supernatant was discarded and 
pellets were carefully resuspended in 2 ml of fixative, which was freshly prepared by 
combination of methanol and acetic acid in a 3:1 ratio. These prepared metaphase 
chromosomes were incubated for at least 30 minutes to a maximum of 4 h at -20°C 
followed by gentle centrifugation at 860 rpm and RT for 5 min. Then, pelleted 
metaphase chromosomes were washed with fixative and centrifuged as described above 
for three times, before they were carefully resuspended in 2 ml of the fixative. Glass 
slides were prepared prior to metaphase dropping by incubation for 5 minutes in 
absolute ethanol and subsequent 2x1 minute washing in ddH2O to prepare a 
homogenous surface. Single drops of the metaphase cells pipetted on the slide were by 
using a glass pipette. The pre-fixed metaphase chromosome slides were dehydrated by 
incubation in increasing ethanol concentrations (70%, 90%, and 100%) for 5 minutes 
each and finally air dried. 
2.2.7.3 FISH on metaphase chromosomes 
For the removal of cytoplasm, nuclear membranes and cell membranes, and to enhance 
hybridization with the probe, treatment of the metaphase slides with pepsin was 
performed. Pepsin digestion of the metaphase chromosomes was carried out by 
incubation of the slides in 0.01 N HCl including 1 mg/ml pepsin at 37°C for 3 minutes. 
Residual pepsin or HCl was washed away by incubation in 1x PBS for 10 minutes. 
Subsequently, slides were post-fixed in 1x PBS containing 10% (v/v) PFA for 5 minutes at 
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4°C and washed again in 1x PBS for 10 minutes. Another step of dehydration in 
increasing ethanol concentrations (70%, 90%, 100%) at RT was followed by air-drying of 
slides for 10 minutes and final incubation at 63°C for 20 minutes. In order to denature 
the DNA fixed on the slides, they were incubated in denaturation solution for 2 minutes 
and 10 seconds at 65°C. Prior to application of the respective probes, a third dehydrating 
dilution series with 70%, 90% and absolute ethanol for 5 minutes in each dilution at 4°C 
was carried out. Centromere probes for chromosomes were precipitated together with 
7 μl salmon sperm DNA (10 mg/ml) in 1/20 volume 3 M NaAc and 2.5 volumes absolute 
ethanol for 30 minutes at -80°C. Locus probes for chromosomes were precipitated 
together with 10 μl human CotI (1 μg/μl) DNA and 0.7 μl salmon sperm DNA in 1/20 
volume 3 M NaAc and 2.5 volumes absolute ethanol for 30 minutes at -80°C. The probes 
were precipitated by centrifugation at 13.000 rpm and 4°C for 20 minutes, washed with 
70% ethanol and finally dried for 10-15 minutes at 37°C. In order to denature the probe-
DNA, 5 µl/slide de-ionized formamide and 5 µl/slide HybMix buffer (see material) were 
added to the probe, which then was incubated at 75°C for 6 minutes. After short 
incubation at 4°C the denatured single-stranded probe DNA was applied to the 
denatured single-stranded DNA on the slides, which were incubated overnight at 37°C in 
a humid chamber to allow hybridization. Hybridized slides were washed in WashA buffer 
(see material) at 42°C for 10 minutes and 3x5 minutes. After each incubation step the 
buffer was changed. The hybridized slides were incubated 3x5 minutes at 42°C in pre-
warmed WashB buffer (see material). Prior to probe-detection the single stranded DNA 
on the slides was blocked in blocking buffer for 30 minutes at 37°C in a humid chamber. 
Successful hybridization of the probe was detected by addition of detection buffer (see 
material), FITC binds to avidin and DIG binds to antiDig-Rhodamin. The slides were 
incubated for 30 minutes at 37°C in the humid chamber. Unbound dyes and detection 
buffers were removed with WashC buffer 3x5 minutes at 42°C. The nuclei were stained 
with DAPI, which was contained in the mounting medium (Vectashield). The results were 
visualized and quantified using a fluorescence detecting microscope that was capable of 
exciting the dyes.  
2.2.8 Functional assays 
2.2.8.1 Dual-Luciferase Reporter assay  
Genetic reporter systems are widely used to study regulation of eukaryotic gene 
expression. The term ‘dual’ refers to the simultaneous expression and measurement of 
two individual reporter enzymes within a single system. The experimental reporter 
(firefly luciferase) is correlated with specific experimental conditions, while the activity 
of the co-transfected ‘control’ (renilla luciferase) provides an internal control that serves 
as a baseline for transfection efficiency. Normalizing the activity of the firefly luciferase 
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to the activity of the renilla luciferase minimizes experimental variability caused by 
differences in cell viability or transfection efficiency. The firefly luciferase plasmid 
containing six binding sites for NFkB (Bergmann et al., 1998) and the renilla luciferase 
plasmid were given to us as generous gifts from Dr. Mathas of the division of Prof. 
Doerken at the Max-Delbrueck Center in Berlin. A total of 4x105 HEK-293T cells were 
transfected with 1.25 µg of the plasmid, coding for the gene of interest or 50nM of the 
siRNA of interest using the TransIT transfection reagent. In addition the two reporter 
plasmids (0.83 µg of the firefly plasmid containing the 6 NFkB binding sites and 0.42 µg 
of the renilla plasmid) were co-transfected. After 24h, NFκB activity was induced by 
adding 50 ng/ml TNFα to the cells. Immediately (0h), 3h, and 6h after TNFα induction, 
firefly and renilla luciferase activities were assayed using a Dual-Luciferase Reporter 
System (Promega, Madison, USA) and a luminometer (LB-940 Mithras Multilabel Reader, 
Berthold Technologies, Bad Wildbach, Germany). Transfected cells grown in a 6-well 
plate were centrifuged for 10 minutes at 1000 rpm at RT. Cell pellets were lysed with 65 
µl of 1x passive lysis buffer (Promega) for 15 minutes at RT on a shaker (310 rpm). 15 µl 
of each lysate was pipette into a reader plate of the luminator in triplicates. The firefly 
luciferase activity was measured by adding 100 µl of LAR II reagent (Promega) to 
generate a stabilized luminescent signal. After quantifying the firefly luminescence, this 
reaction is quenched and the renilla luciferase reaction is initiated by adding 100 µl of 
Stop- and Glo reagent to the same tube.  The Stop- and Glo reagent (Promega) produces 
a stabilized signal of the renilla luciferase, which is measured in the luminometer. After 
normalizing the firefly luciferase activity to the renilla luciferase activity, a direct 
comparison of samples regarding NFκB activity in the nucleus is possible. 
2.2.8.2 Cell Viability assay 
The proliferation of the transfected cells was assayed by Cell Titer Glo Luminescent Cell 
Viability Assay (Promega, Madison, USA) in opaque-walled multiwell plates (Costar, Baar, 
Germany). At 24h, 48h, and 72h after nucleofection, an aliquot of 100 µl suspension cells 
was assayed for its ATP content according to the maufacturer´s protocol. Each assay was 
performed in triplicate.  An integration time of 0.3 second per well was used. 
2.2.8.3 Fluorescence Activated Cell Sorting 
Fluorescence activated cell sorting (FACS) is a type of flow cytometry (FCM), a method 
for sorting a suspension of cells into several fraction. Cells labeled with fluorescent dyes 
like propidium iodide are detected by emission of specific spectra. The intensity of light 
emission correlated with the amount of bound, labeled antibodies to specific epitopes 
on the cell surface.  
Before staining, cells transfected by nucleofection were separated from medium by 
centrifugation (1000 rpm, 10 min) in tubes for FACS analysis.  Cells were washed twice 
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with 1x sterile and cold PBS. 1x106 cells were re-suspendend afterwards in 100 µl of the 
staining solution PBS:propidium iodide (500:1). Cells were incubated for 15 minutes at 
RT in the dark and analyzed with FACS. GFP expression after nucleofection was 
measured by flow cytometry, and transfection efficiency was calculated as percentage of 
100% viable cells by excluding propidium iodide positive, i.e dead cells from the analysis. 
To determine the percentages of B-cells isolated from perpheral blood and purified over 
MACS columns, MACS preparations were quantified using PE-conjugated monoclonal 
antibodies specific to CD19 (clone LT19; Miltenyi Biotec) and CD20 (clone LT20; Miltenyi 
Biotec). All flow cytometry analyses were carried out using a FACS CantoII flow 
cytometer equipped with BD FACS Diva software (BD Biosciences). 
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3 Results  
In order to identify, modulate, and functionally characterize upregulated candidate 
genes in MCL and CLL cells, a proper characterization of these cells were performed. 
Therefore, the utilization of different transfection techniques determined the optimal 
method and efficiency (chapter 3.1.). Gene expression profiling was suitable to discover 
a ‘hit-list’ of potential candidate genes (chapter 3.2). The use of a siRNA sceen could 
finally uncover those genes with impact on cell survival (chapter 3.3.). Following gene 
modulations, i.e. transient silencing of the candidate genes in primary cells (chapter 3.4) 
as well as stable knockdown or overexpression in tumor model cell lines (chapter 3.5), 
served to validate the impact of candidates in survival stimulating pathways in MCL and 
CLL cells.  
3.1 Transfection of suspension cells 
To functionally modulate gene expression, siRNAs and plasmid DNA need to enter the 
cell with high efficiency. The ability to specifically silence target genes at optimal low 
concentrations without inducing the interferon response or off-target effects depends 
on the efficient siRNA delivery and on the siRNA sequence itself. Low transfection 
efficiency is the most frequent cause of unsuccessful gene silencing experiments 
(Boutros et al., 2008; Zumbansen et al., 2008). Since MCL and CLL cells belong to the 
group of ‘difficult-to-transfect’ B-cells, determination and optimization of transfection 
efficiency was established in order to perform functional studies. 
3.1.1 Optimization of transfection efficiencies 
The non-viral introduction of recombinant DNA into cultured cells (transfection) has 
become an essential tool for studying gene function and regulation. Transfection 
technologies include chemical and lipid-mediated reagents or physical introduction 
through microinjection and electroporation. (1) Lipofection is a technique used to 
introduce genetic material into a cell by means of liposomes. It belongs to biochemical 
methods including also polymers, DEAE dextran (Diethylaminoethyl cellulose), and 
calcium phosphate. The main advantages of lipofection are its high efficiency, its ability 
to transfect all types of nucleic acids in a wide range of cell types, its ease of application, 
reproducibility and low toxicity. (2) Microinjection refers to the process of using a very 
fine needle to insert substances at a microscopic or borderline macroscopic level into a 
single living cell. (3) Nucleofection is a combination of chemical transfection and 
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electroporation that enables efficient and reproducible transfer of nucleic acids such as 
DNA, RNA and siRNA into hardly accessible cells. As DNA transfected by nucleofection 
can directly enter the nucleus, very high transfection efficiencies can be obtained 
(Gresch et al., 2004; 2006; Seiffert et al., 2007). MCL and CLL cell lines were either 
transfected via nucleofection and Superfect using a small GFP plasmid (pmaxGFP) or via 
RNAiFect, Dharmafect and X-tremeGENE using a Cy3-labeled siRNA (Figure 9). Moreover, 
transfection has been performed using the chemical reagents HiPerFect, Oligofectamine 
and Geneporter (not shown). Transfection efficiencies were determined by fluorescence 
activated cell sorting (FACS). The survival rates of cells and the transfection efficiencies 
after nucleofection are shown in Figure 10.  
 
Figure 9: Transfection efficiencies of MCL and CLL cell lines. (a) Comparison of chemincal transfection 
efficiencies and nucleofection in three MCL (Jeko-1, Granta-519, JVM-2) cell lines and three CLL (Mec-1, 
Mec-2, Eheb) cell lines determined by FACS. (b) Microinjection of MCL cell line Granta-519. 24 
microinjection approaches have been performed with a mean transfection efficiency of 30%, ranging 
between 0-100%. 
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Figure 10: FACS results follwing transfection of the pmaxGFP vector into MCL and CLL cell lines via 
nucleofection. Surviving cells are highlighted as separate cell population in a black box and the number of 
surviving cells is shown in percentage for each experiment, respectively (‘survival’, left columns). 
Nucleofection without the pmaxGFP plasmid (‘mock’, central columns) and nucleofection using the 
pmaxGFP (‘pmaxGFP’, right columns) have been performed for each cell line using program O-017 and 
Solution T. The percentage of GFP-transfected, surviving cells are shown in the up-right corner of the 
appropriate boxes, respectively. 
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Most of the chemical and lipid-based reagents did not succeed in efficiently transfecting 
cell lines (true for Superfect, HiPerfect, Oligofectamie, and Geneporter). Dharmafect was 
a suitable reagent at least for the cell lines Eheb (58%), JVM-2 (53%), and Jeko-1 (80%). 
Xtremegene showed little overall transfection efficiencies (less than 5%). Transfection 
with RNAi-fect was successfull in the cell line Mec-2 (80%), but in none of the other cell 
lines tested. Microinjection of 10-40 individual cells per experiment revealed a median 
transfection efficiency of 30% (Figure 9) with large variations between individual 
experiments. Nucleofection resulted in the best and most importantly, overall constant 
transfection efficiencies between 41-65% (Figure 10). Even though many cells died after 
electroporation (Solution T, Program O-017), the optimization approach clearly showed 
most convincing transfection results using nucleofection. 
3.1.2 Optimization of nucleofection parameters 
As DNA transfected by nucleofection can directly enter the nucleus, very high 
transfection efficiencies can be obtained even in difficult to transfect cells such as MCL 
and CLL cell lines or freshly isolated primary CLL cells. One disadvantage of the 
nucleofection technology is the high percentage of cell death following electroporation. 
Initial testing for the optimal transfection method was performed using uniform 
nucleofection conditions: Solution T, Program O-017. In order to determine optimized 
nucleofection conditions for each cell line individually, MCL and CLL cell lines were 
transfected with different reagents and electroporation programs. Viable cells 
expressing GFP were measured 24h post transfection via FACS analysis (Figure 11a-c). A 
‘no-program-control’ (NP) indicated the cell death rate, induced by the chemical 
component of the solution. Transfection approaches without plasmid (‘no GFP’) were 
performed to determine the influence of nucleofection pulses and the background 
fluorescence in cells for FACS analysis. For the cell lines JVM-2, Granta-519 and Mec-1 
optimal conditions have already been established in our group. Optimal transfection 
conditions for all cell lines tested are summarized in Figure 11d. Mec-1, Mec-2, Eheb, 
JVM-2, and Jeko-1 show best transfection efficiencies with Solution V and program X-
001. Granta-519 and JVM-2 show optimal transfection efficiencies with Solution T and 
program O-017. Granta-519 can moreover be electroporated using Solution V and 
program A-023. In all further transfection studies these optimized nucleofection 
conditions were applied. 
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Figure 11: Advanced tranfection optimization using different transfection solutions and electroporation 
programs of the Lonza system. Transfection optimization is shown for (a) Jeko-1, (b) Eheb and (c) Mec-2 
cell lines. Transfection optimization for cell lines Granta-519, Mec-1 and JVM-2 have been tested earlier. 
(a-c) Blue bars indicate the percentage of surviving cells after transfection. Setting the number of surviving 
cells to 100%, a certain percentage thereof was GFP transfected as indicated in green bars. The optimal 
transfection condition for each cell line is highlighted in a red box. (d) Summary of the electroporation 
programs and solution showing best transfection efficiencies and highest cell survival rates. NP=No 
Program, Sol=Solution, noGFP=Mock control, cells were pulsed without GFP.  
 
3.1.3 96-well nucleofection of MCL cell lines and primary CLL cells 
Based on the well established nucleofection technology, Lonza has developed a 96-well 
format shuttle approach for siRNA high-throughput screens in primary cells or difficult-
to-transfect cell lines. Transfection is performed in a special disposable plate with 
conductive polymer electrodes that rule out any metal ion contamination. In this 
‘Nucleocuvette plate’ the 96 samples are processed sequentially within three to four 
minutes, assuring reproducible homogeneous electrical conditions in each sample, 
thereby excluding plate effects and parameter variances. However, such screenings have 
so far mostly been limited to easy-to-transfect adherent cell lines. The efficiency of 
siRNA delivery into the cell needs to be as high as possible, as limits in the effectiveness 
of delivery lead to a decrease in knockdown. In this study the 96-well shuttle technology 
was optimized for MCL cell lines JVM-2 and Granta-519 as well as for primary CLL cells. 
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In MCL cell lines, the three chemical solutions SE, SF, and SG (termed by the company) 
were tested in combination with 31 different electroporation programs and one 
electroporation control (‘No Program’). The combination of Solution SF with program 
96-DN-100 showed best transfection efficiencies in JVM-2 and Granta-519 (Figure 12a,b) 
which were with 70% and 79% even higher than single cuvette nucleofection (50% and 
68%, Figure 9). Transfection results of cell lines using solutions SE and SG are not shown. 
In primary CLL cells, the primary B-cell solution was tested using 31 electroporation 
programs and one electroporation control (‘No Program’). Freshly isolated human B-cells 
were transfected with the plasmid pmaxGFP and 24 h later, cells were analyzed by flow 
cytometry. The overall transfection efficiency in primary CLL cells in this experiment was 
very low with a maximum efficiency of 16%. The overall comparison revealed 96-DN-100 
as the optimal transfection program (Figure 12c). 
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Figure 12: Optimization of 96-well nucleofection in cell lines and primary cells. FACS analysis was 
performed after 96-well nucleofection of the plasmid pmaxGFP in the MCL cell lines JVM-2 (a) and 
Granta-519 (b) and in primary CLL cells (c). The percentage of surviving cells is shown as a blue bar. Setting 
the number of surviving cells to 100%, a certain percentage thereof was successfullly GFP transfected, as 
indicated in green bars. Optimal transfection condition for each cell line is highlighted in a red box. 
Transfection of MCL cell lines JVM-2 and Granta-519 was performed using Solution SE, SF, and SG in 
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combination with 32 different electroporation programs including the ‘No Program’ control, respectively. 
Since Solution SF showed the best transfection efficiencies, transfection results using solution SE and SG 
are not shown. Transfection of primary CLL cells was performed using 32 different pulses in combination 
with the ‘Primary B-cell solution’. In all of the tested cells the program 96-DN-100 showed the best 
transfection efficiency.  
 
3.2 Expression arrays  
In order to identify overexpressed genes in the frequent chromosomal gain regions 
3q25-q29, 12q13-q14, and 18q21-q22 of MCL and CLL cells, high resolution expression 
arrays of primary cells and cell lines were performed. Overexpressed genes resulting 
from expression profiling were selected as potential candidates for further functional 
studies. 
3.2.1 Expression profiling of cells from MCL and CLL patients and cell 
lines 
Expression arrays are able to analyze changes in the transcriptome of MCL and CLL 
tumor cells in comparison to control cells of healthy donors. Transcriptomes of 6 
primary MCL and 24 primary CLL patient samples, as well as 6 cell lines were profiled to 
identify overexpressed genes. Gene expression of cell lines was normalized to the 
lymphoblastoid non-tumor cell line LCL-WEI (Figure 27, supplementary material) 
whereas gene expression of primary MCL and CLL cells was normalized to a pool of 
CD19+ sorted B-cells from healthy donors (Figure 13). Thereby, four MCL patients were 
profiled in duplicate (MCL3-6, replicates ‘a’ and ‘b’, respectively) in order to test 
reproducibility of expression profiling results. Expression profiling performed in this 
study offered an increased resolution compared to the earlier published microarray 
platform (Rosenwald et al., 2003). Statistical analysis of microarray (SAM) and 
hierarchical clustering of significant overexpressed genes on chromosomes 3q25-q29, 
12q13-q14, and 18q21-q22 were performed following normalization. The threshold for 
gene overexpression was defined as 1.5-fold compared to the control cells (LCL-WEI or 
CD19+). These results are shown as heatmaps in Figure 13. Obtained results were 
compared to recent publications and revealed 37 novel and 35 predicted candidate 
genes (Table 4). Detailled information about the gene expression levels and about recent 
publications discussing these candidate genes can be found in Table 6 (supplementary). 
This set of 72 genes was selected on the basis of high expression levels and localization 
of the respective genes in commonly gained chromosomal regions in MCL and CLL: 27 
genes on chromosome 3q25-q29, 32 genes on chromosome 12q13-q14 and 13 genes on 
chromosome 18q21-q22. 
Results 
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Figure 13: Differentially regulated genes in primary cells from MCL and CLL patients. Overexpressed genes 
in primary cells are shown for chromosomes 3q (a), 12q (b) and 18q (c) in comparison to CD19+ cells of 
healthy donors. Two-class unpaired SAM analysis was performed. Hierarchical clustering shows genes with 
similar gene expression patterns. Green=downregulated genes; black=median gene expression; 
red=upregulated genes. CD19 female/male=pool of two CD19 sorted B-cells of female/male origin. CD19 
pool: pool of 2 male and 2 female CD19+ sorted B-cells. (a-c) Left heatmap=primary MCL, right 
heatmap=primary CLL. Four MCL patients were profiled in duplicate on the Illumina platform: MCL3-6 
whereas ‘a’ and ‘b’ are duplicates. Chr=Chromosome. 
(a)
(b)
(c)
Primary MCL cells Primary CLL cells
Chr 3
Chr 12
Chr 18
medlow high
Expression level
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Table 4: 72 overexpressed genes resulted from expression profiling and publications.  
 
Chromosome 3  Chromosome 12  Chromosome 18 
No. Gene Chr. band  No. Gene Chr. band  No. Gene Chr. band 
1 RARRES1  3q25  28 IRAK3* 12q13  60 PIAS2 18q21 
2 PFN2 3q25  29 SLC38A2* 12q13  61 IER3IP1* 18q21 
3 GPR160* 3q26  30 HOXC6 12q13  62 RKHD2* 18q21 
4 ACTL6A 3q26  31 RAPGEF3  12q13  63 NARS* 18q21 
5 USP13 3q26  32 KIAA0286 12q13  64 TXNL1* 18q21 
6 BCHE* 3q26  33 ARHGAP9 12q13  65 MALT1* 18q21 
7 APOD 3q26  34 DDIT3 12q13  66 BCL2 18q21 
8 PIK3CA* 3q26  35 MBD6 12q13  67 VPS4B 18q21 
9 SerpinI2 3q26  36 RHEBL1* 12q13  68 ZNF532 18q21 
10 ECT2 3q26  37 TIMELESS 12q13  69 SerpinB2 18q21 
11 SMC4 3q26  38 SMARCC2 12q13  70 ZADH2 18q22 
12 YEATS2 3q27  39 RARG 12q13  71 CCDC5 18q21 
13 RFC4 3q27  40 STAT6* 12q13  72 TCF4 18q21 
14 ECE2 3q27  41 CDK2 12q13     
15 C3ORF40* 3q27  42 FAM112B* 12q13     
16 DVL3 3q27  43 PA2G4 12q13     
17 KLHL6 3q27  44 FAM113B  12q13     
18 ETV5 3q28  45 ITGB7 12q13     
19 LEPREL1 3q28  46 INHBE* 12q13     
20 FLJ42393 3q28  47 GLI1* 12q13     
21 CCDC50* 3q29  48 MYL6B  12q13     
22 LAMP3 3q29  49 METTL1 12q13     
23 FAM43A 3q29  50 DTX3 12q13     
24 C3orf34* 3q29  51 DGKA 12q13     
25 RPL39L 3q29  52 TUBA1B 12q13     
26 PAK2 3q29  53 PTGES3* 12q13     
27 LRCH3 3q29  54 GDF11 12q14     
    55 CDK4 12q14     
    56 FAM119B 12q14     
    57 MARCH-IX 12q14     
    58 TSFM* 12q14     
    59 KUB3 12q14     
 
 
Genes labeled with an asterisk (*) were previously published to be overexpressed in primary cells, but 
identified only overexpressed in cell lines in this study. Chr=Chromosome. 
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3.2.2 Validation of overexpressed candidate genes 
Out of the set of 72 selected candidates, 13 genes were tested by quantitative real-time 
PCR (qRT-PCR) in MCL and CLL patient cells and cell lines. Three selection criteria were 
chosen for the validation of predicted gene expressions: (1) A different expression 
between MCL and CLL based on Illumina expression array results (ACTL6A, DDIT3, PAK2 
and RHEBL1), (2) high gene expression based on Illumina expression array results (APOD 
and ARHGAP9), and (3) predicted candidate genes from recent publications (CCDC50, 
PFN2, ECT2, Timeless, IER3IP1, MALT1 and RKHD2). Validation of these overexpressed 
genes by qRT-PCR was shown in primary cells of 8 MCL and 28 CLL patients (Table 5), 
and in 6 cell lines including both neoplasias (Figure 14).  
 
 
Table 5: Mean overexpression of candidate genes is shown in primary MCL and CLL cells on chromosomes 
3q, 12q and 18q measured by qRT-PCR. 
 
 Primary MCL Primary CLL 
Gene Mean Range Mean Range 
CCDC50 3.4  0.5 - 7.5 3.5 0.2 - 9.3 
DDIT3 2.2  0.7 - 10.4 3.9  0.1 - 10.4 
YEATS2 3.1  1.1 - 6.5 1.7  0.1 - 5.5 
ARHGAP9 2.0  1.4 - 8.6 1.1  0.1 - 2.0 
RHBL1 3.3  0.6 - 2.7 1.8  0.1 - 7.9 
ACTL6A 2.0  0.5 - 3.0 2.6  0.1 - 9.5 
Timeless 3.1  0.9 - 5.1 2.1  0.1 - 7.3 
APOD 716  0 - 1273 262.0  0 - 1926 
RKHD2 19.0  0 - 44.9 40.0  10.8 - 65.3 
ECT2 68.7  0 - 213.0 6.5  2.3 - 14.1 
PAK2 19.9  0.2 - 55.2 19.6  6.9 - 29.9 
PFN2 14.7  14.6-15.8 58.8  4.3 - 346 
MALT1 0.9  0.5 - 2.0 0.8  0.4 - 1.4 
 
 
Correlation between gene overexpression and copy number gain was shown in the MCL 
cell line JVM-2 on chromosome 3q25-q29 for the genes CCDC50, YEATS2, APOD, and 
PFN2. The genomic copy number gains and a correlated gene overexpression on 
chromosomes 12q (chromosomal gain in JVM-2 and Jeko-1), and 18q (chromosomal gain 
in Granta-519) could be proven for all tested genes. Exemplary, the gene expression 
status of the gene FLJ42393 that was not identified by microarray expression profiling, 
could be validated by qRT-PCR (Figure 14d). 
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Figure 14: qRT-PCR of 14 selected candidate genes. Gene expression of candidates on chromosome 3q (a), 
12q (b, d), and 18q (c) was measured in primary CLL and MCL cells (left column) and in cell lines (right 
column). X-axis reveals primary MCL (red bars) and CLL (blue bars) patients and cell lines (green bars). Y-
axis shows fold change gene expression after correlating gene expression levels to the appropriate 
normalization control (NC). Expression levels of candidate genes in cell lines were normalized to the 
lymphoblastoid non-tumor cell line LCL-WEI. Expression levels of genes in primary cells were normalized 
to a pool of CD19+ B-cells (n=10). (a-d) Cell lines with chromosomal gain on the chromosome 3q, 12q, or 
18q are labeled ‘+’. Cell lines with a normal caryotype in this genomic region are labled with ‘-‘. (d) The 
recently predicted candidate gene in primary MCL cells (FLJ42393) was validated by qRT-PCR in cell lines.  
3.3 RNAi screen 
The 72 overexpressed genes were antagonized via siRNA pools applying the 96-well 
shuttle nucleofection technology in MCL cell lines JVM-2 and Granta-519. After transient 
gene knockdown in the leukemic cells, luminescent-based cell viability assays and FACS 
analyses were performed in order to reveal changes in cell viability and vitality. 
3.3.1 Optimization of the screening set-up 
During optimization of the screening set-up, experimental conditions were defined such 
that they offered the best possible screening window, reflecting good sensitivity, strong 
signal-to-noise ratio and low variability (high robustess and reproducibility). The dynamic 
range of the chosen read-out assay therefore represented the difference between 
‘baseline values’ that were obtained from negative control genes and representative 
‘positive hit values’ that were obtained from positive control genes. Negative control 
samples primarily allowed the evaluation of sequence-independent off-target effects 
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and the normalization of all data subsets from different plates into a single coherent 
data set. Positive control samples primarily offered a quality control to ensure that all 
screened genes are subjected to the same or at least a similar stringency of testing 
conditions. It was therefore crucial to select these control genes carefully. Negative 
control siRNAs were critical for setting the ‘hit’ threshold that determined, whether a 
siRNA was considered as having a positive, negative or neutral effect in a particular 
assay. These siRNAs lack similarity to nucleotide sequences in all known human genes. 
Therefore, it was worthwhile to screen multiple control genes in MCL and CLL cell lines 
before selecting one that accurately represents the baseline for each chosen cell line 
and assay (Figure 15). Different negative controls, such as scrambled siRNAs (pools and 
individual molecules), siRNAs directed against firefly luciferase and GFP, were tested to 
ascertain how faithfully they represent the baseline of each assay. Depending on the cell 
type and timepoint of readout, different siRNAs seem to positively or negatively induce 
cell proliferation. 
 
 
Figure 15: Testing of siRNA functionality in MCL cell lines JVM-2 and Granta-519. (a) Single siRNAs were 
transfected into Granta-519. Cell viability was measured as change of the ATP levels 72h post transfection 
(p.t.) compared to the mean of four negative controls (three scrambled siRNA molecules (siRNA #1-#3) 
and one siRNA molecule targeting GFP (siRNA#4)). (b-c) Cell viability and the induction of apoptosis were 
measured in Granta-519 (b) and JVM-2 (c) as ATP levels or caspase 3/7 activity 72h p.t.. Changes in cell 
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viability or apoptosis were compared to the mean of three different negative controls: two scrambled 
siRNA molecules (siRNA #1 and #2) and a siRNA targeting a luciferase sequence (siRNA #3).  
3.3.2 siRNA screen to identify genes with impact on cell survival  
The most obvious application of RNAi screening, i.e. loss-of-function (LOF) screening, 
involves identifying and functionally characterizing genes of interest on the basis of their 
LOF phenotypes. Such studies offer the broadest discovery potential, as they simply 
analyze single-gene LOF phenotypes in otherwise unmodified cells. Each of the 72 
candidate genes was represented by a pool of four siRNA molecules transfected into the 
appropriate cell line. siRNAs targeting genes on chromosomes 3q and 12q were 
transfected into JVM-2, whereas siRNAs targeting genes on chromosome 18q were 
transfected into Granta-519 due to the presence of respective gained regions. The 
optimal siRNA concentration of 500nM and the optimal read-out timepoint at 72h post 
transfection (p.t.) had been previously determined. An ATP-dependent luminescent cell 
viability assay (Figure 16a) and FACS analysis in 96-well format (Figure 16b) were chosen 
as read-out approaches. Three biological replicates of the siRNA screen have been 
performed and positive ‘hits’ were selected according to four criteria. A candidate gene: 
(1) revealed a ‘loss-of-viability’ phenotype, (2) showed an increased cell death rate, (3) 
reached a certain threshold: >20% reduction in cell viability and >20% dead cells when 
compared to three independent negative controls and (4) showed criteria (1)-(3) in two 
out of the three biological replicates. Functional read-out assays of the loss-of-function 
screen revealed 18 genes that corresponded to these criteria and were selected for 
further validation experiments (Figure 16). The full data set resulting from the original 
screen is shown in the supplementary data (Figure 28-29). 
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Figure 16: Cell viability assay and FACS analysis of the candidate genes resulting from the siRNA screen. (a) 
Cell viability assay shows the change in ATP levels after silencing of the gene of interest compared to the 
mean of three negative controls (‘Negative’). The chromosomal location of the genes as well as the cell 
line, in which the knockdown was performed, is indicated. (b) FACS analysis was performed 72h after 
transfection. Cells were stained with propidium iodide (PI). Dead cells are indicated in red=PI positive cells. 
Living cells are indicated in green=PI negative cells. Positive controls shown are CCND1, KIF11, BCL2, and 
PLK1. The three negative controls are shown: two independent non-template controls (‘NTC-1’ and ‘NTC-
2’) and a siRNA targeting the luciferase sequence (‘Luciferase’). Cells after silencing of the gene MALT1 are 
not shown by FACS analysis due to limited availability of cell material. 
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3.3.3 Validation of candidate genes  
Validation of the 18 candidate genes was performed by transfecting up to four single 
siRNA molecules for each gene separately into the appropriate cell line. Due to limited 
availability of primary CLL material, pools of 2-4 siRNA molecules were transfected and 
cells were cultivated 72h in conditioned medium. Every 24h, fresh medium was added. 
Cell viability was measured at 24h, 48h, and 72h after transfection. Validation of a 
candidate gene was scored positive, if two out of four siRNA molecules reduced cell 
viability in cell lines and the pool of siRNAs reduced cell viability in primary CLL cells. The 
single siRNA or the pool of siRNAs, showing most significant reduction in cell viability is 
shown in Figure 17a,b. The whole data set from the validation experiment can be found 
in the supplementary data (Figure 30). For three genes, the reduction in cell viability was 
detected in cell lines and in primary cells: CCDC50, SERPINI2, and SMARCC2. Five genes 
were not tested in primary CLL cells due to limited availability of primary cell material 
(USP13, FAM43A, PAK2, KLHL6 and MALT1). For four genes (DDIT3, USP13, FAM43A, 
HOXC6) the majority of tested individual siRNAs did not show a reduction in cell viability 
in the tested cell line. For nine genes, the loss-of-viability could only be shown in the 
JVM-2 cell line but not in primary CLL cells (ARHGAP9, KLHL6, PAK2, ECT2, IRAK3, 
RAPGEF3, RHEBL1, ITGB7, and TSFM). Interestingly, DDIT3 showed a loss-of-viability only 
in primary CLL cells (Figure 17b). The successful knockdown of the two genes CCDC50 
and SMARCC2 was validated by qRT-PCR in cell lines and primary cells (Figure 17c,d). The 
gene CCDC50 showed most prominent reduction in cell viability after gene knockdown in 
primary cells and was selected for further analysis.  
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Figure 17: Cell viability assay after silencing of the candidate genes. (a) A single siRNA that revealed the 
most significant reduction in cell viability is shown for each candidate gene. Cell viability was measured as 
ATP level of the cells and was normalized to the mean of three negative controls (‘NC’). Changes in cell 
viability are shown for one negative control and four positive controls (BCL2, CyclinD1, KIF11, and PLK1). 
Cell viability changes were measured 24h, 48h, and 72h after transfection (blue, red and green bars). (b) 
Primary CLL cells were transfected with a pool of siRNA molecules. Changes in cell viability were measured 
24h, 48h, and 72h after transfection (blue, red, and green bars). The effect on cell survival after 
transfection of a negative control and three positive controls (PLK1, BCL2, and KIF11) is shown. (c-d) 
Knockdown was measured for SMARCC2 and CCDC50 via qRT-PCR in the cell line JVM-2 (c) and in primary 
CLL cells (d).  
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3.3.4 Determination of CCDC50 RNA expression levels in various B-cell 
lymphomas 
CCDC50 was analyzed in B-cell lymphoma cell lines and in primary MCL and CLL cells. 
Quantitative real-time PCR experiments performed with 16 lymphoma cell lines, 
comprising Burkitt lymphoma, Hodgkin lymphoma, diffuse large B-cell lymphoma, 
mantle cell lymphoma and chronic lymphocytic leukemia (Figure 18) revealed increased 
expression of CCDC50 only in MCL and CLL cells (ranging from 1.3 - 2.9-fold), except in 
the cell line Jeko-1. The median upregulation of CCDC50 in CLL (1.7-fold) and MCL (1.4-
fold) cell lines was significantly higher than in burkitt lymphoma (0.28-fold), DLBCL (0.05-
fold) and Hodgkin lymphoma (0.47-fold). Expression of genes was normalized to the 
housekeeping genes, PGK1 (phosphoglycerate kinase 1) and DCTN2 (dynactin 2), and 
was finally compared to the lymphoblastoid non-tumor cell line LCL-WEI (Figure 18a). 
Quantitative real-time PCR experiments with primary cells showed that 5 out of 8 MCL 
patients and 23 out of 26 CLL patients displayed an upregulation of CCDC50 ranging from 
1.5 – 10-fold with a mean expression of 3.4-fold (MCL) and 3.5-fold (CLL) and a threshold 
of 1.5-fold overexpression when compared to CD19+ selected B-cells of healthy donors 
(Figure 18b).  
 
Figure 18: Expression of CCDC50 in B-cell lines and primary MCL and CLL cells was measured by qRT-PCR. 
(a) Expression of CCDC50 was analyzed by qRT-PCR in 16 cell lines: 5 Burkitt lymphoma (BL), 3 diffuse large 
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B-cell lymphoma (DLBCL), 2 Hodgkin lymphoma (HL), 3 mantle cell lymphoma (MCL), and 3 chronic 
lymphocytic leukemia (CLL) cell lines. Expression levels were first normalized to the expression of two 
housekeeping genes PGK1 and DCTN2. Each sample was then compared to the lymphoblastoid non-tumor 
B-cell line LCL-WEI. (b) CCDC50 expression was analyzed in 26 primary CLL and 8 primary MCL samples. 
Results were normalized to gene expression of CD19+ B-cells from healthy donors (n=10). M=median 
expression, T=Threshold for overexpression was set at 1.5-fold expression after normalization. 
3.3.5 Transient knockdown of CCDC50  
In order to validate the reduction in cell viability and identify the optimal siRNA 
sequence for efficient gene knockdown, the silencing effect of three independent siRNAs 
was determined (siCCDC50#1, siCCDC50#2, and siCCDC50#3) in the cell line JVM-2. All 
siRNAs tested, displayed reproducible gene knockdown 48h after transfection: 
siCCDC50#3 (92%), siCCDC50#2 (87%) and siCCDC50#1 (67%) (Figure 19). Functional 
investigations revealed the most significant decrease in cell viability after 72h. 
JVM-2+siCCDC50#1 showed comparable viability to JVM-2+siNegativeControl. In cells 
transiently transfected with siCCDC50#2 and #3, cell viability was reduced to 50% and 
44%. CCDC50 was therefore considered to play a crucial role in processes regulating cell 
cycle, proliferation and survival. The siRNA sequence siCCDC50#3 revealed the most 
efficient gene knockdown and was therefore used for stable knockdown experiments.  
 
 
 
 
Figure 19: Transient knockdown of CCDC50 in the MCL cell line JVM-2. (a) qRT-PCR 48h p.t. showed 
reduction in mRNA levels of transient transfected cells with siCCDC50#1, #2, and #3 in comparison to a 
GFP negative control (‘si Negative Control’). (b) Cell viability assay was performed at 24h, 48h, and 72h 
p.t.. Cell viability was determined in an ATP-based viability assay.  
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3.4 Stable silencing of candidate genes 
3.4.1 Generation of stable cell lines for RMCE 
The first step for the generation of stable cell lines was the successful integration of a 
single selection cassette into the genome of parental cell lines. The cassette codes for a 
neomycin gene for positive selection, a Herpes Simplex Virus thymidine kinase (HSV-tk) 
gene for negative selection and harbors two lox sites (loxP and loxP511) for site specific 
Cre-mediated homologous recombination. To obtain subclones of successful transfected 
cells, selection was performed with 2mg/ml neomycin (G418) in MCL and CLL cell lines 
following limited dilution over a period of four weeks. PCR analysis confirmed the 
integration of the selection cassette in all further analyzed single cell clones. Southern 
blot analysis revealed the number of integration events and FISH analysis on metaphase 
chromosomes can identify the chromosomal site, where the integration of the cassette 
took place (Figure 20). The final step was the substitution of the selection cassette 
against the shRNA coding plasmid pSUPERdL (dL for ‘double Lox’), which contained an 
additional zeocin gene for positive selection. Upon cotransfection with a Cre-expression 
plasmid (pCMXhCre), the recombinant pSUPERdL was exchanged against the selection 
cassette. Stable subclones were finally selected for ganciclovir (negative selection) and 
zeocin (positive selection) resistance. A successful recombination event was validated by 
genomic PCR. 
 
 
 
Figure 20: Schematic overview of the experimental procedure to generate and validate a single integration 
event of the selection cassette in cell lines. (a) Transfection of the cassette via nucleofection. (b) Selection 
of single cell clones in 96-well cultivation plates. (c) PCR analysis to validate the complete integration of 
the cassette. (d) Southern blot analysis to reveal the number of cassette integration events into the 
genome of a single cell clone. (e) FISH analysis to identify the chromosomal site of cassette integration.  
 
 
Stable clones from MCL cell lines Granta-519 (GE82+) and JVM-2 (JEP4+C6) have already 
been established in previous work in our laboratories. Genomic DNA of these cells was 
chosen as positive control for Southern blot analysis. Successful generation of stable 
clones was shown for the cell lines Jeko-1, Eheb, Mec-2, and Mec-1. Single clones were 
tested by PCR for the integration of the selection cassette, which is exemplary shown for 
two single clones in Figure 21a. Single clones were further tested in Southern blot 
analysis, if PCR revealed a complete loxP and lox-P511 site and the full-length selection 
cassette (Figure 21a). Jeko-1+TKneo clones #3, #6, #8, #9, #12, #15 and #19 were 
a) Nucleofection c) PCR d) Southern Blotb) Selection e) FISH
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validated by Southern blot analysis for a single cassette integration event (Figure 21c). 
Jeko-1+TKneo clone #9 was in addition validated by FISH analysis on metaphase 
chromosomes (Figure 21e). Single clones of Mec-1+TKneo#8, #9 and #10, 
Mec-2+TKneo#4 and #29 and Eheb+TKneo#26 could also be validated by Southern blot 
analyses (Figure 21c). Single integration of the cassette in Mec-2+TKneo#4 and 
Eheb+TKneo#26 were validated further in FISH analysis (Figure 21e). Transfection of the 
TKneo selection cassette into the cell line Mec-1 showed repeated times multiple 
integration events in all cell clones (Figure 21d). Consequently, all of the selected single 
clones showed the same signal pattern after genomic DNA digestion in Southern blot 
analysis. The enzyme HindIII cuts only outside the selection cassette in the genome, 
whereas the enzymes NcoI and BglII are single cutters within the cassette. Digestion 
with one of the the later enzymes was therefore appropriate to reveal clones with 
multiple integration events. Double digestion with HindIII and BglII was appropriate to 
validate single integration of the HSV-TK-neo cassette (Figure 21c). FISH analyses have 
been performed for Mec-1+TKneo#17 and #34 (Figure 21e), showing multiple 
integration events (Figure 21d). Validated subclones carrying a single integration of the 
selection cassette could be further used for functional studies in the RMCE system for 
stable knockdown of shRNA coding inserts.  
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Figure 21: Generation of MCL and CLL cell lines with stable integration of the HSV-TK-neo cassette. (a) PCR 
amplification of loxP, loxP511 and the selection cassette. PCR analysis from two single Jeko-1 cell clones is 
shown. GE82+ cells served as a positive control (C2) and parental cells as negative control (NC). (b) 
Schematic overview of the possible integration events that could occur after transfection of the HSV-TK-
neo cassette into the genome. (c) Southern blot analysis revealed the number of integration events. 
Clones with a single integration event were labeled with a red asterisk (*). C1=control JEP4+C6, C2=control 
GE81+, E=event of integration, N=number of integrations. I, II, III represent integration events shown in 
(b). (d) In the cell line Mec-1 multiple integration events occured. (e) FISH analysis identified the 
chromosomal site, where the stable integration event occurred. FISH was performed using a FITC-labeled 
(green) TKneo probe (Mec-2+TKneo#4, Jeko-1#TKneo#9, Eheb+TKneo#26) or a DIG-labeled (red) TKneo 
probe (Mec-1+TKneo#20, #21 and #34). (f) FISH analysis is exemplary shown for metaphase cells of the 
cell line Jeko#TKneo#9 (left side), and for Mec1+TKneo#21. The arrow indicates the site of chromosomal 
integration of the TKneo cassette. BAC contol= RP11-369L4. 
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3.4.2 Stable CCDC50 knockdown via RMCE ? 
In order to stably knock down CCDC50 in the disease background of MCL and CLL, the 
siRNA sequence of siCCDC50#3 was cloned as a short-hairpin coding insert into the 
pSUPERdL-Zeo expression vector. To establish an appropriate negative control, a 
luciferase short hairpin coding insert was cloned in an independent approach. Stable 
transfection approaches were performed in the stable JVM-2 clone JEP4+C6, carrying a 
single TKneo cassette for RMCE. Following co-transfection of a Cre-expression plasmid 
(pCMXhCre) with the recombinant pSUPERdL-Zeo, the selection markers HSV-Tk and neo 
should be substituted by the cloned insert. New subclones were negatively selected by 
ganciclovir and positively selected by zeocin. Tranfected JEP4+C6 cell lines were selected 
over a period of four weeks. Alternating antibiotic treatments, the addition of 
antioxidants (sodium pyruvate, -thioglycerol and bathocuproine disulfonate) and the 
addition of 10% conditioned medium was intended to increase the survival rate of 
transfected cells and avoid long selection periods with both antibiotics. This approach 
did not reveal stable cell lines, neither for CCDC50 nor for the recombination of the 
luciferase sh-coding insert. All cells died within four weeks while under selection. Even 
the transfection of different plasmid concentrations in order to increase the possibility 
of a recombination event as well as the decrease of the antibiotic selection pressure by 
lowering the antibiotics concentration did not promote the generation of stable cell lines 
that exchanged the selection cassette for the sh-coding construct. The use of an 
alternative Cre-recombinase plasmid did not overcome initial problems. In summary, it 
was not possible to generate stable MCL cell lines by exchanging the single cassette via 
RMCE. Therefore random integration of sh_CCDC50 was the method of choice.  
3.5 Functional studies of CCDC50 
3.5.1 Stable CCDC50 silencing in MCL and CLL cell lines  
The generation of stable cell lines with random integration of the short hairpin coding 
insert sh_CCDC50 was performed in the MCL cell line JVM-2 and the CLL the cell line 
Mec-1. According to qRT-PCR results (Figure 18) JVM-2 and Mec-1 showed high 
expression values for CCDC50 among all cell lines (2.9 and 2.0-fold). The strategy to 
validate the genomic integration of pSUPERdL-Zeo-sh_CCDC50 is shown in Figure 22a. 
Transfected cells were selected over a period of four weeks for zeocin resistance. PCR on 
genomic DNA validated the availability of the short hairpin coding CCDC50 insert (PCR I) 
and the vector backbone including the zeocin resistance gene (PCR II) in stable cell 
clones (Figure 22b). This PCR demonstrated which part of the original pSUPERdL-Zeo-
sh_CCDC50 vector has integrated into the genome of the stable selected cell lines. 
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CCDC50 RNA levels were reduced after stable CCDC50 silencing by 50% 
(JVM-2+sh_CCDC50#1,#3) and by 80% (Mec-1+sh_CCDC50#1) when compared to their 
parental cell lines (Figure 22c), and was accompanied by reduced protein levels  
(Figure 22Figure 21d) and reduced cell viability (Figure 22e, f). 
 
 
Figure 22: Stable CCDC50 knockdown and functional analysis in JVM-2 and Mec-1 cell lines. (a) Strategy to 
validate genomic integration of pSUPERdL-Zeo-sh_CCDC50. (b) PCR to validate integration of sh_CCDC50 
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insert in JVM-2 and Mec-1 cell lines. The integrated sh_CCDC50 is shown with PCR I. PCR II showed which 
part of the vector backbone was additionally integrated. Control=pSUPERdL-Zeo-sh_CCDC50 vector. (c) 
Analysis of CCDC50 expression by qRT-PCR in parental and stable cell clones. LCL-WEI was used as a 
reference cell line due to a balanced CCDC50 expression status. Expression of CCDC50 was finally 
normalized to wild type (WT) cells JVM-2 or Mec-1. (d) Western blot analysis showed the reduction in 
protein levels of CCDC50 in parental and stable cell lines. GAPDH served as a loading control. (e) Cell 
viability assay was performed by seeding 3x10
6
 parental JVM-2 and stable transfected JVM-2 cells and 
measuring ATP-dependent cell viability every 24h for 4 days. (f) Cell proliferation was measured in Mec-1 
WT and Mec-1 stable clones by counting cells via a cell counter device. Measurement was performed after 
initial seeding of 1x10
5
 cells every 24h for 10 days.  
 
3.5.2 Silencing of CCDC50 in primary CLL cells 
Interestingly, quantitative real-time PCR experiments revealed overexpression of 
CCDC50 in five out of eight MCL patients (mean: 3.4-fold) and 24 out of 28 CLL patients 
(mean: 3.5-fold) in comparison to CD19+ selected B-cells of healthy donors. In order to 
investigate whether silencing of CCDC50 has also an antiproliferative impact on primary 
cells, transient knockdown experiments were performed in freshly isolated B-cells from 
peripheral blood of CLL patients. Transfection of primary B-cells was performed via 
nucleofection of 5x106 cells with an optimized concentration of 500nM siRNA. CLL cells 
were cultured in conditioned medium of HS5 stroma cells. Every 24h fresh and sterile 
filtered medium was added to the CLL cells. Following transient transfection of 
siCCDC50#3 into primary B-cells from CLL patients (B-CLL 48, 49, 50, 51, and 61), the 
cells were cultured for 72h in conditioned medium. Quantitative real-time PCR and a cell 
viability assay revealed in all patients a CCDC50 gene knockdown between 40-80% 
(Figure 23a) correlating with 50-60% reduction in cell viability (Figure 23c). Analysis of 
the CCDC50 protein level in CLL patient 49 at 48h and 72h after transfection showed a 
reduction compared to a negative and a mock control (Figure 23b). 
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Figure 23: Silencing of CCDC50 in primary CLL cells. (a) qRT-PCR showed CCDC50 knockdown in patients 48, 
49, and 50 in comparison to a non-template control (‘siNTC’). (b) Western blot analysis showed CCDC50 
protein expression in CLL patient 49 at 48h and 72h after transfection of siCCDC50#3. CCDC50 protein 
expression was measured additionally in cells transfected with siNTC and in mock transfected cells. 
GAPDH served as loading control. (c) Cell viability assay in CLL patients 48, 49, 50, 51, and 61 was 
performed, measuring the ATP level of primary CLL cells, transiently transfected with siCCDC50 and siNTC.  
 
3.5.3 Involvement of CCDC50 in the NFκB pathway 
CCDC50 was previously identified to suppress NFκB activity through its interaction with 
TNFAIP3. Knockdown of CCDC50 was shown to activate NFκB signaling, even without 
TNF  stimulation (Bohgaki et al., 2008). NFκB can either promote or inhibit 
carcinogenesis and cancer progression. In MCL and CLL, NFκB activity is often correlated 
with increased cell survival (Malynn et al., 2009; Schmitz et al., 2009). To investigate the 
correlation between CCDC50 induced cell survival and NFκB signaling, NFκB reporter 
assays have been performed in HEK-293T cells. These cells combine three major 
advantages: (1) a higher transfection efficiency (90%) than MCL or CLL cells (40-80%), (2) 
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a high inducibility of the NFκB reporter by TNFα (7-fold) and (3) low CCDC50 expression 
levels (0.9-fold) in comparison to JVM-2 cells (8.4-fold), when comared to the mean of 
two housekeeping genes (Figure 24a). NFκB reporter plasmids (p6xNFκB-firefly-
luciferase and pCMV-renilla-luciferase) were co-transfected together with either a 
siCCDC50 or a plasmid coding for CCDC50 (pCMV_CCDC50). 24 h after transfection, the 
NFκB activity was induced by 50 ng/ml TNFα and measured before (0h) as well as 3h and 
6h post induction (Figure 24b). After normalizing the activity of the firefly luciferase to 
the activity of the renilla luciferase, our results showed a direct correlation of inducibility 
and CCDC50 expression. High CCDC50 expression levels resulted in a 16-fold NFκB 
induction by TNFα, while low CCDC50 expression levels only showed a 6-7-fold 
induction.  
 
 
 
Figure 24: NFκB reporter assay in HEK-293T cells after CCDC50 gene modulation. (a) Quantitative RT-PCR 
shows the CCDC50 expression level of HEK-293T and JVM-2 cells after normalization to the mean of two 
housekeeping genes (PGK1 and DCTN2). (b) TNF  induction in HEK-293T cells was performed 24h after co-
transfection of the reporter plasmids alone (HEK-293T) or together with either a siRNA (siCCDC50, siNTC) 
or an expression plasmid (pCMV_CCDC50 or pCMX). NFκB reporter activity was measured before (0h) as 
well as 3h and 6h after TNFα induction. Normalization was performed when comparing the activity of the 
firefly luciferase to the activity of the renilla luciferase. Finally, the fold induction was calculated as 
correlation between TNFα induced cells to uninduced cells.  
 
3.5.4 Involvement of CCDC50 in CLL cell survival  
As previously shown, conditioned medium obtained from HS5 cells have promotional 
effects on primary CLL cell survival (Seiffert et al., 2007). Expression array data 
comparing CLL cells before and after co-culture with HS5 cells provide evidence that the 
NF B cascade is induced, explaining the enhanced in vitro survival of CLL cells in co-
culture. In CLL cells, the NF B cascade is discussed in having promotional effects on cell 
proliferation. The IL8 expression is induced following NF B activation and found among 
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the top genes upregulated after co-cultivation (Seiffert et al., manuscript in 
preparation). TNFAIP3 is, on the one hand, induced after NF B activation but is, on the 
other hand, a negative feedback regulator of NF B signaling. TNFAIP3 is downregulated 
in co-culture experiments. These findings support the hypothesis, that NF B has 
promotional effects on cell survival. To answer the question whether CCDC50 was 
differentially expressed during co-cultivation of primary CLL cells and to understand the 
effects that CCDC50 has on NF B-induced cell survival, freshly isolated CLL cells from 
peripheral blood were cultivated in conditioned medium for 48h. In qRT-PCR 
experiments the gene expressions of CCDC50, TNFAIP3 and IL8 were measured before 
and after cultivation (Figure 25). Interestingly, in CLL patient 48, a decrease of CCDC50 
and TNFAIP3 expression was observed 48h after cultivation in conditioned medium. The 
IL8 expression level increased which correlated with the induction of the NFκB pathway 
and the survival of B-cells.  
 
 
Figure 25: Quantitative RT-PCR showing the expression levels of IL8, TNFAIP3 and CCDC50 in primary cells 
of CLL patient 48. Expression levels were measured in B-cells directly after their isolation from peripheral 
blood (0h) and after cultivation in conditioned media (CM) for 48h. Genes were first normalized to 
housekeeping genes PGK1 and DCTN2. Finally, expression was compared to CD19+ B-cells of healthy 
donors (n=9).  
3.5.5 Genome wide expression changes after CCDC50 modulation 
As investigated in this study by quantitative real-time PCR experiments, the three MCL 
cell lines JVM-2, Granta-519, and Jeko showed different CCDC50 expression levels 
(2.9-fold, 1.3-fold and not detectable). Therefore, genome wide gene expression 
changes after CCDC50 modulation in the two MCL cell lines JVM-2 and Granta-519 were 
performed on the Illumina expression array platform. For modulation of CCDC50 
expression, siCCDC50#3 and pCMV_CCDC50 as well as the negative controls siNTC (‘Non-
Template-Control’) and pCMX were transiently transfected into JVM-2 and Granta-519. 
After seventy two hours, RNA was isolated, examined for the CCDC50 expression status, 
and profiled for genome wide expression changes. Quantitative RT-PCR revealed a 0.6-
fold expression of cells silenced for CCDC50 and a 4.3-fold overexpression in JVM-2 cells 
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after transfection of pCMV_CCDC50, setting the controls siNTC and pCMX to basal level 
expression. In the cell line Granta-519 similar results were achieved after modulation of 
CCDC50 expression (Figure 26a,b). 
 
 
Figure 26: Modulation of CCDC50 gene expression in MCL cell lines. CCDC50 silencing and overexpression 
was performed in MCL cell lines JVM-2 (a) and Granta-519 (b). Genome wide gene modifications after 
CCDC50 downregulation (siCCDC50) or overexpression (pCMV_CCDC50) are shown in JVM-2 (c) and 
Granta-519 (d). Expression was normalized to a non-template control, which is siNTC or pCMX. 
Green=downregulated genes; black=median gene expression; red=upregulated genes. 
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Expression profiling revealed in the cell line JVM-2 a total of 28 deregulated genes (17 
upregulated and 11 downregulated), and in the cell line Granta-519, 39 aberrantly 
expressed genes (20 upregulated and 19 downregulated) as shown in Figure 26c-d  and 
in Table 7-8 (see supplementary). Among them, a majority of genes was involved in p53 
signaling pathways. Beside TP53I3, two further oxidoreductases were found 
overexpressed in JVM-2: FDXR (rank 9) and SESN1 (rank 17). In the cell lines JVM-2 and 
Granta-519 the genes TP53I3 (rank 2, 17), CDKN1A (rank 6, 5), and FDXR (rank 9, 20) 
were upregulated following CCDC50 silencing. Among upregulated genes affected only in 
the cell line JVM-2 that are involved in apoptosis induction or cell cycle inhibition, were 
PRODH (rank 3), LAMP3 (rank7), FAM129A (rank 11), MXD4 (rank 14), and SENS1 (rank 
17), whereas genes found upregulated only in Granta-519 were PHLDA3 (rank 2), 
GADD45A (rank 9), BAX (rank 13), and RARRES3 (rank19). Among the downregulated 
genes, involved in maintenance of cell cycle affected in JVM-2 were BNIP3L (rank 3) and 
LGMN (rank 7), whereas in Granta-519 the genes MDM4 (rank 19), and BRWD1 (rank 15) 
were identified.  
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4 Discussion 
The two B-cell non-Hodgkin lymphoma entities CLL and MCL show recurrent 
chromosomal gains of 3q25-q29, 12q13-q14 and 18q21-q22. The genetic 
pathomechanisms affected by these aberrations are mainly not understood. The aim of 
this study was to identify genes, located within these gained regions, which are involved 
in cell survival pathways. 24 CLL patients, 6 MCL patients and 6 cell lines, representing 
both malignancies, were analyzed by expression profiling. 72 candidate genes were 
identified through comparison of array CGH and expression profiling studies. After gene 
silencing of these 72 genes in a microtiter-format-based RNAi screen, changes in cell 
viability were investigated. CCDC50, SERPINI2 and SMARCC2 emerged as candidates 
mediating reduction in cell viability. Furthermore, gene knockdown and reporter gene 
assays revealed a role of CCDC50 in cell survival pathways of MCL and CLL cells. 
4.1 Optimal transfection of MCL and CLL cells via nucleofection 
RNAi-based screening has become a powerful in vitro tool to identify drug targets that 
play a role in disease development and progression (Zumbansen et al., 2008). Successful 
screening experiments using siRNAs require efficient delivery of highly functional and 
specific siRNA molecules into appropriate cells (Boutros et al., 2008). While lipid-
mediated transfection is a common approach for siRNA delivery, many cell types, 
including B-lymphocytes like MCL and CLL cells, are not accessible using this technology 
(Gresch et al., 2004; Pscherer et al., 2006; Seiffert et al., 2007). This limitation prevents 
analysis of many biologically relevant cell types and restricts siRNA screenings mainly to 
adherent cell lines that often exhibit specific phenotypic and genetic abnormalities after 
extended periods of culturing. The use of cancer cells for functional screening is a 
relevant approach for studying cancer mechanisms. Moreover, the diversity of biological 
questions requires functional studies in primary cells (Zumbansen et al., 2008). 
In this work, optimization of transfection conditions for three MCL and CLL cell lines and 
for primary CLL cells were performed for cuvette nucleofection, as well as for the 96-well 
shuttle transfection. Using nucleofection, transfection efficiencies between 40-80% 
could be achieved. In contrast, MCL cells showed very low transfection efficiencies using 
microinjection (Figure 9). Moreover, microinjection is usually applied for stable 
transfection of single clones and is not applicable in the context of transient transfection 
approaches. Most of the tested chemical transfection reagents were highly inefficient in 
MCL and CLL cell lines. Dharmafect showed good transfection efficiencies for Jeko-1 
(80%), JVM-2 (53%) and Eheb (58%) but not for Mec-1, Mec-2 and Granta-519 (all 0%). 
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For siRNA screening in a 96-well format, a transfection method suitable for all MCL and 
CLL cell lines had to be established. Nucleofection was therefore the method of choice, 
which showed best overall transfection efficiencies. The only disadvantage applying this 
method was the induction of 20-50% cell death. Since the extent of cell death was 
comparable among different transfection experiments, and since positive and negative 
controls set the ‘hit’ threshold that determined whether an siRNA is considered as 
mediating a positive, negative, or neutral effect in a particular assay, this side effect can 
be neglected (Echeverri et al., 2006). These experiments were the basis for the siRNA 
screen discussed in chapter 4.4. 
4.2 Limitations of the RMCE system in cell lines 
In the field of reverse genetics, a technique like RMCE (recombinase-mediated cassette 
exchange) is of increasing relevance (Baer et al., 2001; Wirth et al., 2007). The procedure 
permits the systematic modification of higher eukaryotic genomes by targeted 
integration (Sauer et al., 1988; Gu et al., 1993; Araki et al., 1997; Seibler et al., 1997; 
Seibler et al., 1998). For the RMCE strategy applied in our group, this is achieved by the 
complete exchange of a preexisting ‘selection cassette’ (HSV-TK-neo) for an analogous 
cassette carrying the ‘gene of interest’, either a short hairpin RNA coding insert for gene 
knockdown or a coding insert for stable gene overexpression. The Cre-lox recombination 
system has proven to be a useful tool for complementation or genetic manipulation of 
mammalian cells (Sauer et al., 1988; Gu et al., 1993; Araki et al., 1997; Baer et al., 2001; 
Oumard et al., 2006). Integration of the gene of interest into inactive heterochromatin 
results in little or no transgene expression, whereas integration into active euchromatin 
frequently allows transgene expression. Since the site of integration can have severe 
effects on the transcription rate of the gene of interest, the RMCE system clearly defines 
the integration site and avoids unspecific phenotypic effects (Baer et al., 2001). 
Recently, our lab could show stable integration following cassette exchange thereby 
stably silencing CyclinD1 or overexpressing CDKN2a in the MCL cell line Granta-519 
(Pscherer et al., 2006). This current work, in addition, shows the stable integrate the 
HSV-TK-neo selection cassette into further MCL and CLL cell lines (Eheb, Mec-1, Mec-2, 
and Jeko-1). The growth of transfected cell clones carrying multiple cassette integration 
events has been observed repeated times in the cell line Mec-1 (Figure 21). 
Consequently, most of the selected Mec-1 clones showed the same signal pattern after 
genomic DNA digestion in Southern blot analysis (Figure 21b). Multiple cassette 
integration may also be the reason for the high signal intensity and the occurrence of 
numerous cassette signals in FISH analysis (Figure 21e). The selection of one ‘dominant 
clone’ may occur due to a high neomicine (G418) concentration. In this scenario, only 
cells with multiple integration events may have a certain survival advantage (i.e. 
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Mec-1+TKneo#17, #21, #34, Figure 21c). Limited dilution following nucleofection and a 
decreased neomicine concentration, from 2mg/ml to 1mg/ml, solved the problem of the 
‘dominant’ clone selection. In this way Mec-1+TKneo clones, carrying a single integration 
event, were successfully generated (Mec-1+TKneo#8, #9, and #10, Figure 21b). One 
major limitaton of the RMCE approach was the site directed cassette exchange against 
the gene of interest. After co-transfection with the Cre-recombinase and pSUPERdL 
vectors, cells died under optimized selection conditions, independently of the integrated 
sh-RNA sequence. The short hairpin constructs targeting CCDC50 and luciferase 
(pSUPERdL_Zeo-shCCDC50 and pSUPERdL_Zeo-shLuciferase) have been tested repeated 
times for RMCE, but none of the transfected cells survived. Titration of plasmid 
concentrations have been tested in addition to decreasing antibiotic concentration 
without any success. Two further system limitations were identified during validation of 
the cassette integration: Low signal intensities in Southern blot and FISH analyses. 
Southern blot analyses were perfomed using digoxigenin-labled probes (Figure 21c) as 
well as radioactively labled probes (Figure 21b). Most prominent results were achieved, 
when (1) probes were radioactively labeled, (2) a minimum of 10µg of endogen-free, 
highly purified DNA was used for restriction analysis, (3) X-ray intensification screens 
were applied for higher signal intensities, and (4) a minimum film exposure time of one 
week was applied (Figure 21b). In FISH analyses the low signal intensity of a 3 kb probe 
resulted in hardly detectable localization of a single integrated HSV-TK-neo cassette on 
metaphase chromosomes. In cell clones with multiple HSV-TKneo cassette integration 
events, as validated in advance by Southern blot analysis, the fluorescent signals on 
metaphase chromosomes could easily be detected (Figure 21e). The utilization of 
increased fluorescent dyes resulted in high background signals and did not overcome 
these limitations. Since the attempts for the generation of a stable JVM-2 cell line via 
RMCE did not reveal the homologous recombination event, random integration was the 
method of choice in order to establish stable cell lines for functional approaches. To 
overcome locus dependent integration effects, two independent clones of each stable 
cell line were functionally characterized. When both clones showed comparable 
phenotypic behavior, which differed from the parental cells, the phenotype was further 
analyzed and correlated with stable silencing of the candidate gene. A successful stable 
silencing of CCDC50 was performed in MCL cell line JVM-2 and CLL cell line Mec-1. Two 
independent stable clones for JVM-2 and Mec-1, showing a random integration of 
sh_CCDC50, were obtained after the first round of transfection and zeocin selection 
(Figure 22b). In summary, the RMCE system is a tool for the directed site specific 
recombination event, but is most probably limited to easy to transfect cells. Failure of 
RMCE may be caused by the nucleofection procedure, which caused up to 50% cell 
death. In this study, the integration and characterization of a single recombination event 
turned out to cause unexpected problems. Therefore, random integration of the short 
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hairpin construct was the method of choice showing successful and time efficient 
generation of stable cell lines for functional analysis.  
4.3 Expression profiling studies of MCL and CLL cells reveal 
candidate genes 
Expression analysis of genes located in commonly gained chromosomal regions revealed 
72 overexpressed genes in MCL and CLL. Antagonizing these genes using the RNAi 
technology identified 18 of these as candidates, of which 12 were novel and 6 were 
previously discussed: CCDC50 (Schmechel et al., 2004; Bertoni et al., 2006; Salaverria et 
al., 2007), ECT2 (Rubio-Moscardo et al., 2005; Jares et al., 2008; Sander et al., 2008), 
SERPINI2 (Tagawa et al., 2005), PAK2 (Salaverria et al., 2007), KLHL6 (Salaverria et al., 
2007) and ITGB7 (Greiner et al., 2006). DDIT3, which showed loss-of-viability only in 
primary CLL, was previously identified as expressing increased RNA levels in progressive 
CLL in comparison to stable CLL primary cells (Falt et al., 2005). Other previously 
reported genes like GLI1 (Sander et al., 2008), Timeless (Haslinger et al., 2004) or TCF4 
(Rizzatti et al., 2005) did not induce reduction in cell viability after their gene 
knockdown.  
It was recently shown that highly proliferative and clinically aggressive variants of MCL 
have a complex phenotype with frequent gains on 3q and 12q (Bea et al., 1999; Rubio-
Moscardo et al., 2005; Salaverria et al., 2007). Based on the expression profiling of 71 
primary MCL patients on the lymphochip platform, a recent publication characterized 
especially overexpressed candidate genes on chromosome 3 (Salaverria et al., 2007). 
Among them are genes involved in cell proliferation (YEATS2, PICK3, ACTL6A, RFC4, and 
CENTB2) and cellular homeostasis (SIAH2). Ten genes were identified as being 
specifically upregulated in MCL compared to B-cell like diffuse large B-cell lymphoma 
(DLBCL): GPR160, PH3, PIK3CA, FXR1, SIAT1, LPP, CCDC50, CENTB2, ACK1 and TFRC. 
Seven genes were found upregulated in MCL and DLBCL: SIAH2, PDCD10, RFC4, OPA1, 
PPP1R2, PAK2 and KIAA0226. Further overexpressed genes, detected on the lymphochip 
platform, were KLHL6, ETV5, DVL3 and GPR160. Expression profiling, performed in this 
work, confirmed the candidates YEATS2, CCDC50, ACTL6A, BCL6, RFC4, PAK2, DVL3, 
KLHL6 and KIAA00226. An interesting candidate gene identified on expression array was 
APOD with a mean overexpression of 130-fold in primary MCL and 15-fold in primary CLL 
cells. Knockdown of APOD did not reveal changes in cell viability in primary CLL cells or in 
MCL cell lines (not shown). So far, none of the discussed candidate genes located on 
chromosome 3q was functionally characterized for its role in the pathogenesis of MCL or 
CLL. Gains on chromosome 12 are found frequently in CLL and MCL (17% and 16%, 
respectively) (Bea et al., 2008). Overexpression of CDK4, the most frequently discussed 
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candidate gene on chromosome 12q13, was successfully correlated with enhanced 
induction of cell survival pathways and thereby inhibited apoptotic stimuli.  
In this study, a large set of further candidate genes were identified as overexpressed on 
chromsome 12q in primary CLL cells: RAPGEF3 (47-fold), DGKA (7.6-fold), SMARCC2 
(3.5-fold), Timeless (3.4-fold), DDIT3 (3-fold), and ARHGAP9 (2.3-fold). Among 
overexpressed genes in MCL cells, the following genes were discovered: CDK2 (6-fold), 
HOXC6 (4-fold), DGKA (4-fold), Timeless (3.7-fold), CDK4 (3.7-fold), MYL6B (3.6-fold), 
TUBA1B (3.5-fold), KIAA0286 (3-fold) and ARHGAP9 (2-fold). An overexpressed gene in 
recurrently gained genomic region 18q21 was TCF4 that showed an even higher 
expression level (8.3-fold) than the candidate gene BCL2 (2-fold) in patients (Rosenwald 
et al., 2003, Rizatti et al., 2005, Rubio-Moscardo et al., 2005; Jares et al., 2008). In 
summary, expression profiling of primary MCL and CLL cells identified recently published 
as well as novel candidate genes on chromosomes 3q, 12q, and 18q. Previous studies 
reported overexpressed genes predominantly without their functional investigation. In 
this work, further characterization of the 72 candidate genes was performed applying an 
RNAi screen in MCL and CLL cells and investigating the effects on cell survival and cell 
proliferation.  
4.4 siRNA screen in MCL cell lines JVM-2 and Granta-519 
The remarkable gene knockdown technique based on RNAi has opened exciting new 
avenues for genetic screens in human cells. The success of large-scale RNAi studies 
depends on a careful development of phenotypic assays and their interpretation in a 
relevant biological context (Boutros et al., 2008). The focused RNAi screen, which was 
performed in this study using the MCL cell lines Granta-519 and JVM-2, will only be the 
first step in the comprehensive analysis of the pathomechanisms affected by the 
genomic gains 3q, 12q, and 18q; the end of the screen is actually the beginning of a new 
experiment. 
4.4.1 The use of siRNA, shRNA and esiRNA   
In this work, a loss-of-function screen was applied using a pool of four siRNA sequences 
per gene in a primary screen. Validation of candidates was performed in a validation 
experiment by testing the phenoypic effect of the four siRNA sequences separately. 
Investigations of a specific gene function were analyzed in stable silencing experiments 
using a shRNA coding expression vector. Because long intracellular dsRNAs activate the 
interferon response, leading to unspecific apoptosis, RNAi in human cells need to be 
initiated by siRNAs of 21–23 nucleotides in length, which evade the interferon response 
(Elbashir et al., 2001). Since the knockdown efficiencies of single siRNAs vary strongly, 
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multiple independent siRNAs per gene are required. These can be screened individually 
or in pools. Pooling of siRNAs can reduce the costs of screening, but it increases the 
likelihood that the phenotype is caused by an off-target effect of a single siRNA (Elbashir 
et al., 2001). This can be determined by retesting hits with multiple independent siRNAs 
separately. Several laboratories have developed vector-based shRNA libraries that can 
be either transfected into cells or packaged into viruses, and transduced into cells that 
are difficult to transfect, such as primary cells. Because retroviruses and lentiviruses 
integrate stably, these libraries are often screened in pools. Clonal cell populations of 
the desired phenotype can be selected and the ‘causative’ shRNA is identified. 
Alternatively, barcoding screens can be performed in which cells are transduced with 
pooled viruses that contain shRNAs, which can be uniquely identified with a molecular 
barcode (Berns et al., 2004; Paddison et al., 2004; Silva et al., 2008; Schlabach et al., 
2008). After phenotypic selection, enrichment of integrated shRNAs fused to barcode 
sequences is measured using a microarray that contains sequences of the barcode 
(Berns et al., 2004; Paddison et al., 2004; Silva et al., 2008; Schlabach et al., 2008). 
Another approach for generating a large-scale RNAi library involves endoribonuclease-
cleaved siRNAs (esiRNAs). In this approach, long dsRNA are synthesized in vitro, digested 
into smaller dsRNA fragments, and transfected into cells. Such libraries have been shown 
to be highly efficient and have fewer off-target effects than siRNAs (Kittler et al., 2007). 
The smaller the transfected construct, the better the transfection efficiency in MCL and 
CLL cell lines. siRNAs are more easily to transfect than larger expression plasmids coding 
for shRNAs. In this study, the use of 21–23 nucleotide long siRNAs showed better 
transfection efficiencies compared to esiRNAs (not shown). Therefore the siRNA screen 
was performed with a pool of four siRNA molecules. Positive controls such as PLK1, 
CCND1, DUSP5, KIF11 or BCL2 resulted, as expected, in a reduction in cell viability. 
Testing a variety of independent negative controls such as scrambled siRNAs (pools or 
single sequences) or siRNAs targeting luciferase or GFP was necessary to reveal controls 
mediating no off-target effect or interferon response in MCL and CLL cell lines. Since 
each negative control can cause an unspecific effect on the cells, a minimum of three 
negative control siRNAs were included in each experiment. In this way, a reliable 
baseline was established, which was calculated as the mean of all negative controls. The 
dynamic range of the chosen read-out assay therefore represented the difference 
between ‘baseline values’ that were obtained from negative control genes and 
representative ‘positive hit values’ that were obtained from positive control genes. The 
focused loss-of-function screen was performed by applying siRNA pools (Qiagen) in the 
primary screen, while using either the single siRNA sequences from the initial screen or 
three to four independent siRNA duplexes from a different supplier (Ambion, 
Dharmacon) in the validation experiments. After successful validation of the ‘loss-of-
viability’ phenotype, shRNA coding plasmids were used for stable silencing experiments.  
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4.4.2 Candidate genes with impact on cell survival 
In this study, a loss-of-function screen was performed in MCL cell lines applying the 96-
well shuttle nucleofection technology. A previous siRNA screen had been performed in 
Granta-519 applying the single nucleofection approach (Ortega-Paino et al., 2008). The 
reliable transfection efficiency of primary CLL cells and cell lines using nucleofection has 
been reported earlier (Gresch et al., 2004; Seiffert et al., 2007; Pscherer et al., 2006). A 
lentiviral-based RNAi screen has recently been performed in B-NHL cell line RAMOS 
(Ruiz-Vela et al., 2008) and in diffuse large B-cell lymphoma cell lines (Shaffer et al., 
2006). Moreover, shRNA libraries were used succesfully to screen for phenotypes in 
cancer cells, leading to the discovery of five target genes of p53 that regulate p53-
dependent cell cycle arrest and a new tumor suppressor gene for the phosphatidyl-
inositol-3 kinase (PI3K) pathway (Berns et al., 2004; Westbrook et al., 2005). In contrast 
to the screen applied in this work, the shRNA screens by Berns and Westerbrook 
employed a ‘positive selection’ experimental scheme. First selective pressure was 
exerted that prevented cells from growing and/or surviving. shRNAs that allowed cells to 
circumvent these inhibitory constraints were positively selected. Three to six different 
shRNA coding vectors that were inducible by tetracycline were transduced into DLBCL 
cell lines. The aim of this work was to screen for genes with oncogenic potential, which 
induced cell cycle arrest or inhibition of cell survival after functional gene knockdown. 
The 96-well nucleofection technology enabled a simultaneous and efficient transfection 
of siRNAs into cells in a multiwell format. The focused set of 72 siRNAs was selected 
according to identified overexpressed genes coded on the gained regions 3q, 12q and 
18q. The initial screen resulted in 18 candidates with a phenotype of reduced cell 
viability (Figure 16). Off-target effects, low silencing efficiency of the respective gene or 
technical limitations may have contributed to the results of 4 of 18 genes, where the loss 
of cell viability could not be validated in the majority of tested individual siRNA 
sequences (DDIT3, USP13, FAM43A and HOXC6) as shown in Figure 30. The reason may 
be technical limitations, low knockdown efficiencies or off-target effects of single siRNA 
sequences. The latter play major roles in the generation of false positives and are key 
limitations in all types of screening approaches. siRNAs are known to produce a 
‘signature’ of inhibited transcripts in addition to the targets being analyzed (Jackson et 
al., 2003; Snove et al., 2004; Tschuch et al., 2008). Off-target effects and induction of the 
interferon response can be examined to rule out non-specific effects of the introduced 
sequence. At first, by studying similar target sequences using bioinformatics; secondly, 
by examination of interferon markers such as OAS1 (Bridge et al., 2003); and thirdly, by 
transcriptional profiling with multiple siRNAs that are directed against the same target 
(Jackson et al., 2004). In this work, 14 of 18 candidate genes from the initial screen were 
validated by the use of different individual siRNA sequences for each investigated gene 
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(ARHGAP9, CCDC50, ECT2, IRAK3, ITGB7, KLHL6, MALT1, PAK2, RAPGEF3, RARRES1, 
RHEBL1, SERPINI2, SMARCC2, and TSFM; Figure 17a). In this validation experiment, 
primary CLL cells have also been tested for the phenotypic changes after gene 
knockdown. Interestingly, DDIT3 showed a reduction in cell viability only in primary CLL 
cells. Six genes (USP13, FAM43A, PAK2, KLHL6, and MALT1) were not tested in primary 
CLL cells due to limited availability of primary cell material. Eight candidate genes (ECT2, 
PAK2, IRAK3, ARHGAP9, RAPGEF3, RHEBL1, ITGB7, and TSFM) displayed the phenotype 
only in MCL cell lines. Interestingly, three candidates showed a loss-of-viability 
phenotype both cell lines and primary CLL cells: CCDC50, SERPINI2 and SMARCC2. 
Published data on these candididates documented an overexpression for SERPINI2 in 32-
70% and for CCDC50 in 80% of MCL patients (Tagawa et al., 2005; Rosenwald et al., 
2003). SMARCC2 is a novel, so far unpublished gene on 12q13 related to MCL and CLL 
neoplasias.  
4.4.3 The importance of screening conditions 
Primary screens are usually conducted in replicates to increase the confidence of 
positives and to avoid the false negatives that arise in large-scale screening (Boutros et 
al., 2008). All candidate hits are usually retested to confirm specificity. The result of a 
primary screen will be a list of candidates that reproducibly score as positive in the 
primary assay (Boutros et al., 2008). It is important to have a detailed screening 
schedule of every step in the process and to keep track of the screen parameters: date, 
time of day, person setting up the assay, person scoring the screen, lot numbers of 
reagents used, equipment used, temperature variations, drying of plates and possible 
contaminations. To keep all screening parameters constant, each replicate in this study 
was set up at the same time of the day (morning) and a single task (siRNA preparation, 
cultivation of cells, 96-well nucleofection, pipetting of the transfected cells from 96-well-
cuvette-plate into cultivation plates, adding medium, and conduct read-out assays) was 
carried out repeatedly by the same person. Pipettes and tips were used from the same 
supplier and kept constant throughout the screening and read-out procedure. In order 
to avoid evaporation effects, due to multiple opening of the incubator following 
uncontrolled temperature and C02 decrease, the incubator was only occupied by 
screening plates from one person. Throughout the incubation period of 72h, the 
incubator remained closed and cultivation plates were placed in the same position in 
each replicate. All reagents for the read-out-assays (Cell Titer Glo Reagent, Propidium-
Iodide) were used from one batch. The read-out time (72h) and pipetting procedure was 
also kept constant for all replicates throughout the screen. Following these rules, the 
occurrence of false positives or false negatives, due to technical or handling approaches, 
was minimized as much as possible.  
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A recent publication showed a loss-of-function study in MCL cell line Granta-519 by 
applying the single nucleofection method (Ortega-Paino et al., 2008). Major advantages 
of the 96-well-shuttle format are the simultaneous treatment of all transfections within 
a short time window (three to four minutes), enhanced transfection efficiency and low 
variations when compared to single transfections. By minimizing (1) edge dependent 
evaporation effects (‘edge effects’) by filling two outer rows of a 96-well plate with 
medium, (2) plate variances by using one batch of cultivation plates and (3) positives and 
negatives by applying a minimum of 3 different negative and positive controls on each 
cultivation plate, aimed to increase the number of true positive candidates. Applying 
these guidelines, three out of 72 genes could be validated as functionally related to cell 
survival in MCL and CLL cells.  
4.4.4 The selection of proper controls 
The false negative rate is usually estimated by measuring the hit rate for known positive 
genes. Comparing reproducibility between duplicate or triplicate wells can also provide 
information on false negative rates (Boutros et al., 2008). In some cases, the insufficient 
silencing of a gene might not generate an observable phenotype, thereby contributing to 
the false negative rate of the screen. In addition, there can be considerable 
experimental variability in the degree of knockdown. The false positive rate of a primary 
screen can be estimated using the results of the secondary assays. In a well-designed 
and well-controlled screen, the final false positive rate should be negligible. 
Nevertheless, the false negative rate in this work was unexpectedly high. In previous 
studies, the knockdown of genes like BCL2, CCND1, KIF11, PLK1 or DUSP5 were reported 
to decrease cell viability in MCL cells (Guan et al., 2005; Reagan-Shaw et al., 2005; 
Pscherer et al., 2006; Ortega-Paino et al., 2008, Tucker et al., 2008). In this work, these 
positive controls did not show the expected phenotype in all of the three replicates. A 
reproducible decrease in cell viability was achieved after functional gene knockdown of 
PLK1, which was placed in four independent wells of a screening plate. Surprisingly, 
reduction in cell viability could not be observed in all of the four wells on a 96-well plate. 
Position dependent effects were excluded since the well position on a plate, where PLK1 
was showing the corresponding loss-of-viability phenotype, was different in each of the 
three replicates. All of the other controls were used just once per plate and did not show 
reduction in viability in all of the three replicates. A possible explanation could be an 
unequal transfection efficiency throughout one plate resulting in a low knockdown of 
the gene. Evidence for this explanation was given by corresponding FACS analysis, which 
showed a comparable result for the same PLK1 sample as the cell viability assay. In 
summary, the cell viability assay was highly sensitive and reliable, that could be 
validated by FACS analysis (Figure 16). 14 of the 18 candidates from the primary screen 
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could be validated in the validation experiment. The occurrence of false negatives was 
most probably due to the siRNA sequence itself or technical difficulties (i.e. unequal 
transfection efficiency) in the nucleofection approach.  
4.4.5 The identification of weak and strong targets  
The five independent controls (PLK1, BCL2, CCND1, KIF11, and DUSP5) used in this 
screen covered both weak and strong positives that allowed for the detection of weak 
and strong candidate genes. Weak read-out effects could be caused either by partial 
knockdown of a gene with a strong effect or a strong knockdown of a gene with a weak 
effect (Boutros et al., 2008). Since the gene knockdown was not tested in the RNAi 
screen, siRNAs causing a reduction in cell viability comparable to the positive controls 
were further tested in the validation assay. To also take partial knockdown events into 
consideration, siRNAs fulfilling a lower threshold (chapter 3.3.2) were additionally 
retested in the validation experiment. 
4.4.6 Hit validation of the siRNA screen  
No matter how specific a primary screen is, validation experiments are important for 
identifying the genes that are particularly relevant (Moffat et al., 2006; Boutros et al., 
2008). Validation of the 18 candidate genes was performed by transfecting up to four 
single siRNA sequences for each gene separately into the appropriate cell line. Due to 
limited availability of primary material, pools of two to four siRNA sequences were 
transfected into primary CLL cells. Validation of a candidate gene was scored positive, if 
two out of four siRNA sequences reduced cell viability in cell lines and the pool of siRNAs 
reduced the cell viability in primary CLL cells. Recent publications discussed that two or 
more siRNA sequences that knockdown target protein levels and elicit the same 
phenotype, are a sufficient proof of target specificity (Moffat et al., 2006; Boutros et al., 
2008). Moreover, independent siRNA sequences from different suppliers were used in 
this work in order to minimize the rate of sequence dependent effects. In addition, the 
multiwell format was changed to a 6-well format and cuvette nucleofection for the 
validation assays. Following this straight forward approach, validation of 14 of the 18 
candidate genes from the primary screen was successful in the validation analysis. For 
three genes, the loss-of-viability was detected in cell lines and in primary cells: CCDC50, 
SERPINI2, and SMARCC2. The most prominent reduction in cell viability after gene 
knockdown in primary cells and cell lines revealed the gene CCDC50. Although an 
unexpected number of false negatives occurred in the primary screen, the high 
validation rate of candidates in the validation experiment revealed that a reliable cut-off 
for the selection of candidates was chosen in this study (chapter 3.3.2).  
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4.4.7 Validation of a candidate gene with different siRNA sequences 
RNAi screens in mammalian cells have the potential to shed light on processes that are 
directly relevant to human health; however, important challenges remain. Validation 
strategies have to be carefully adapted for RNAi screens. One approach is to only 
consider and validate common hits that are identified using different libraries or siRNA 
sequences. This would yield in a short list of highly validated phenotypes, although it 
would greatly increase the false negative rate. Because siRNA efficiency and specificity is 
still improving, certain issues remain unresolved and recommendations of how many 
independent siRNAs should be used are evolving (Boutros et al., 2008). One way to 
overcome sequence dependent effects is to use multiple siRNAs from different 
suppliers. The candidate gene CCDC50 has been identified using a pool of four siRNA 
sequences (Qiagen). Validation experiments were set up with three different individual 
siRNA duplexes (Ambion). Due to a comparable phenotype that could be shown in both 
approaches, CCDC50 was proven as candidate gene, showing effects on cell survival in 
MCL and CLL cells. 
4.5 The candidate genes CCDC50, SERPINI2 and SMARCC2 
Loss-of-function screens offer the highest discovery potential, as they simply analyze 
single gene loss-of-function phenotypes in otherwise unmodified cells. In this study, 
CCDC50, SERPINI2 and SMARCC2 were identified as inducing reduction in cell viability 
following functional gene knockdown in MCL cell line JVM-2 and in primary CLL cells. 
Moreover, CCDC50 was shown to be overexpressed in MCL and CLL cell lines specifically. 
CCDC50 is located in genomic gained region 3q29 which is reported to have prognostic 
impact, mainly in MCL patients with low survival (Salaverria et al., 2007). Pathologically 
relevant genes are reported to be located in genomic gained region 3q26-q29 (Bentz et 
al., 2000). So far, none of the predicted candidate genes (mainly: SERPINI2 and ECT2) 
were functionally characterized in MCL or CLL cells (Rubio-Moscardo et al., 2005; 
Tagawa et al., 2005; Jares et al., 2008; Sander et al., 2008). This study showed that 
CCDC50 has survival stimulating effects in both neoplasias. The identification of robust 
molecular and genetic prognostic predictors on chromosome 3q may become an 
essential tool in the clinical practice. As each patient shows different chromosomal 
aberrations, the identification of novel molecular markers is a significant prerequisite in 
order to predict the best therapy for each patient. 
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4.5.1 CCDC50 is involved in NFκB signaling pathways and has survival 
stimulating effects 
CCDC50 was shown during the course of this thesis work to be overexpressed in MCL 
cells in comparison to other lymphomas (Salaverria et al., 2007) and to benign reactive 
lymph node tissue of MCL patients (Schmechel et al., 2004). We showed that CCDC50 is 
upregulated in primary MCL and CLL cells and in respective cell lines, in comparison to 
CD19 positive cells of healthy donors, or to the cell line LCL-WEI. CCDC50 was identified 
as a candidate gene with a 3.5-fold mean overexpression ranging from 1.5-fold up to 10-
fold, in 5 MCL and in 24 CLL patients. This is in accordance with published data, showing 
CCDC50 as 2.6-fold overexpressed in MCL in comparison to B-cells of healthy donors 
(Schmechel et al., 2004). Moreover, this study showed that CCDC50 was upregulated in 
MCL and CLL cell lines. The mean RNA expression of CCDC50 in CLL (1.7-fold) and MCL 
(1.4-fold) cell lines was significantly higher than in Burkitt´s lymphoma (0.28-fold), DLBCL 
(0.05-fold) and Hodgkin´s lymphoma (0.47-fold). Recent publications reported an 
involvement of CCDC50 in NFκB and EGFR signaling pathways (Bohgaki et al., 2008; 
Tashiro et al., 2006; Kameda et al., 2009). CCDC50 is phosphorylated and ubiquitinated 
upon EGF stimulation and inhibits EGF receptor downregulation (Tashiro et al., 2006). 
Phosphorylated CCDC50 is mainly located at the plasma membrane together with the 
EGF receptor and functions in EGF receptor endocytosis and its degradation. 
Consequently, CCDC50 plays an essential role for the positive maintenance of the 
growth factor receptor expression on the cell surface. When activated, overexpressed or 
phosphorylated, CCDC50 contributes to positive receptor signaling and acts tumorigenic. 
CCDC50 was also postulated as a negative regulator of the NFκB pathway, investigated in 
Hela cells (Bohgaki et al., 2008 and Kameda et al., 2009). Interestingly, CCDC50 was 
found to interact with the cytoplasmatic zinc finger protein TNFAIP3 that inhibits NFκB 
activation. In addition, IKKγ and CCDC50 were described to interact with the K63-linked 
polyubiquitin chain of the RIP1 protein. Therefore, CCDC50 competes for the interaction 
between IKKγ and RIPK1, resulting in the attenuation of the NFκB signaling. 
Furthermore, CCDC50 can directly interact with RIPK1 and thereby inhibit its function 
(Bohgaki et al., 2008). In contrast to results shown in Hela cells, our data gave rise to a 
survival stimulating effect of CCDC50 (Figure 17, Figure 19) and since knockdown of 
CCDC50 in primary CLL cells and in cell lines showed a loss-of-viability phenotype ( Figure 
22, Figure 23). We could validate the reduction in cell viability in 6 CLL patients and in 
MCL and CLL cell lines, following CCDC50 knockdown. Reduction in CCDC50 expression 
levels correlated with decreasing cell proliferation in stable cell lines. Expression of 
TNFAIP3 is induced by TNFα stimulation, i.e. an active NFκB pathway. On the other hand, 
once expressed TNFAIP3 functions as a negative regulator of NFκB signaling and 
inhibited cell survival (Pham et al., 2003). Depending on the cell type in which NFκB acts, 
 Discussion 
 
99 
 
it can either inhibit or promote carcinogenesis and cancer progression (Yamaoka et al., 
1996; Dajee et al., 2003; Bogaki et al., 2008). It is broadly discussed, that NFκB signaling 
is constitutively active in MCL cell lines and stimulates cell survival (Beyaert et al., 2000; 
Pham et al., 2003; Malynn et al., 2009; Schmitz et al., 2009). Therefore, further 
activation by TNFα may be difficult to detect and could not be seen in MCL cell line 
JVM-2 and CLL cell line Mec-1 (not shown). In order to validate the involvement of 
CCDC50 in NFκB signaling, reporter assays have been performed in HEK-293T cells. These 
cells were easy and efficient to transfect (90%) and showed a 7-fold stimulation of the 
NFκB reporter plasmid following TNFα stimulation. Our data showed that TNFα 
induction of the NFκB reporter plasmid revealed 50% less inducibility in cells transiently 
silenced for CCDC50 compared to cells with CCDC50 overexpression (Figure 24). These 
findings supported the hypothesis, that CCDC50 has a survival stimulating effect. Low 
CCDC50 expression levels correlated with reduced cell viability that may be caused by 
low NFκB inducibility. 
4.5.2 SMARCC2 is upregulated in MCL and CLL and promotes cell survival 
SMARCC2, also called BAF170, was identified in this study as candidate gene in the loss-
of-function screen. Silencing of SCMARCC2 resulted in decreased cell viability in the MCL 
cell line JVM-2 and in primary CLL cells. SMARCC2 is mapped to the recurrently gained 
genomic region 12q13 and is a so far unpublished candidate in the pathogenesis of MCL 
or CLL. SMARCC2 is a member of the SWI/SNF family of proteins, which display helicase 
and ATPase activities and which are identified as transcriptional regulators by modifying 
chromantin accessibility in the context of target genes (Phelan et al., 1999; Decristofaro 
et al., 2001; Chen et al., 2005; Wang et al., 2005; Zhang et al., 2007). SMARCC2 is 
involved in transcriptional activation and repression of target genes by chromatin 
remodeling (alteration of DNA-nucleosome topology) (Nagl et al., 2006). The protein is 
part of the large ATP-dependent chromatin remodeling complex SNF/SWI and contains a 
leucine zipper motif typical of many transcription factors. In lymphoid cells, SWI/SNF 
subunits are also associated with the transcriptional regulator Ikaros required for normal 
B- and T-cell differentiation (Kim et al., 1999; O'Neill et al., 2000). In mice, heterozygous 
mutation of some SWI/SNF components results in an increased risk of cancer, whereas 
homozygous mutation causes embryonic lethality (Klochendler-Yeivin et al., 2000). 
These studies suggest that SWI/SNF complexes play important roles during normal 
development and differentiation in mammals. This would also explain the reduction in 
cell viability following functional gene knockdown. Therefore, further functional 
characterization of SMARCC2 in CLL and MCL pathogenesis is necessary. 
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4.5.3 SERPINI2 has proliferation stimulating activity in MCL and CLL 
In this study, SERPINI2 was identified in this loss-of-function screen to reduce cell 
viability in MCL cell line JVM-2 and in primary CLL cells after functional gene knockdown. 
SERPINI2 was published earlier as a candidate gene on chromosome 3q26 in MCL, 
although no correlation to its functional impact on MCL cells has been shown so far 
(Tagawa et al., 2005). SERPINI2 was initially identified and implicated as a potential 
tumor suppressor gene because it was downregulated in pancreatic cancer cell lines 
when compared to normal pancreatic cells (Ozaki et al., 1998). SERPINI2, also known as 
MEPI, is expressed in normal breast myoepithelial cells, but not in malignant breast 
carcinoma cells (Xiao et al., 1999). It is a member of the serpin superfamily of proteins 
that have been implicated in a variety of functions, including blood coagulation, 
angiogenesis, inflammation, and programmed cell death (Scarff et al., 2004). SERPINI2 is 
involved in growth control, growth-suppressing pathways and, when impaired, is 
involved in pancreatic carcinogenesis. SERPINI2 is a highly interesting candidate in MCL 
and CLL showing survival stimulating effects. In future experiments, functional assays 
have to be performed in primary MCL and CLL cells to gain further insights into its 
function in the pathogenesis of both neoplasias.  
4.6 Involvement of CCDC50 in survival of primary CLL cells 
In CLL patient 48, a decrease of CCDC50 and TNFAIP3 expression was measured 48h 
after cultivation in conditioned medium by qRT-PCR experiments. In addition, the IL8 
level increased, which correlated with the induction of the NFκB pathway and the 
survival of B-cells. These results indicate that CCDC50 is maybe not essential for B-cell 
survival, while cells were cultivated in HS5 conditioned medium or were in co-culture. 
This co-culture system mainly resembles the natural environment in bone marrow or 
lymph node. Here cells can survive due to cytokine stimuli of T-cells and nurse-like cells, 
while cells in peripheral blood may show different expression patterns and may need 
distinct survival factors due to a changing environment (Shen et al., 2004; Caligaris-
Cappio et al., 2008). The overexpression of CCDC50 in most primary CLL cells isolated 
from peripheral blood may therefore reflect the original expression pattern of cells in 
peripheral blood. As soon as they enter the bone marrow, lymph node or the so called 
proliferation center  (Caligaris-Cappio et al., 2008), they might change their gene 
expression according to their microenvironment and survive due to T-cell or stroma-cell 
contact. Proliferation centers are focal aggregates of variable size scattered in lymph 
nodes and to a lesser extent in the bone marrow (Schmid et al., 1994; Granziero et al., 
2001; Soma et al., 2006). The changing expression patterns due to their location and 
survival stimuli in lymph node, bone marrow and peripheral blood may be a reasonable 
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explanation for the decrease of CCDC50 expression levels seen in primary CLL cells, 
cultured in conditioned medium. Future studies showing evidence on this theory need 
to be performed in cells deriving from these different tissues.  
4.7 CCDC50 is involved in p53 signaling pathways 
Genome wide expression arrays were performed in order to identify differentially 
regulated genes following CCDC50 modulation, i.e. silencing and overexpression. 
Bioinformatic analysis revealed that after CCDC50 knockdown, a majority of 
overexpressed genes were involved in p53 signaling pathways (CDKN1A, FDXR, 
GADD45A, LAMP3, PRODH, PHLDA3, SESN1, and TP53I3). Further upregulated genes 
identified in this study were tumor suppressor genes and genes, inducing cell death or 
the suppression of cell proliferation (BAX, FAM129A, MDX4, and RARRES3). 
Downregulated genes following CCDC50 silencing were predominantly involved in the 
activation of cell survival pathways (BNIP3L, BRWD1, LGMN, and MDM4). TP53I3 was 
identified as overexpressed in JVM-2 and Granta-519 following a decrease in CCDC50 
expression levels (Figure 26). Further publications showed that the protein encoded by 
this gene is similar to oxidoreductases which are activated upon oxidative stress and 
irradiation (Contente et al., 2002). TP53I3 was described as activated by the tumor 
suppressor gene p53 and mediated cell death (Contente et al., 2002). As a component of 
the response to acute stress, p53 has a well established role in protecting against cancer 
development. It was shown that p53 directly binds and activates the TP53I3 promoter 
(Contente et al., 2002). Beside TP53I3, CDKN1A, and FDXR were upregulated in both cell 
lines JVM-2 and Granta-519, and were reported as p53 target genes (Kerley-Hamilton et 
al., 2005). CDKN1A is a potent, tight-binding inhibitor of CDKs that inhibits 
phosphorylation of the retinoblastoma protein and mediates p53 suppression of tumor 
cell growth i.e. acts pro-apoptotic. PHLDA3, GADD45A, BAX, and RARRES3 were 
upregulated only in Granta-519 and described to be involved in p53 signaling (Smith et 
al., 1994; Chipuk et al., 2004; Kerley-Hamilton et al., 2005). Kawase et al. identified 
PHLDA3 as a p53 target gene. Activation of PHLDA3 depended on phosphorylation of 
p53, and endogenous PHLDA3 was required for p53-dependent apoptosis (Kawase et al., 
2009). BAX was identified as a protein partner of BCL2 and is responsible in the p53-
regulated pathway for the induction of apoptosis (Oltavi et al., 1993; Chipuk et al., 
2004). GADD45A was shown to stimulate DNA excision repair in vitro and inhibited entry 
of cells into S-phase. These results established GADD45A as a link between the p53-
dependent cell cycle checkpoint and DNA repair (Smith et al., 1994). Moreover, 
GADD45A was found to be involved in JNK signaling and in the MAPK pathway, which 
promoted the induction of apoptosis. PRODH, LAMP3, and SESN1 were described as 
apoptosis inducing genes in the p53 pathway. FAM129A was identified to inhibit cell 
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proliferation and MXD4 was described as tumor-suppressor gene and contributed to the 
regulation of cell growth in differentiating tissues (Pulverer et al., 2000; Adamsen et al., 
2007; Phang et al., 2008). LAMP3 was found as a novel TP53 target (Adamsen et al., 
2007). Among the downregulated genes with functions in cell cycle progression were 
BNIP3L, LGMN (JVM-2), as well as MDM4 and BRWD1 (Granta-519) (Pulverer et al., 
2000; Contente et al., 2002). Apoptosis-protecting genes like BNIP3L and LGMN were 
downregulated in accordance with CCDC50 silencing. In recent studies it was shown that 
BNIP3L and CCDC50 were both found overexpressed in a cohort of 71 primary MCL cells 
(Salaverria et al., 2007). Since silencing of CCDC50 in our study was accompanied by 
BNIP3L downregulation, a direct correlation of both genes can be assumed. The 
decrease of the anti-apoptotic gene BNIP3L may therefore be a plausible explanation for 
the reduction in cell viability seen in MCL and CLL cells with low CCDC50 expression 
levels. In summary, the observed reduction in cell viability following CCDC50 knockdown 
can be explained by the overexpression of apoptosis-stimulating genes involved in the 
p53 signaling pathways like TP53I3 and the downregulation of apoptosis protecting 
genes like BNIP3L.  
4.8 Conclusion 
In this study primary cells of 24 CLL and 6 MCL patients and cells of 3 MCL and 3 CLL cell 
lines were profiled in order to identify novel overexpressed genes in recurrently genomic 
gained regions. When correlating these data with recent publications, a set of 72 
upregulated genes was identified on chromosomes 3q25-q29, 12q13-q14, and 18q21-
q22. These genes were investigated for their phenotypic behavior after functional gene 
knockdown applying an RNAi screen. This study uncovered three major candidate genes 
with survival promoting effects in CLL and MCL cells: CCDC50, SERPINI2 and SMARCC2. 
Functional investigations on the candidate gene CCDC50 confirmed its involvement in 
NFκB signaling. Genome wide expression profiling identified several target genes of the 
p53 signaling pathway as significantly upregulated in accordance with low CCDC50 
transcript levels. Overexpression of pro-apoptotic genes like TP53I3 and BAX and 
downregulation of apoptosis protecting genes like BNIP3L and GADD45A were a 
plausible cause for the reduction in cell viability in primary CLL cells and MCL cell lines 
after CCDC50 silencing. Detailed analysis have to be performed to get a deeper insight 
into CCDC50 function, its involvement in the NFκB and the p53 pathway, and its 
influence in mechanisms leading to the pathogenesis of MCL and CLL.  
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Figure 27: Expression profiling of MCL and CLL cell lines. Expression of three MCL and CLL cell lines compared to 
the lymphoblastoid non-tumor cell line LCL-WEI (left column). Expression profiling of the MCL cell lines JVM-2 
and Granta-519 compared to the non-tumor cell line LCL-WEI (right column). Two class unpaired SAM analyses 
and hierachical clustering were performed for genes in recurrently genomic gained regions 3q25-q29 (a), 
12q13-q14 (b) and 18q21-q22 (c).  
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Table 6: 72 overexpressed candidate genes identified by expression profiling and/or prediction in recent 
publications.  
No. Gene Chr. 
Log2 
(MCL/CD19+) 
Log2 
(CLL/CD19+) Recent publications 
1 RARRES1  3q25 5.4   -   -  
2 PFN2 3q25 1.6 2.3 Salaverria et al., 2007 
3 *GPR160 3q26 *CL : 5.3 Salaverria et al., 2007 
4 ACTL6A 3q26 6.0 1.2 Salaverria et al., 2007 
5 USP13 3q26 1.8 1.7  -  
6 *BCHE 3q26 *CL : 7.2 Schraders et al., 2005 
7 APOD 3q26 130.0 15.0 Schmechel et al., 2004 
8 *PIK3CA 3q26 *CL: 1.7 Salaverria et al., 2007 
9 SerpinI2 3q26 -  -  Tagawa et al., 2005 
10 ECT2 3q26 2.0  -  Rubio-Moscardo et al., 2005; Jares et al., 
2008; Sander et al., 2008 
11 SMC4 3q26 3.8 1.2  -  
12 YEATS2 3q27 5.0 2.3 Salaverria et al., 2007 
13 RFC4 3q27 4.0 1.1 Salaverria et al., 2007 
14 ECE2 3q27 1.8  -   -  
15 *C3ORF40 3q27 *CL : 1.9 -  
16 DVL3 3q27 3.6 3.0 Salaverria et al., 2007 
17 KLHL6 3q27 6.0  -  Salaverria et al., 2007 
18 ETV5 3q28 2.7  -  Korz et al., 2002, Salaverria et al., 2007, 
Sander et al., 2008 
19 LEPREL1 3q28 1.5 1.2  -  
20 FLJ42393 3q28 -  -  Salaverria et al., 2007 
21 *CCDC50 3q29 *CL: 1.5 Schmechel et al., 2004; 2007; Bertoni et al., 
2006; Salaverria et al., 2007 
22 LAMP3 3q29 1.95  -  Rinaldi et al., 2005 
23 FAM43A 3q29 3.6 5.4  -  
24 *C3orf34 3q29 *CL: 2.3  -  
25 RPL39L 3q29 4.8  -   -  
26 PAK2 3q29 2.0 4.6 Salaverria et al., 2007 
27 LRCH3 3q29 4.1 2.3  -  
28 *IRAK3 12q13 *CL: 4.0 -  
29 *SLC38A2 12q13 *CL: 4.4 -  
30 HOXC6 12q13 4.0  -   -  
31 RAPGEF3  12q13 3.8 35.0 -  
32 KIAA0286 12q13 3.0 2.0  -  
33 ARHGAP9 12q13 2.0 2.3  -  
34 DDIT3 12q13 0.7 10.0 Rosenwald et al., 2003 
35 MBD6 12q13 1.4 1.3 Rosenwald et al., 2003 
36 *RHEBL1 12q13 *CL : 1.7 -  
37 TIMELESS 12q13 3.7 2.0 Haslinger et al., 2004 
38 SMARCC2 12q13 1.8 5.4  -  
39 RARG 12q13   Rosenwald et al., 2003 
40 *STAT6 12q13 *CL: 1.5 Rosenwald et al., 2003; Winkler et al., 2005 
41 CDK2 12q13 6.0 1.5 Korz et al., 2002 
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No. Gene Chr. 
Log2 
(MCL/CD19+) 
Log2 
(CLL/CD19+) Recent publications 
42 *FAM112B 12q13 *CL: 41 -  
43 PA2G4 12q13 2.7 1.9  -  
44 FAM113B  12q13 2.9 1.3  -  
45 ITGB7 12q13  -  1.3 Rosenwald et al., 2003; Greiner et al., 2006 
46 *INHBE 12q13 *CL : 3.8 -  
47 *GLI1 12q13 *CL : 1.4 Sander et al., 2008 
48 MYL6B  12q13 3.6 1.3 -  
49 METTL1 12q13 1.7  -   -  
50 DTX3 12q13 2.9 6.3  -  
51 DGKA 12q13 4.0 6.9 Rosenwald et al.,  2003 
52 TUBA1B 12q13 3.5  -  Rosenwald et al.,  2003 
53 *PTGES3 12q13 *CL: 3.1  -  
54 GDF11 13q13 *CL : 1.5  -  
55 CDK4 12q14 3.7  -  Hoffmann et al., 2001; de Leuuw et al., 
2005; Rubio-Moscardo et al.,2005; Kienle et 
al., 2005; Jares et al., 2008 
56 FAM119B  12q14 1.5  -  -  
57 MARCH-IX 12q14 -  -  Rosenwald et al.,  2003 
58 *TSFM 12q14 *CL : 1.4  -  
59 KUB3 12q14 1.4 1.5  -  
60 PIAS2 18q21  -  3.7  -  
61 *IER3IP1 18q21 *CL: 3.0 -  
62 *RKHD2 18q21 *CL: 3.5 Rosenwald et al., 2003 
63 *NARS 18q21 *CL: 3.4 -  
64 *TXNL1 18q21 *CL : 3.7 -  
65 *MALT1 18q21 *CL : 1.5 Rosenwald et al., 2003 
66 BCL2 18q21  -  1.5 Hofmann et al., 2001 ; Korz et al., 2002 ; 
Martinez et al., 2003; de Leeuw et al., 2004 
67 VPS4B 18q21 1.8 1.3 Rinaldi et al., 2005 ; Rizatti et al., 2005, 
Rubio-Moscardo et al., 2005 
68 ZNF532 18q21 2.6  -  Rinaldi et al., 2005 
69 SerpinB2 18q21 2.0 1.5  -  
70 ZADH2 18q22 4.7 1.8  -  
71 CCDC5 18q21 1.8 1.5   -  
72 TCF4 18q21 3.2  -  Rizatti et al., 2005 
 
Expression levels are calculated as log2 (tumor cells/healthy control), Chr=Chromosome, CL=Cell lines, 
(*)=Overexpressed only in cell lines, not in primary cells, 3 genes were not identified by expression profiling in 
this study, 37 genes were novel identified by expression profiling in this study and not correlated previously 
with MCL or CLL, 32 genes were identified both, in recent publications and by expression profiling in this study.  
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Figure 28:  Cell viability assay of the three replicates of the siRNA screen. Cell viability was measured 72h p.t. of 
the 72 candidate genes and the controls, which are distributed in three independent 96-well plates: plate1 (a), 
plate 2 (b) and plate 3 (c). Cell viability assay was measured as the change in ATP levels after transfection of the 
gene of interest compared to transfection of a negative control (‘NC’). The three replicates of the screen 
(replicate 1, 2, and 3) are shown as blue, red and green bars.  
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Figure 29: Evaluation of cell viability assay and FACS analysis. Blue boxes indicate cells, after gene knockdown, 
which fulfilled the following criteria: (1) ‘loss-of-viability’ phenotype (luminescent based viability assay), (2) 
increased cell death rate (FACS), (3) a certain threshold: >20% reduction in cell viability in assay (1) and >20% 
dead cells in assay (2) compared to the mean of three independent negative controls, and (4) criteria (1)-(3) are 
fulfilled in two out of the three biological replicates. n.a.=value was not determined.  
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Figure 30: Cell viability assay of candidate genes from the siRNA screen. Cell viability was measured 24h, 48h, 
and 72h post transfection (blue, red and green bars). (a) Validation of the ‘loss-of-viability’ phenotype after 
silencing of 14 candidate genes in the MCL cell lines JVM-2 and Granta-519 using single siRNA molecules. 
Change in cell viability was measured 72 h post transfection in comparison to the mean of 3 negative controls: 
Control-AllStars-1, NegativeControl #1, and Silencer Firefly Luc GL2/3. (b) Validation of the ‘loss-of-viability’ 
phenotype in primary CLL cells using siRNA pools of 2-4 molecules. Changes in cell viability were measured in 
primary CLL cells at 72 h post transfection in comparison to the mean of 4 negative controls: si Silencer Firefly 
Luc GL2/3, ON TARGET plus siCONTROL, si Control Non-Targeting siRNA, siNegative Control. Positive controls 
(BCL2, PLK1, and KIF11) were used as pool of four siRNA molecules. (c) The four candidate genes HOXC6, DDIT3, 
FAM42A, and USP13 could not be validated in the majority of tested individual siRNA sequences to reduce cell 
viability in the cell line JVM-2. (d) The four candidate genes ECT2, ARHGAP9, RHEBL1, and ITGB7 could not be 
validated in the majority of tested pooled siRNA molecules to reduce cell viability primary CLL cells.   
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Table 7:  Results after expression profiling of JVM-2 cells after CCDC50 knockdown (siCCDC50) and CCDC50 
overexpression (pCMV_CCDC50).  
 
   
CCDC50 Silencing 
 
CCDC50 Overexpression 
JVM-2 Rank Symbol 
log2 
(siCCDC50/siNTC) Fold change   
log2 (pCMV-
CCDC50 / pCMX) Fold change 
U
p
re
gu
la
te
d
 
1 KRT17 1.02 2.03   -0.40 0.76 
2 TP53I3 1.01 2.01   -0.42 0.75 
3 PRODH 0.89 1.85   -0.66 0.63 
4 SPATA18 0.69 1.61   -0.41 0.75 
5 FCER2 0.67 1.59   -0.10 0.93 
6 CDKN1A 0.67 1.59   -0.12 0.92 
7 LAMP3 0.67 1.59   -0.14 0.91 
8 TRIP6 0.66 1.58   -0.06 0.96 
9 FDXR 0.65 1.57   -0.19 0.88 
10 EBI3 0.63 1.55   -0.55 0.68 
11 FAM129A 0.62 1.54   -0.38 0.77 
12 IGF2R 0.61 1.53   -0.07 0.95 
13 DUSP 0.59 1.51   -0.30 0.81 
14 MXD4 0.59 1.51   -0.31 0.81 
15 LAMP1 0.56 1.47   0.13 1.09 
16 CCND2 0.54 1.45   -0.00 1.00 
17 SESN1 0.47 1.39   -0.44 0.74 
                
D
o
w
n
re
gu
la
te
d
 
11 SLC16A3 -0.57 0.67   -0.13 0.91 
10 PHYH -0.58 0.67   0.10 1.07 
9 PBK -0.59 0.66   -0.04 0.97 
8 SLC2A3 -0.63 0.65   -0.07 0.95 
7 LGMN -0.67 0.63   -0.22 0.86 
6 CCDC58 -0.68 0.62   0.22 1.16 
5 ALDOC -0.81 0.57   -0.45 0.73 
4 ZNF395 -0.9 0.54   0.14 1.10 
3 BNIP3L -1 0.50   -0.29 0.82 
2 ANKRD37 -1.48 0.36   0.02 1.01 
1 PFKFB4 -2.05 0.24   -0.07 0.95 
 
Table 8: Results after expression profiling of Granta-519 cells after CCDC50 knockdown (siCCDC50) and CCDC50 
overexpression (pCMV_CCDC50). 
 
   
CCDC50 Silencing 
 
CCDC50 Overexpression 
Granta-
519 Rank Symbol 
log2 
(siCCDC50/siNTC) Fold change   
log2 (pCMV-
CCDC50 / pCMX) Fold change 
U
p
re
gu
la
te
d
 
1 APOBEC3H 1.81 3.51   -0.50 0.71 
2 PHLDA3 1.51 2.85   -0.55 0.68 
3 CMBL 1.38 2.60   -0.92 0.53 
4 LCE1B 1.37 2.58   -0.26 0.84 
5 CDKN1A 1.28 2.43   -0.09 0.94 
6 AMBP 1.11 2.16   0.11 1.08 
7 RPS27L 0.99 1.99   -0.84 0.56 
8 HMOX1 0.91 1.88   -0.49 0.71 
9 GADD45A 0.90 1.87   -0.06 0.96 
10 SPINK2 0.87 1.83   0.03 1.02 
11 VWCE 0.80 1.74   -0.02 0.99 
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CCDC50 Silencing 
 
CCDC50 Overexpression 
Granta-
519 Rank Symbol 
log2 
(siCCDC50/siNTC) Fold change   
log2 (pCMV-
CCDC50 / pCMX) Fold change 
U
p
re
gu
la
te
d
 
12 AHR 0.79 1.73   0.13 1.09 
13 BAX 0.78 1.72   0.13 1.09 
14 ATPIF1 0.77 1.71   0.43 1.35 
15 TNFSF4 0.74 1.67   0.36 1.29 
16 PLXNB2 0.73 1.66   -0.42 0.75 
17 TP53I3 0.73 1.66   0.14 1.10 
18 PHPT1 0.73 1.66   -0.33 0.80 
19 RARRES3 0.73 1.66   -0.03 0.98 
20 FDXR 0.71 1.64   -0.23 0.85 
21 C16orf5 0.71 1.64   -0.18 0.89 
22 SCNN1G 0.71 1.64   -0.03 0.98 
23 HERC5 0.70 1.62   -0.14 0.91 
24 C12orf5 0.69 1.61   -0.14 0.91 
25 PRPF4B 0.66 1.58   0.28 1.21 
26 AC012621.8 0.65 1.57   -0.09 0.94 
27 HIST1H2BJ 0.64 1.56   -0.19 0.88 
28 PLEKHF1 0.63 1.55   -0.19 0.88 
29 MCM8 0.63 1.55   -0.03 0.98 
30 ZRANB2 0.62 1.54   0.44 1.35 
31 FUCA1 0.62 1.54   -0.35 0.79 
32 GLIPR1 0.62 1.54   0.14 1.10 
33 TMEM163 0.59 1.51   -0.25 0.84 
34 MFI2 0.59 1.51   -0.11 0.93 
35 ZNF14 0.56 1.47   -0.02 0.99 
36 NLRP7 0.54 1.45   -0.15 0.90 
37 NHLRC2 0.53 1.44   -0.14 0.91 
38 TOB1 0.52 1.43   0.59 1.50 
39 PLAC8 0.51 1.42   0.22 1.17 
               
D
o
w
n
re
gu
la
te
d
 
19 MDM4 -0.45 0.73   0.18 1.13 
18 DAP3 -0.51 0.70   0.76 1.69 
17 ABCG1 -0.51 0.70   -0.27 0.83 
16 ABCA1 -0.53 0.69   -0.24 0.85 
15 BRWD1 -0.54 0.69   -0.34 0.79 
14 SLC2A3 -0.54 0.69   0.14 1.10 
13 CABLES2 -0.55 0.68   -0.47 0.72 
12 NCOA1 -0.55 0.68   -0.14 0.91 
11 ZRANB1 -0.56 0.68   0.34 1.27 
10 ANAPC1 -0.58 0.67   0.01 1.01 
9 PTGER4 -0.58 0.67   -0.73 0.60 
8 CCDC66 -0.60 0.66   0.22 1.17 
7 DIABLO -0.60 0.66   1.25 2.38 
6 CHL1 -0.60 0.66   0.38 1.30 
5 THOC4 -0.65 0.64   4.10 17.12 
4 MAT2B -0.68 0.62   0.40 1.32 
3 BTBD2 -0.68 0.62   0.06 1.04 
2 AUH -0.69 0.62   -0.17 0.89 
1 DPP7 -0.91 0.53   0.59 1.51 
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Table 9: Information on siRNAs used for screening 
Plate Name Row Col 
Entrez 
Gene Id 
NCBI gene 
symbol siRNA Target Sequence 5´3´ Product ID Product Name 
Farfsing No.2 A 1 5217 PFN2 CTGATTTAATATGCATTTAAA SI02653959 Hs_PFN2_7 
Farfsing No.2 A 2 8975 USP13 AGCGACGATTATGAATATGAA SI00058100 Hs_USP13_2 
Farfsing No.2 A 3 116832 RPL39L TTGCCTCTTTGGAGTAGGAAA SI00706552 Hs_RPL39L_4 
Farfsing No.2 A 4 5062 PAK2 AAGAAAAGGAACGGCCAGAAA SI00301077 Hs_PAK2_6 
Farfsing No.2 A 5 10411 RAPGEF3 CTGGAGCCTCTTCAACAGTAT SI04377296 Hs_RAPGEF3_6 
Farfsing No.2 A 6 3695 ITGB7 ACGCACCTATGTGGAAACTAA SI00017836 Hs_ITGB7_2 
Farfsing No.2 A 7 91419 XRCC6BP1 GACGCTGGAGACAAATCCATA SI04313078 Hs_XRCC6BP1_2 
Farfsing No.2 A 8 29127 RACGAP1 CTGAATGTATCTCCTAGCTAT SI00101171 Hs_RACGAP1_2 
Farfsing No.2 A 9 115106 CCDC5 AAGCGAGAACTAGATAGCATT SI04359824 Hs_CCDC5_10 
Farfsing No.2 A 10 596 BCL2 AACTGGGGGAGGATTGTGGCC SI00299411 Hs_BCL2_11 
Farfsing No.2 A 11 284273 ZADH2 ACGCTTACATTCAATTCTTTA SI00159551 Hs_ZADH2_1 
Farfsing No.2 A 12   AACGTACGCGGAATACTTCGA 1022070 Unspecific_LuciferaseGL2_1 
Farfsing No.2 B 1 55214 LEPREL1 CTGAACCGAATTATTGGATCA SI04265184 Hs_LEPREL1_8 
Farfsing No.2 B 2 23043 TNIK CTGGAATATAAGCGCAAACAA SI02225510 Hs_TNIK_6 
Farfsing No.2 B 3 27074 LAMP3 AGGGCGGATTTGTGAATCTCA SI04231311 Hs_LAMP3_6 
Farfsing No.2 B 4 1894 ECT2 TTGCCTAGAGATAGCAAGAAA SI02643067 Hs_ECT2_5 
Farfsing No.2 B 5 10728 PTGES3 CAGATATGCTGTATTTGCCTA SI02781170 Hs_PTGES3_2 
Farfsing No.2 B 6 8914 TIMELESS ACGGGCCCGAATAGTGGATAA SI04140297 Hs_TIMELESS_5 
Farfsing No.2 B 7 121355 GTSF1 AACTCACTACTCTGACAACAA SI04346965 Hs_FAM112B_2 
Farfsing No.2 B 8 83729 INHBE AGGGCTGTTGAGGTACCTTAA SI02779875 Hs_INHBE_8 
Farfsing No.2 B 9 9063 PIAS2 AGCCCTGCGGTTCAGATTAAA SI03143749 Hs_PIAS2_5 
Farfsing No.2 B 10 9525 VPS4B AGCGATAGATCTGGCTAGCAA SI03144456 Hs_VPS4B_5 
Farfsing No.2 B 11 5347 PLK1 CACCATATGAATTGTACAGAA SI00071631 Hs_PLK1_3 
Farfsing No.2 B 12 5347 PLK1 CACCATATGAATTGTACAGAA SI00071631 Hs_PLK1_3 
Farfsing No.2 C 1 152137 CCDC50 GACCGGGAAGCCCGCGTTAAA SI04261201 Hs_CCDC50_1 
Farfsing No.2 C 2 131583 FAM43A CTGAGCTGTCGCAACTTATTA SI04278001 Hs_FAM43A_7 
Farfsing No.2 C 3 347 APOD ATCTCGGAAGATGGTACGAAA SI04309305 Hs_APOD_9 
Farfsing No.2 C 4 5276 SERPINI2 CTGGCTCAAAGCCAATTTATA SI00085813 Hs_SERPINI2_2 
Farfsing No.2 C 5 23306 TMEM194A CACGGATACAGATCCGAGTAA SI04304867 Hs_KIAA0286_6 
Farfsing No.2 C 6 6601 SMARCC2 CGCCGCCGCAGTGAAAGCTAA SI04173169 Hs_SMARCC2_7 
Farfsing No.2 C 7 25895 FAM119B AGCACTAGTGTTAGAACACCA SI04280052 Hs_FAM119B_2 
Farfsing No.2 C 8 2735 GLI1 ACCCAACTTGCCCAATCACAA SI00074802 Hs_GLI1_2 
Farfsing No.2 C 9 51124 IER3IP1 TGAGTGGTTATCCCTAGATAA SI04172175 Hs_IER3IP1_6 
Farfsing No.2 C 10 5596 MAPK4 AAGGATCGTTGATCAGCATTA SI00606011 Hs_MAPK4_5 
Farfsing No.2 C 11 595 CCND1 GCCCTCGGTGTCCTACTTCAA SI02654547 Hs_CCND1_6 
Farfsing No.2 C 12 595 CCND1 GCCCTCGGTGTCCTACTTCAA SI02654547 Hs_CCND1_6 
Farfsing No.2 D 1 401105 FLJ42393 TAGGATGTTGTGATCGACACA SI04773685 Hs_FLJ42393_5 
Farfsing No.2 D 2 131408 FAM131A CAGGGTGTTAATGCCCACGTA SI00635313 Hs_MGC21688_3 
Farfsing No.2 D 3 5290 PIK3CA CTCCGTGAGGCTACATTAATA SI02665369 Hs_PIK3CA_8 
Farfsing No.2 D 4 10644 IGF2BP2 CAGGGCGTTAAATTCACAGAT SI03176593 Hs_IGF2BP2_1 
Farfsing No.2 D 5 64333 ARHGAP9 CCGCGTGCGCAACAAACTAAA SI00302603 Hs_ARHGAP9_3 
Farfsing No.2 D 6 5916 RARG TACGACTGTATGGAAACGTTT SI04025609 Hs_RARG_8 
Farfsing No.2 D 7 5036 PA2G4 ATGCCATGCCGTTTACTTTAA SI02636858 Hs_PA2G4_4 
Farfsing No.2 D 8 140465 MYL6B CAGGCAGTGGCCAAGAACCGA SI03175312 Hs_MYL6B_1 
Farfsing No.2 D 9 51320 MEX3C CCGCGCAAGAATGATATCCAA SI00703682 Hs_RKHD2_2 
Farfsing No.2 D 10 8932 MBD2 TGGAAAGATGATGCCTAGTAA SI02632280 Hs_MBD2_7 
Farfsing No.2 D 11 3832 KIF11 GCCGATAAGATAGAAGATCAA SI02653770 Hs_KIF11_7 
Farfsing No.2 D 12 3832 KIF11 GCCGATAAGATAGAAGATCAA SI02653770 Hs_KIF11_7 
Farfsing No.2 E 1 55689 YEATS2 CACAAGGACAACAAACGCTAA SI04174639 Hs_YEATS2_5 
Farfsing No.2 E 2 285386 TPRG1 CAAGACTCTCTTGATCTGCAA SI04197781 Hs_FAM79B_3 
Farfsing No.2 E 3 26996 GPR160 ACAGCTGTCATAAGATCATAA SI00105329 Hs_GPR160_3 
Farfsing No.2 E 4 5918 RARRES1 CCCTTGGAAATAGTCAGCATA SI03079762 Hs_RARRES1_8 
Farfsing No.2 E 5 1649 DDIT3 CAGCTTGTATATAGAGATTGT SI00059535 Hs_DDIT3_2 
Farfsing No.2 E 6 92979 MARCH-9 CAGGTTGGATGCCGTTGCAGA SI04236694 Hs_MARCH9_2 
Farfsing No.2 E 7 10220 GDF11 CAGAGCATCGACTTCAAGCAA SI00081529 Hs_GDF11_4 
Farfsing No.2 E 8 4234 METTL1 CTGGTGTATACCATAACCGAT SI00076132 Hs_METTL1_3 
Farfsing No.2 E 9 6925 TCF4 AGCCGAATTGAAGATCGTTTA SI00048965 Hs_TCF4_4 
Farfsing No.2 E 10 55205 ZNF532 CACATAGGTCCGAATAACCTA SI04195765 Hs_ZNF532_7 
Farfsing No.2 E 11 596 BCL2 AACTGGGGGAGGATTGTGGCC SI00299411 Hs_BCL2_11 
Farfsing No.2 E 12 1847 DUSP5 CTGAGTGTTGCGTGGATGTAA SI03206903 Hs_DUSP5_10 
Farfsing No.2 F 1 86 ACTL6A CAACAGTGGAACGGAGGTTTA SI02779994 Hs_ACTL6A_6 
Farfsing No.2 F 2 590 BCHE CAGGAGTGAGTGAGTTTGGAA SI00000924 Hs_BCHE_3 
Farfsing No.2 F 3 2119 ETV5 CCCACCTCCAACCAAGATCAA SI04251835 Hs_ETV5_8 
Farfsing No.2 F 4 11213 IRAK3 CTGGATGTTCGTCATATTGAA SI02224285 Hs_IRAK3_6 
Farfsing No.2 F 5 114785 MBD6 CAGGCACGCGGGAGCTGATTA SI04182353 Hs_MBD6_7 
Farfsing No.2 F 6 6778 STAT6 CAGGATGGCTCTCCACAGATA SI00048447 Hs_STAT6_1 
Farfsing No.2 F 7 91523 FAM113B CCGTCTGGTCACAATGATCTA SI00633941 Hs_MGC16044_3 
Farfsing No.2 F 8 196403 DTX3 TGGGCGGATGCTGGTCTCTAA SI03020871 Hs_DTX3_5 
Farfsing No.2 F 9 4677 NARS AACGTGGATTCTGAATAGGTA SI03126592 Hs_NARS_6 
Farfsing No.2 F 10 8792 TNFRSF11A TTCCTTGGAAAGAGAGTAGAA SI03022544 Hs_TNFRSF11A_5 
Farfsing No.2 F 11 1847 DUSP5 CTGAGTGTTGCGTGGATGTAA SI03206903 Hs_DUSP5_10 
Farfsing No.2 G 1 5984 RFC4 CCGATTCTGTCTTATCTGTAA SI02665719 Hs_RFC4_6 
Farfsing No.2 G 2 10051 SMC4 AAGGGACTTTGTTGAACTTTA SI00727013 Hs_SMC4L1_3 
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Farfsing No.2 G 3 1857 DVL3 TCGGATGACAATGCCAAGCTA SI03116799 Hs_DVL3_8 
Farfsing No.2 G 4 54407 SLC38A2 CAGCGACTTCAACTACTCCTA SI03066756 Hs_SLC38A2_8 
Farfsing No.2 G 5 1019 CDK4 AAGCCTCTCTTCTGTGGAAAC SI00299789 Hs_CDK4_4 
Farfsing No.2 G 6 7786 MAP3K12 CTCAGGCGAGAGCAAGCTTTA SI00087206 Hs_MAP3K12_4 
Farfsing No.2 G 7 25840 METTL7A TAGGTTGGTTAGAGGGTTTAA SI00102928 Hs_DKFZP586A0522_2 
Farfsing No.2 G 8 1606 DGKA ATCCATCTTCTCAACATGCAA SI00605199 Hs_DGKA_5 
Farfsing No.2 G 9 9352 TXNL1 AACTATATTTGTTCAGTCGAA SI03030482 Hs_TXNL1_7 
Farfsing No.2 G 10 5055 SERPINB2 AACCTATGACAAACTCAACAA SI02628962 Hs_SERPINB2_5 
Farfsing No.2 H 1 9718 ECE2 CAGCTCCAACTAGATCCAGAA SI00635845 Hs_MGC2408_3 
Farfsing No.2 H 2 84984 C3orf34 TCCAGCTATTATCTTAATCTA SI00632954 Hs_MGC14126_2 
Farfsing No.2 H 3 84859 LRCH3 AACGGCGGAGTGGAACATGAT SI04271575 Hs_LRCH3_5 
Farfsing No.2 H 4 3223 HOXC6 CGCCCTCAATTCCACCGCCTA SI03193778 Hs_HOXC6_5 
Farfsing No.2 H 5 121268 RHEBL1 TTGGCACATCAATTTGTGGAA SI04216800 Hs_RHEBL1_7 
Farfsing No.2 H 6 1017 CDK2 CACGTACGGAGTTGTGTACAA SI00605353 Hs_CDK2_7 
Farfsing No.2 H 7 10102 TSFM AAGGATCAGTTGGCTTTAGCA SI04200091 Hs_TSFM_6 
Farfsing No.2 H 8 10376 TUBA1B AAGGAGAGGAATACTAATTAT SI00084329 Hs_K-ALPHA-1_4 
Farfsing No.2 H 9 10892 MALT1 CACAGTTGATACATAGTTGTA SI00091903 Hs_MALT1_2 
Farfsing No.2 H 10 9306 SOCS6 TTGATCTAATTGAGCATTCAA SI00061369 Hs_SOCS6_1 
Farfsing No.2 H 12   AACGTACGCGGAATACTTCGA 1022070 Unspecific_LuciferaseGL2_1 
Farfsing No.4 A 1 5217 PFN2 CAAACTGTAGATGGTAGCTAA SI00040677 Hs_PFN2_2 
Farfsing No.4 A 2 8975 USP13 CCACCCGGAATTCTCCTCTAA SI03074498 Hs_USP13_6 
Farfsing No.4 A 3 116832 RPL39L CTGTATCAAGTTCACGATCAT SI04232655 Hs_RPL39L_5 
Farfsing No.4 A 4 5062 PAK2 CCGGATCATACGAAATCAATT SI00605717 Hs_PAK2_9 
Farfsing No.4 A 5 10411 RAPGEF3 AGGGACCGTGTTGTTCAGCCA SI04378157 Hs_RAPGEF3_7 
Farfsing No.4 A 6 3695 ITGB7 GACGGCTACTATGGTGCTCTA SI00017843 Hs_ITGB7_3 
Farfsing No.4 A 7 91419 XRCC6BP1 TTCCATGATGTTGATAGGTGA SI04372228 Hs_XRCC6BP1_4 
Farfsing No.4 A 8 29127 RACGAP1 CTGGTAGATAGAAGAGCTAAA SI02639840 Hs_RACGAP1_5 
Farfsing No.4 A 9 115106 CCDC5 TGGAGTCCTATTTAGACTTAA SI04776926 Hs_CCDC5_13 
Farfsing No.4 A 10 596 BCL2 AAGTTCGGTGGGGTCATGTGT SI00299404 Hs_BCL2_10 
Farfsing No.4 A 11 284273 ZADH2 AAAGGGCGCTTGATAGTAATA SI03026835 Hs_ZADH2_6 
Farfsing No.4 A 12   AACGTACGCGGAATACTTCGA 1022070 Unspecific_LuciferaseGL2_1 
Farfsing No.4 B 1 55214 LEPREL1 CCGAAGCCCTCTCGAGCGTAA SI04252640 Hs_LEPREL1_7 
Farfsing No.4 B 2 23043 TNIK CCGGAATATTGCTACATACTA SI02794470 Hs_TNIK_8 
Farfsing No.4 B 3 27074 LAMP3 AAGGTGTCAATCATCTGGATA SI04356303 Hs_LAMP3_8 
Farfsing No.4 B 4 1894 ECT2 GTCGCCCGTTGTATTGTACAA SI03106390 Hs_ECT2_7 
Farfsing No.4 B 5 10728 PTGES3 TTCCAGGTGTATCTTAGCTAA SI04438735 Hs_PTGES3_6 
Farfsing No.4 B 6 8914 TIMELESS ACCGGCTCATGGGATCAGTAA SI04282880 Hs_TIMELESS_7 
Farfsing No.4 B 7 121355 GTSF1 GAGCAAGATGTTGTCAACCAA SI00407477 Hs_FLJ32942_4 
Farfsing No.4 B 8 83729 INHBE AAGGGTTAGGGTGATGGTCCA SI02646399 Hs_INHBE_6 
Farfsing No.4 B 9 9063 PIAS2 AAGCCCACGAGTTTAGTTCAA SI04367433 Hs_PIAS2_7 
Farfsing No.4 B 10 9525 VPS4B CAGGAAAGTCCTACTTAGCCA SI04198579 Hs_VPS4B_8 
Farfsing No.4 B 11 5347 PLK1 CCCGAGGTGCTGAGCAAGAAA SI00071638 Hs_PLK1_4 
Farfsing No.4 B 12 5347 PLK1 CCCGAGGTGCTGAGCAAGAAA SI00071638 Hs_PLK1_4 
Farfsing No.4 C 1 152137 CCDC50 CTGTATCTACTCCATCACGAA SI04372074 Hs_CCDC50_4 
Farfsing No.4 C 2 131583 FAM43A TACACGGACCCTGCTGCTATA SI04327757 Hs_FAM43A_8 
Farfsing No.4 C 3 347 APOD TTGGGAGAGGCCAGTCACCAA SI04225760 Hs_APOD_8 
Farfsing No.4 C 4 5276 SERPINI2 CTCCCTAGATTTAAAGTAGAA SI00085820 Hs_SERPINI2_3 
Farfsing No.4 C 5 23306 TMEM194A CCAGACTTACTGGCTCACCAA SI04334288 Hs_KIAA0286_8 
Farfsing No.4 C 6 6601 SMARCC2 CACCGTGACCCAGTTCGACAA SI04277560 Hs_SMARCC2_8 
Farfsing No.4 C 7 25895 FAM119B CCGAGGCAAGAAGGTGATCGA SI04316221 Hs_FAM119B_4 
Farfsing No.4 C 8 2735 GLI1 CAGACGGTTATCCGCACCTCA SI03063641 Hs_GLI1_6 
Farfsing No.4 C 9 51124 IER3IP1 CAGACCAGTGTCTACAGATTT SI04299477 Hs_IER3IP1_8 
Farfsing No.4 C 10 5596 MAPK4 GAGGACCTGCCGGACAATAAA SI00042497 Hs_MAPK4_4 
Farfsing No.4 C 11 595 CCND1 ATGCATGTAGTCACTTTATAA SI00147819 Hs_CCND1_2 
Farfsing No.4 C 12 595 CCND1 ATGCATGTAGTCACTTTATAA SI00147819 Hs_CCND1_2 
Farfsing No.4 D 1 401105 FLJ42393 CTGTGCCTGACTGGTCAGAAA SI04773699 Hs_FLJ42393_7 
Farfsing No.4 D 2 131408 FAM131A ATGGGTTGAGCCGTCCCTCAA SI04263469 Hs_FAM131A_1 
Farfsing No.4 D 3 5290 PIK3CA TGCGAAATTCTCACACTATTA SI00085841 Hs_PIK3CA_2 
Farfsing No.4 D 4 10644 IGF2BP2 CCCGGGTAGATATCCATAGAA SI04367020 Hs_IGF2BP2_4 
Farfsing No.4 D 5 64333 ARHGAP9 CCAGGACAAGAAGGTCGGTTA SI04373950 Hs_ARHGAP9_6 
Farfsing No.4 D 6 5916 RARG AAGCCGGGTCGCGATGTACGA SI04025602 Hs_RARG_7 
Farfsing No.4 D 7 5036 PA2G4 CTACAGAACAGGGCTAAATTA SI04383253 Hs_PA2G4_9 
Farfsing No.4 D 8 140465 MYL6B CGAGGCCTTCTTGAAACACAT SI04337697 Hs_MYL6B_4 
Farfsing No.4 D 9 51320 MEX3C AACCATGTTGGCCTTCCAATA SI03028487 Hs_RKHD2_5 
Farfsing No.4 D 10 8932 MBD2 CGAAACGATCCTCTCAATCAA SI03083605 Hs_MBD2_10 
Farfsing No.4 D 11 3832 KIF11 CTAGATGGCTTTCTCAGTATA SI00064855 Hs_KIF11_4 
Farfsing No.4 D 12 3832 KIF11 CTAGATGGCTTTCTCAGTATA SI00064855 Hs_KIF11_4 
Farfsing No.4 E 1 55689 YEATS2 TACGGTCAGTTCTGTAACGAA SI04351032 Hs_YEATS2_7 
Farfsing No.4 E 2 285386 TPRG1 ATCCTTATCATCAGCCTTATA SI04287864 Hs_FAM79B_4 
Farfsing No.4 E 3 26996 GPR160 TTGGTACAGGCTATCAGGATA SI04901043 Hs_GPR160_11 
Farfsing No.4 E 4 5918 RARRES1 TACCTGATAATCATGGACATA SI03109225 Hs_RARRES1_10 
Farfsing No.4 E 5 1649 DDIT3 AGGGAGAACCAGGAAACGGAA SI00059542 Hs_DDIT3_3 
Farfsing No.4 E 6 92979 MARCH-9 CCAGCAGTGGAAGGTCCTAAA SI04316424 Hs_MARCH9_4 
Farfsing No.4 E 7 10220 GDF11 TGCGAGTACATGTTCATGCAA SI03118724 Hs_GDF11_6 
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Farfsing No.4 E 8 4234 METTL1 CAGAAGCGCTACTACCGGCAA SI03063088 Hs_METTL1_5 
Farfsing No.4 E 9 6925 TCF4 CACGAAATCTTCGGAGGACAA SI00048944 Hs_TCF4_1 
Farfsing No.4 E 10 55205 ZNF532 AACGAAAGGGCTGGACTACTA SI04243393 Hs_ZNF532_9 
Farfsing No.4 E 11 596 BCL2 AAGTTCGGTGGGGTCATGTGT SI00299404 Hs_BCL2_10 
Farfsing No.4 E 12 1847 DUSP5 CAAGTGCGAGTTCCTCGCCAA SI04345124 Hs_DUSP5_14 
Farfsing No.4 F 1 86 ACTL6A TACGAGGTCTTGGCACAATTA SI00062405 Hs_ACTL6A_1 
Farfsing No.4 F 2 590 BCHE CAGAACGTTGAACTTAGCTAA SI00000931 Hs_BCHE_4 
Farfsing No.4 F 3 2119 ETV5 CAGGCTCTTGGTGCTAACTAT SI04189738 Hs_ETV5_7 
Farfsing No.4 F 4 11213 IRAK3 TCGGTCATCTGTGGCAGTATA SI00095431 Hs_IRAK3_4 
Farfsing No.4 F 5 114785 MBD6 CGGTCTGGAGTGTCCACTTAA SI04272044 Hs_MBD6_9 
Farfsing No.4 F 6 6778 STAT6 CAGCGGCTCTATGTCGACTTT SI03067414 Hs_STAT6_6 
Farfsing No.4 F 7 91523 FAM113B CACCGAGGCACGTAAACATAA SI04216506 Hs_FAM113B_2 
Farfsing No.4 F 8 196403 DTX3 TGGCGAGACTTCTGACATCTA SI03120264 Hs_DTX3_7 
Farfsing No.4 F 9 4677 NARS TTGGTGCGTTAGAAGGATATA SI04324719 Hs_NARS_8 
Farfsing No.4 F 10 8792 TNFRSF11A CTGGGACGGTGCTGTAACAAA SI03098578 Hs_TNFRSF11A_7 
Farfsing No.4 F 11 1847 DUSP5 CAAGTGCGAGTTCCTCGCCAA SI04345124 Hs_DUSP5_14 
Farfsing No.4 G 1 5984 RFC4 GCCGAAGTTGACAAATGCCTA SI00045689 Hs_RFC4_2 
Farfsing No.4 G 2 10051 SMC4 GCCCGGTGTCATGAAATGAAA SI04294738 Hs_SMC4_2 
Farfsing No.4 G 3 1857 DVL3 CCCGGCTAAATGGAACTGCGA SI00063476 Hs_DVL3_3 
Farfsing No.4 G 4 54407 SLC38A2 TACGAACATGTTGAGTCAGAA SI02643550 Hs_SLC38A2_5 
Farfsing No.4 G 5 1019 CDK4 CAAGGTAACCCTGGTGTTTGA SI00001421 Hs_CDK4_2 
Farfsing No.4 G 6 7786 MAP3K12 CTCGTATTCCTTGTACATAGA SI02637194 Hs_MAP3K12_6 
Farfsing No.4 G 7 25840 METTL7A GACAGTTTAGTATATCCATAA SI00102942 Hs_DKFZP586A0522_4 
Farfsing No.4 G 8 1606 DGKA CGGAAGGACATTGGTGTCCAA SI04434871 Hs_DGKA_10 
Farfsing No.4 G 9 9352 TXNL1 CAGCTGCTTATTACTGTGGCA SI03068394 Hs_TXNL1_9 
Farfsing No.4 G 10 5055 SERPINB2 TGCGAGCTTCCGGGAAGAATA SI03118710 Hs_SERPINB2_7 
Farfsing No.4 H 1 9718 ECE2 CAGATCATGAGGACTTCCTTA SI03064656 Hs_MGC2408_5 
Farfsing No.4 H 2 84984 C3orf34 CAGCGCATTATGCCAGTTCGA SI04180120 Hs_C3orf34_1 
Farfsing No.4 H 3 84859 LRCH3 CACGGTAGCGTCGGGAGGTAA SI04292162 Hs_LRCH3_7 
Farfsing No.4 H 4 3223 HOXC6 CCGTATGACTATGGATCTAAT SI04178377 Hs_HOXC6_7 
Farfsing No.4 H 5 121268 RHEBL1 CTGGGCATTATTTATCCAGGA SI04243463 Hs_RHEBL1_8 
Farfsing No.4 H 6 1017 CDK2 GACGGAGCTTGTTATCGCAAA SI00299782 Hs_CDK2_6 
Farfsing No.4 H 7 10102 TSFM TGGGTTCTACGTTGGCTCTTA SI04360132 Hs_TSFM_8 
Farfsing No.4 H 8 10376 TUBA1B CAGCTTAACTGACAGACGTTA SI02636634 Hs_K-ALPHA-1_6 
Farfsing No.4 H 9 10892 MALT1 CTGGATGTTTGCGACATCCCA SI03097724 Hs_MALT1_6 
Farfsing No.4 H 10 9306 SOCS6 CAGCTGCGATATCAACGGTGA SI03068359 Hs_SOCS6_5 
Farfsing No.4 H 12   AACGTACGCGGAATACTTCGA 1022070 Unspecific_LuciferaseGL2_1 
Farfsing No.1 A 1 5217 PFN2 CAGACAGATGAAATAAATTTA SI02654127 Hs_PFN2_8 
Farfsing No.1 A 2 8975 USP13 TCGCTTATGAACTAACGAGAA SI00058093 Hs_USP13_1 
Farfsing No.1 A 3 116832 RPL39L CAGATGAAACCTGGTAGTAAA SI00706531 Hs_RPL39L_1 
Farfsing No.1 A 4 5062 PAK2 CCGCGACCGGATCATACGAAA SI00605710 Hs_PAK2_8 
Farfsing No.1 A 5 10411 RAPGEF3 AGGGCACTTCGTGGTACATTA SI00698530 Hs_RAPGEF3_2 
Farfsing No.1 A 6 3695 ITGB7 CCGGCTCTCGGTGGAAATCTA SI00017829 Hs_ITGB7_1 
Farfsing No.1 A 7 91419 XRCC6BP1 ACCGTGATCGGTATTATTCAA SI00467411 Hs_KUB3_2 
Farfsing No.1 A 8 29127 RACGAP1 CACCACAGACACCAGATATTA SI00101164 Hs_RACGAP1_1 
Farfsing No.1 A 9 115106 CCDC5 CCGCTAGGAGTTCCTAGTAAA SI00339465 Hs_CCDC5_1 
Farfsing No.1 A 10 596 BCL2 TCCATTATAAGCTGTCGCAGA SI00299397 Hs_BCL2_9 
Farfsing No.1 A 11 284273 ZADH2 TACGATGGTCTCAACACCTTT SI02779518 Hs_ZADH2_5 
Farfsing No.1 A 12   AACTTACGCTGAGTACTTCGA 1022073 Unspecific_LuciferaseGL3_1 
Farfsing No.1 B 1 55214 LEPREL1 CCCAAGATAGATCGAGACCTA SI04179539 Hs_LEPREL1_5 
Farfsing No.1 B 2 23043 TNIK AAGGACCATATTGATAGAACA SI02225503 Hs_TNIK_5 
Farfsing No.1 B 3 27074 LAMP3 ACAACCGATGTCCAACTTCAA SI04287458 Hs_LAMP3_7 
Farfsing No.1 B 4 1894 ECT2 ATCGCAAACGACGTCGTTTAA SI00120568 Hs_ECT2_4 
Farfsing No.1 B 5 10728 PTGES3 CAGCTTAGGGAAAGAGAATAA SI02780911 Hs_PTGES3_1 
Farfsing No.1 B 6 8914 TIMELESS TTGGAGCTCCTTAGCAAATAA SI00745017 Hs_TIMELESS_3 
Farfsing No.1 B 7 121355 GTSF1 TTGAATCCTCATTTAATGCAA SI04240628 Hs_FAM112B_1 
Farfsing No.1 B 8 83729 INHBE TAGGGTGATGGTCCAGAGCAA SI02779854 Hs_INHBE_7 
Farfsing No.1 B 9 9063 PIAS2 CAGGTGGTAGGAGAGATTATA SI00684397 Hs_PIAS2_3 
Farfsing No.1 B 10 9525 VPS4B AAGACGGAGTTCCTAGTGCAA SI04194127 Hs_VPS4B_7 
Farfsing No.1 B 11 5347 PLK1 CGCGGGCAAGATTGTGCCTAA SI02223844 Hs_PLK1_7 
Farfsing No.1 B 12 5347 PLK1 CGCGGGCAAGATTGTGCCTAA SI02223844 Hs_PLK1_7 
Farfsing No.1 C 1 152137 CCDC50 AAGAAATCGCTCGACTTCTAA SI04338544 Hs_CCDC50_3 
Farfsing No.1 C 2 131583 FAM43A AACGCGCTGGCGGAATTTAAA SI00383915 Hs_FAM43A_3 
Farfsing No.1 C 3 347 APOD TCCCATCTTTGTGTTTCGATA SI04152939 Hs_APOD_6 
Farfsing No.1 C 4 5276 SERPINI2 AAGGTGATGAATTTAGCTTAA SI00085806 Hs_SERPINI2_1 
Farfsing No.1 C 5 23306 TMEM194A TCAGATGGATGCCTACGTAAA SI04244240 Hs_KIAA0286_5 
Farfsing No.1 C 6 6601 SMARCC2 CAGGTGGATGCTGAGAGTCGA SI04134466 Hs_SMARCC2_5 
Farfsing No.1 C 7 25895 FAM119B CTCCTTCAGTCCATTCCGCAA SI04207770 Hs_FAM119B_1 
Farfsing No.1 C 8 2735 GLI1 CCAGCCCAGATGAATCACCAA SI00074795 Hs_GLI1_1 
Farfsing No.1 C 9 51124 IER3IP1 CAGCTAATGAACCTTATTCGA SI04153569 Hs_IER3IP1_5 
Farfsing No.1 C 10 5596 MAPK4 CGCCTTAAATCTAATCAGCAA SI00606018 Hs_MAPK4_6 
Farfsing No.1 C 11 595 CCND1 AACACCAGCTCCTGTGCTGCG SI02654540 Hs_CCND1_5 
Farfsing No.1 C 12 595 CCND1 AACACCAGCTCCTGTGCTGCG SI02654540 Hs_CCND1_5 
Farfsing No.1 D 1 401105 FLJ42393 CTGGTCTCTGTTTATGATATA SI00415457 Hs_FLJ42393_4 
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Farfsing No.1 D 2 131408 FAM131A TCGGATAATGTGAACCACTAA SI00635299 Hs_MGC21688_1 
Farfsing No.1 D 3 5290 PIK3CA CTGAGTCAGTATAAGTATATA SI02622207 Hs_PIK3CA_5 
Farfsing No.1 D 4 10644 IGF2BP2 CAGCGAAAGGATGGTCATCAT SI04138820 Hs_IGF2BP2_3 
Farfsing No.1 D 5 64333 ARHGAP9 TTGGGTGGTGTTAACGGGTAA SI00302596 Hs_ARHGAP9_2 
Farfsing No.1 D 6 5916 RARG AAGAGCTGGACGGAGGCTAAA SI04025595 Hs_RARG_6 
Farfsing No.1 D 7 5036 PA2G4 CCCACTCCCTTCCAACAACAA SI00085344 Hs_PA2G4_2 
Farfsing No.1 D 8 140465 MYL6B CAGCAACGGCTGCATCAACTA SI00646240 Hs_MLC1SA_4 
Farfsing No.1 D 9 51320 MEX3C TAGGCTAAAGTTGTTAGTAAA SI00703675 Hs_RKHD2_1 
Farfsing No.1 D 10 8932 MBD2 AAGATGATGCCTAGTAAATTA SI02663787 Hs_MBD2_8 
Farfsing No.1 D 11 3832 KIF11 ACGGAGGAGATAGAACGTTTA SI02653693 Hs_KIF11_6 
Farfsing No.1 D 12 3832 KIF11 ACGGAGGAGATAGAACGTTTA SI02653693 Hs_KIF11_6 
Farfsing No.1 E 1 55689 YEATS2 GCGGATAGATATCATACATAA SI00764421 Hs_YEATS2_3 
Farfsing No.1 E 2 285386 TPRG1 AAGGATCAGCCTGACAATCGA SI04167688 Hs_FAM79B_2 
Farfsing No.1 E 3 26996 GPR160 CAACTTTAAGATATCAACCTA SI00105315 Hs_GPR160_1 
Farfsing No.1 E 4 5918 RARRES1 CCGCGCGTGGATTAATCCAAA SI00045290 Hs_RARRES1_1 
Farfsing No.1 E 5 1649 DDIT3 AAGGAAGTGTATCTTCATACA SI00059528 Hs_DDIT3_1 
Farfsing No.1 E 6 92979 MARCH-9 CTGCGGTTATACAATCTTGCA SI04141872 Hs_MARCH9_1 
Farfsing No.1 E 7 10220 GDF11 AAGGTGATGTTCACAAAGGTA SI00081515 Hs_GDF11_2 
Farfsing No.1 E 8 4234 METTL1 CAGAATATGCCTACGTGCTAA SI00076118 Hs_METTL1_1 
Farfsing No.1 E 9 6925 TCF4 CACAGCTGTTTGGTCTAGAAA SI00048958 Hs_TCF4_3 
Farfsing No.1 E 10 55205 ZNF532 CCAGATATGGTCGATCCTAAA SI00775733 Hs_ZNF532_3 
Farfsing No.1 E 11 596 BCL2 TCCATTATAAGCTGTCGCAGA SI00299397 Hs_BCL2_9 
Farfsing No.1 E 12 1847 DUSP5 CGCGACCCACCTACACTACAA SI03194282 Hs_DUSP5_9 
Farfsing No.1 F 1 86 ACTL6A AAAGCTTTAACTGGCTCTATA SI02779987 Hs_ACTL6A_5 
Farfsing No.1 F 2 590 BCHE CGGGTTGAAAGAGTTATTGTA SI00000917 Hs_BCHE_2 
Farfsing No.1 F 3 2119 ETV5 CAGGATCTCAGTCAACTTCAA SI03019394 Hs_ETV5_5 
Farfsing No.1 F 4 11213 IRAK3 CACATTCGAATCGGTATATTA SI02224278 Hs_IRAK3_5 
Farfsing No.1 F 5 114785 MBD6 TTCCACTGTAGTGATGCCTTA SI04147864 Hs_MBD6_6 
Farfsing No.1 F 6 6778 STAT6 ACGGATAGGCAGGAACATACA SI02662905 Hs_STAT6_5 
Farfsing No.1 F 7 91523 FAM113B AGGGACGAGATCTAGAATCAA SI00633934 Hs_MGC16044_2 
Farfsing No.1 F 8 196403 DTX3 TCAGATACAGTTCTCCCTTAA SI00374626 Hs_DTX3_4 
Farfsing No.1 F 9 4677 NARS ATGCGTATCTTTGATAGTGAA SI00655179 Hs_NARS_1 
Farfsing No.1 F 10 8792 TNFRSF11A ACCCGCTAGGTGGTTAATTTA SI00056616 Hs_TNFRSF11A_1 
Farfsing No.1 F 11 1847 DUSP5 CGCGACCCACCTACACTACAA SI03194282 Hs_DUSP5_9 
Farfsing No.1 G 1 5984 RFC4 CAGAAGTCTATTATCACAGAA SI02665726 Hs_RFC4_7 
Farfsing No.1 G 2 10051 SMC4 CAGCGTTTAATAGAGCAAGAA SI04324873 Hs_SMC4_3 
Farfsing No.1 G 3 1857 DVL3 CTCCTGGTTACTTCATCACAA SI02781387 Hs_DVL3_6 
Farfsing No.1 G 4 54407 SLC38A2 CTCATCAGGCATAATGTCTAA SI02777845 Hs_SLC38A2_6 
Farfsing No.1 G 5 1019 CDK4 AAGGTAACCCTGGTGTTTGAG SI00299803 Hs_CDK4_6 
Farfsing No.1 G 6 7786 MAP3K12 CTGGAATAGCAAACCACGAAA SI00087185 Hs_MAP3K12_1 
Farfsing No.1 G 7 25840 METTL7A CTGGCTTTCAGAATTAACATA SI00102921 Hs_DKFZP586A0522_1 
Farfsing No.1 G 8 1606 DGKA CACGACCAGTGTGCCATGAAA SI00605206 Hs_DGKA_6 
Farfsing No.1 G 9 9352 TXNL1 AACTCAAGCTCTGGAACTGAC SI00302064 Hs_TXNL1_5 
Farfsing No.1 G 10 5055 SERPINB2 CAGAAGGGTAGTTATCCTGAT SI00039753 Hs_SERPINB2_2 
Farfsing No.1 H 1 9718 ECE2 CAAGGGCGCGAGTATGACAAA SI03054639 Hs_ECE2_5 
Farfsing No.1 H 2 84984 C3orf34 CCAGAGCTGCTGAACAATTAA SI00632947 Hs_MGC14126_1 
Farfsing No.1 H 3 84859 LRCH3 CTGGATCAGATTGACTACATA SI00623308 Hs_LRCH3_4 
Farfsing No.1 H 4 3223 HOXC6 ACCGTCAGTGTTCCTATCCAA SI00440874 Hs_HOXC6_3 
Farfsing No.1 H 5 121268 RHEBL1 CTCCAGTGGCCTGGATGTCAA SI04142341 Hs_RHEBL1_6 
Farfsing No.1 H 6 1017 CDK2 CAGGTTATATCCAATAGTAGA SI00605360 Hs_CDK2_8 
Farfsing No.1 H 7 10102 TSFM CAGACCGAGAATGCATGGGTA SI03167402 Hs_TSFM_5 
Farfsing No.1 H 8 10376 TUBA1B TCCATCATATCTCAAAGTAAA SI00084308 Hs_K-ALPHA-1_1 
Farfsing No.1 H 9 10892 MALT1 TAGATAGAGGTTAAGAATCAA SI00091896 Hs_MALT1_1 
Farfsing No.1 H 10 9306 SOCS6 TAGAATCGTGAATTGACATAA SI00061383 Hs_SOCS6_3 
Farfsing No.1 H 12   AACTTACGCTGAGTACTTCGA 1022073 Unspecific_LuciferaseGL3_1 
Farfsing No.3 A 1 5217 PFN2 CCGGGAAGGTTTCTTTACCAA SI00040670 Hs_PFN2_1 
Farfsing No.3 A 2 8975 USP13 CACTACGAGCAACGAATAATA SI03061968 Hs_USP13_5 
Farfsing No.3 A 3 116832 RPL39L TCGGAGTCTCAGAGACACCAA SI00706545 Hs_RPL39L_3 
Farfsing No.3 A 4 5062 PAK2 AAGAGACTGCTCCTCCCGTTA SI00301084 Hs_PAK2_7 
Farfsing No.3 A 5 10411 RAPGEF3 AACTCGGTGAAGCGAGAATTA SI03126928 Hs_RAPGEF3_5 
Farfsing No.3 A 6 3695 ITGB7 ACGGTCGTGCTCAGAGTGAGA SI03041815 Hs_ITGB7_5 
Farfsing No.3 A 7 91419 XRCC6BP1 TGGAAGGATCCCACATAACAA SI04358704 Hs_XRCC6BP1_3 
Farfsing No.3 A 8 29127 RACGAP1 CAGGTGGATGTAGAGATCAAA SI00101178 Hs_RACGAP1_3 
Farfsing No.3 A 9 115106 CCDC5 CGCAGGTTGCTGCGTGGTTAA SI04776919 Hs_CCDC5_12 
Farfsing No.3 A 10 596 BCL2 AACCGGGAGATAGTGATGAAG SI00299418 Hs_BCL2_12 
Farfsing No.3 A 11 284273 ZADH2 ACCCGTAGGTACCGTCCTTAA SI00159558 Hs_ZADH2_2 
Farfsing No.3 A 12   AACTTACGCTGAGTACTTCGA 1022073 Unspecific_LuciferaseGL3_1 
Farfsing No.3 B 1 55214 LEPREL1 TACTATCGAGTTGGTGAGTAT SI04244849 Hs_LEPREL1_6 
Farfsing No.3 B 2 23043 TNIK CACCTATGGCCGGATAACTAA SI02794463 Hs_TNIK_7 
Farfsing No.3 B 3 27074 LAMP3 CACCTCGGAGATACTTCAACA SI04153226 Hs_LAMP3_5 
Farfsing No.3 B 4 1894 ECT2 ATGACGCATATTAATGAGGAT SI03049249 Hs_ECT2_6 
Farfsing No.3 B 5 10728 PTGES3 CGGAGAGAAGTCGACTCCCTA SI03085740 Hs_PTGES3_3 
Farfsing No.3 B 6 8914 TIMELESS CACCTGAATACTGTTCCTCGA SI04142194 Hs_TIMELESS_6 
Farfsing No.3 B 7 121355 GTSF1 GCCGTATGTTCTGCCATGGAA SI04353069 Hs_FAM112B_3 
Supplementary 
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Farfsing No.3 B 8 83729 INHBE TGGCTTATACTTTCTTAATAA SI02646392 Hs_INHBE_5 
Farfsing No.3 B 9 9063 PIAS2 TCCGCCTTCATTAACAGACTA SI04338215 Hs_PIAS2_6 
Farfsing No.3 B 10 9525 VPS4B AGCGATATATGAACGGCATAA SI03144463 Hs_VPS4B_6 
Farfsing No.3 B 11 5347 PLK1 CCGGATCAAGAAGAATGAATA SI02223837 Hs_PLK1_6 
Farfsing No.3 B 12 5347 PLK1 CCGGATCAAGAAGAATGAATA SI02223837 Hs_PLK1_6 
Farfsing No.3 C 1 152137 CCDC50 CGGCGCGTCACTGAGCACAAA SI04272254 Hs_CCDC50_2 
Farfsing No.3 C 2 131583 FAM43A CCCGCTAGTGCCGCTGCGCAA SI04154794 Hs_FAM43A_6 
Farfsing No.3 C 3 347 APOD GCCTGCCAAGCTGGAAGTTAA SI04173750 Hs_APOD_7 
Farfsing No.3 C 4 5276 SERPINI2 AAGAGGTTTCCTTATCTCATA SI00085827 Hs_SERPINI2_4 
Farfsing No.3 C 5 23306 TMEM194A TAGGTAGTGGTCAGTTATCTT SI04309242 Hs_KIAA0286_7 
Farfsing No.3 C 6 6601 SMARCC2 GAAGTCCTTGGTGCAGAATAA SI04135383 Hs_SMARCC2_6 
Farfsing No.3 C 7 25895 FAM119B CAGTGAGGTGCCTGCTTACAA SI04300646 Hs_FAM119B_3 
Farfsing No.3 C 8 2735 GLI1 CTCGGGCACCATCCATTTCTA SI02634835 Hs_GLI1_5 
Farfsing No.3 C 9 51124 IER3IP1 CAGCGTAAATATTAGCCCACA SI04209009 Hs_IER3IP1_7 
Farfsing No.3 C 10 5596 MAPK4 CACAGAGGACCTCGTGCTCAA SI00042483 Hs_MAPK4_2 
Farfsing No.3 C 11 595 CCND1 AAGGCCAGTATGATTTATAAA SI00147812 Hs_CCND1_1 
Farfsing No.3 C 12 595 CCND1 AAGGCCAGTATGATTTATAAA SI00147812 Hs_CCND1_1 
Farfsing No.3 D 1 401105 FLJ42393 CGCAGTGGGTGAAGTATTGTA SI04773692 Hs_FLJ42393_6 
Farfsing No.3 D 2 131408 FAM131A AACGGGCACAAGCATTCTATA SI00635320 Hs_MGC21688_4 
Farfsing No.3 D 3 5290 PIK3CA ATGGCTGAATTATGATATATA SI00085834 Hs_PIK3CA_1 
Farfsing No.3 D 4 10644 IGF2BP2 TCCGCTAGCCAAGAACCTATA SI03232481 Hs_IGF2BP2_2 
Farfsing No.3 D 5 64333 ARHGAP9 CTGGACGCTGCTTCTACATAA SI04228987 Hs_ARHGAP9_5 
Farfsing No.3 D 6 5916 RARG TCCTGTTTCGCCGGACTTGAA SI04025616 Hs_RARG_9 
Farfsing No.3 D 7 5036 PA2G4 TCCCACCAGCATTTCGGTAAA SI02636865 Hs_PA2G4_5 
Farfsing No.3 D 8 140465 MYL6B CAAGAAGGATGTTCCCGTGAA SI04266696 Hs_MYL6B_3 
Farfsing No.3 D 9 51320 MEX3C AGGAAACTATATAGAGCTCAA SI00703696 Hs_RKHD2_4 
Farfsing No.3 D 10 8932 MBD2 CAAGTGGTAAGAAGTTCAGAA SI03054996 Hs_MBD2_9 
Farfsing No.3 D 11 3832 KIF11 CTCGGGAAGCTGGAAATATAA SI03019793 Hs_KIF11_8 
Farfsing No.3 D 12 3832 KIF11 CTCGGGAAGCTGGAAATATAA SI03019793 Hs_KIF11_8 
Farfsing No.3 E 1 55689 YEATS2 CTGGCACTAAACTCTACCTAA SI04211956 Hs_YEATS2_6 
Farfsing No.3 E 2 285386 TPRG1 AAGACTAGATAAAGTCGATAT SI04145323 Hs_FAM79B_1 
Farfsing No.3 E 3 26996 GPR160 CACATCTGCCTATTTACTCAA SI04901022 Hs_GPR160_8 
Farfsing No.3 E 4 5918 RARRES1 CGCGGCGCTTCACTTCTTCAA SI03085229 Hs_RARRES1_9 
Farfsing No.3 E 5 1649 DDIT3 ACGGCTCAAGCAGGAAATCGA SI03041633 Hs_DDIT3_5 
Farfsing No.3 E 6 92979 09-Mar CAGCACTCCGAGGTATCTAAA SI04245101 Hs_MARCH9_3 
Farfsing No.3 E 7 10220 GDF11 CCTGCAGATCTTGCGACTAAA SI03083388 Hs_GDF11_5 
Farfsing No.3 E 8 4234 METTL1 CACGTGGATTTGGTAGAGAAA SI00076139 Hs_METTL1_4 
Farfsing No.3 E 9 6925 TCF4 GACGACAAGAAGGATATCAAA SI03101805 Hs_TCF4_5 
Farfsing No.3 E 10 55205 ZNF532 CAGCGTTATCGTCAAGAATGT SI04215701 Hs_ZNF532_8 
Farfsing No.3 E 11 596 BCL2 AACCGGGAGATAGTGATGAAG SI00299418 Hs_BCL2_12 
Farfsing No.3 E 12 1847 DUSP5 CTGCATGGCTTACCTTATGAA SI04228700 Hs_DUSP5_13 
Farfsing No.3 F 1 86 ACTL6A ACCTTACGTTTCATAGCTTTA SI04433933 Hs_ACTL6A_9 
Farfsing No.3 F 2 590 BCHE TTGCAGAGAATCGGAAATCAA SI00000910 Hs_BCHE_1 
Farfsing No.3 F 3 2119 ETV5 CCCGATTATACTTTGACGACA SI03184657 Hs_ETV5_6 
Farfsing No.3 F 4 11213 IRAK3 AAGTATGTAGACCAAGGTAAA SI00095417 Hs_IRAK3_2 
Farfsing No.3 F 5 114785 MBD6 CAGCCTCAATGCTCCCTCATA SI04184691 Hs_MBD6_8 
Farfsing No.3 F 6 6778 STAT6 AACCAAGACAACAATGCCAAA SI00048468 Hs_STAT6_4 
Farfsing No.3 F 7 91523 FAM113B CACCCGCGTGTACTCCGATTA SI03161508 Hs_FAM113B_1 
Farfsing No.3 F 8 196403 DTX3 AAGGGTATCACAGATGACTGA SI03036089 Hs_DTX3_6 
Farfsing No.3 F 9 4677 NARS TTGGGCTTGGAACGATTCTTA SI04323907 Hs_NARS_7 
Farfsing No.3 F 10 8792 TNFRSF11A TTGGATAGCTGGAATGAAGAA SI03024812 Hs_TNFRSF11A_6 
Farfsing No.3 F 11 1847 DUSP5 CTGCATGGCTTACCTTATGAA SI04228700 Hs_DUSP5_13 
Farfsing No.3 G 1 5984 RFC4 AGGGAATAGCTTATCTTGTTA SI00045682 Hs_RFC4_1 
Farfsing No.3 G 2 10051 SMC4 TACCATCGTAGAAATCAATAA SI04137714 Hs_SMC4_1 
Farfsing No.3 G 3 1857 DVL3 CAGCATATCATATCCATTTCA SI00063469 Hs_DVL3_2 
Farfsing No.3 G 4 54407 SLC38A2 CAACGTAGAATTACTTGTTTA SI00123480 Hs_SLC38A2_2 
Farfsing No.3 G 5 1019 CDK4 AAGGTAATCCGGAGTGAGCAA SI00604744 Hs_CDK4_7 
Farfsing No.3 G 6 7786 MAP3K12 CAGGGAGCACTATGAAAGGAA SI02637187 Hs_MAP3K12_5 
Farfsing No.3 G 7 25840 METTL7A AAGCAATCTGTGAGTCTGTAA SI00102935 Hs_DKFZP586A0522_3 
Farfsing No.3 G 8 1606 DGKA CCCATGCAAATTGACGGAGAA SI00025662 Hs_DGKA_2 
Farfsing No.3 G 9 9352 TXNL1 ATGAATGACTTCAAACGAGTA SI03049137 Hs_TXNL1_8 
Farfsing No.3 G 10 5055 SERPINB2 CTGGAAAGTGAAATAACCTAT SI02628969 Hs_SERPINB2_6 
Farfsing No.3 H 1 9718 ECE2 CAGACACTATGCCCAAGCCTA SI00635852 Hs_MGC2408_4 
Farfsing No.3 H 2 84984 C3orf34 ATGGAACAAATTCAACGGGAA SI00632961 Hs_MGC14126_3 
Farfsing No.3 H 3 84859 LRCH3 ACAGACGATCACCCTAGATAA SI04288774 Hs_LRCH3_6 
Farfsing No.3 H 4 3223 HOXC6 TGGGTCCGTTCTCGAATATTT SI03239670 Hs_HOXC6_6 
Farfsing No.3 H 5 121268 RHEBL1 AGGCGAGTTCTCGGAAGGCTA SI04243498 Hs_RHEBL1_9 
Farfsing No.3 H 6 1017 CDK2 AGGTGGTGGCGCTTAAGAAAA SI00299775 Hs_CDK2_5 
Farfsing No.3 H 7 10102 TSFM ATGATGCATTGTCAGACCCTA SI04348848 Hs_TSFM_7 
Farfsing No.3 H 8 10376 TUBA1B CCCGCCCTAGTGCGTTACTTA SI02636627 Hs_K-ALPHA-1_5 
Farfsing No.3 H 9 10892 MALT1 CTGGTAATCCAAGTAATGTTA SI02638062 Hs_MALT1_5 
Farfsing No.3 H 10 9306 SOCS6 CGGGTACAAATTGGCATAACA SI00061376 Hs_SOCS6_2 
Farfsing No.3 H 12   AACTTACGCTGAGTACTTCGA 1022073 Unspecific_LuciferaseGL3_1 
Col=Column in which the siRNA is located in the 96-well plate. 
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